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Brain ischaemia is the defining pathological process in vascular dementia (VaD); however, 
cerebral blood flow is also reduced in Alzheimer’s disease (AD) and there is evidence that 
hypoperfusion contributes to tissue damage. Vascular endothelial growth factor-A (VEGF) is 
a pro-angiogenic factor expressed in response to tissue hypoxia. VEGF receptor 2 
(VEGFR2) mediates the actions of VEGF on endothelial cells leading to angiogenesis. 
VEGF receptor 1 (VEGFR1) has limited kinase activity and its soluble form (sVEGFR1) acts 
as a negative regulator of VEGF. VEGF protein is increased in AD, but without a 
corresponding increase in microvessel density. Aβ1-42 was shown to bind to VEGFR2 and 
block signalling in vitro providing a possible mechanism for impaired angiogenesis; however, 
there are no studies of VEGFR1 or VEGFR2 in AD or VaD. 
This thesis investigates whether altered expression of VEGF receptors might account for the 
lack of angiogenic response to VEGF in AD. Medial parietal cortex and white matter were 
dissected from AD, VaD and control brains. VEGFR1 and VEGFR2 mRNA and protein levels 
were measured and related to VEGF and microvessel density. sVEGFR1 isoforms were 
identified and measured. Human brain microvascular endothelial cells and pericytes were 
used to investigate VEGFR in response to hypoxia, Aβ1-40 and Aβ1-42. 
VEGFR1 was expressed predominantly neuronally and was significantly reduced in AD, 
though blot analysis on a subset of brains showed an increase in the proportion of sVEGFR1 
in AD. VEGFR2 was expressed by neurons, astrocytes and endothelial cells. VEGFR2 level 
was similar in AD, VaD and control. The finding that elevated VEGF fails to increase 
microvessel density in AD despite normal VEGFR2 level raises the possibility that VEGFR2 
signalling is defective in AD. The increased proportion of sVEGFR1, supported by in vitro 
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Chapter 1 General introduction 
1.1 Dementia 
Dementia is a term that encompasses symptoms that occur when the brain is affected by 
certain diseases that affect cognitive function. These symptoms may include memory loss, 
and impairment of problem solving, language and communication 1.  
It is estimated that dementia affects 46.8 million people worldwide, with that number 
predicted almost to double every 20 years 2. Within the UK there are an estimated 850,000 
people living with dementia and over one third of the population have a close friend or family 
member who has dementia 3 . There is no cure and there are no disease-modifying 
treatments available for any form of dementia. Though dementia does shorten the lives of 
those affected, its greatest impact is on quality of life, both for individuals living with 
dementia, and for their families and carers.  
Alzheimer’s disease (AD) and vascular dementia (VaD) are the two most common types of 
dementia.  
1.1.1 Alzheimer’s disease 
AD is the most common neurodegenerative disease and cause of dementia.  
AD patients experience a steady decline in the ability to form new memories. Early 
symptoms include forgetting names, events and faces, misplacing items or becoming 
disorientated. As AD progresses, memory declines as does the ability to make decisions and 
communicate. Patients may become unsteady on their feet and require help with daily 
activities. Significant problems with long and short-term memory, loss of speech, difficulties 
eating, and weight loss occur in the later stages of disease.  
To reach a clinical diagnosis of possible AD a history of symptoms is taken from the patient 
and their carer. The mini mental state examination (MMSE) is one of a battery of tests 
commonly used to assess cognition 4 together with a physical assessment and psychiatric 
evaluation. The advent of positron emission tomography (PET) scans for markers of glucose 
uptake, amyloid and phosphorylated tau can lead provide a near definitive diagnosis during 
life, however these scans are expensive and not commonly available. A definitive diagnosis 
of AD can only be given post mortem following histological assessment as detailed in 
Chapter 2. 
There are no disease-modifying treatments currently available for AD. The National Institute 
for Health and Care Excellence (NICE) has licensed 4 drugs for the symptomatic treatment 
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of AD in the UK: donepezil, galantamine and rivastigmine and memantine 5. 
Acetylcholinesterase (AChE) inhibitors (donepezil, galantamine and rivastigmine) are 
recommended for managing mild and moderate AD. Memantine, an NMDA receptor 
antagonist, is recommended as an option for managing moderate and severe Alzheimer’s 
disease or for those unable to take cholinesterase inhibitors 5. Blocking the effects of high 
levels of glutamate on the NMDA receptor is thought to prevent excitotoxicity and resulting 
neuronal death. Controlling additional cardiovascular contributors to dementia, such as high 
blood pressure, high cholesterol and diabetes, may be of benefit in treating patients with AD 
6 (1.1.3). 
There is a loss of cholinergic neurons in the AD brain compared to controls 7. This leads to a 
reduction in neurotransmitter acetylcholine 8, a finding that prompted the use of AChE drugs 
in AD. These drugs prevent the breakdown of the neurotransmitter acetylcholine to extend 
its actions at the synapse. AChE inhibitors make up 3 of the 4 approved treatments for AD in 
the UK 5. AChE inhibitors offer symptomatic relief to some patients but have no impact on 
disease progression as cholinergic neuronal loss is a consequence of the underlying disease 
9.  
1.1.1.1 Neuropathology 
AD is characterised by two defining pathologies: extracellular amyloid-β (Aβ) plaques and 
intracellular neurofibrillary tangles (NFT) 10.  
1.1.1.1.1 Aβ production, aggregation and clearance 
Aβ fragments are cleaved by β and γ secretases from amyloid precursor protein (APP) 11. 
APP has several defined functions in synaptic maintenance, cholesterol homeostasis, cell 
growth and proliferation but other functions are still being elucidated 12. APP is highly 
expressed in neurons 11. APP processing occurs at cell membrane and Golgi body and it can 
either be processed via an amyloidogenic pathway or non-amyloidogenic pathway as 
detailed in Figure 1-113. In the non-amyloidogenic pathway, APP is cleaved by α secretase 
then γ secretase. In the amyloidogenic pathway APP is cleaved by β secretase (β-secretase 
1, BACE1) and then γ secretase. γ secretase is a multimeric protein in which presenilin 1 
(PSEN1) or presenilin 2 (PSEN2) form the catalytic domain 14. γ secretase cleaves the c-
terminus of the potential Aβ site at between 40-44 amino acids to produce Aβ fragments. 
Aβ1-40 and Aβ1-42 are the most common peptides produced by this process 13.  
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Figure 1-1 APP processing. Non-amyloidogenic pathway – α-secretase first cleaves APP to 
generate sAPPα followed by γ-secretase to generate. Amyloidogenic pathway: β-secretase 
first cleaves APP to form sAPPβ then γ-secretase cleaves to generate an Aβ fragment. Both 
pathways yield intracellular c-terminal fragments APP intracellular domains (AICD).  
Aβ fragments are formed as monomers but readily aggregate into oligomers. Aβ1-42 forms 
oligomers, fibrils and insoluble β sheet structure known as amyloid plaques which are 
observed in the AD brain (Figure 1-2A) 15. Aβ1-40 tends to aggregate in the walls of blood 
vessels to cause cerebral amyloid angiopathy (CAA) as seen in Figure 1-2C and discussed 
further in 1.1.1.1.2.  
The specific role of amyloid plaques in the progression of AD is debated. Plaque load does 
not correlate well with memory impairment or reduced brain volume 16. Oligomers on the 
other hand are known to be toxic to neurons 17, 18. It is now thought that oligomers of Aβ1-42 
are the most damaging Aβ species in AD, while insoluble amyloid plaques may even have a 
protective role 19.  
Aβ1-40 is normally produced at higher concentrations than Aβ1-42. Certain conditions are 
known to increase the formation of Aβ1-42 leading to increased concentration of toxic 
oligomers and aggregation. This shift in Aβ1-42: Aβ1-40 ratio is thought to be key to AD 
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pathogenesis. Certain conditions can lead to this shift, including PSEN mutations (1.1.1.2) 
and neuronal hypoxia (1.1.3).  
As noted above, Aβ1-42 accumulation may result from increased production. However, there 
must be a balance between Aβ production and clearance to maintain a healthy Aβ 
concentration. Reduced Aβ clearance or degradation can also increase the concentration of 
Aβ. 
Aβ can be cleared or degraded in the brain via several mechanisms. Receptor-mediated 
transport across the blood brain barrier (BBB) is thought to be the primary method of Aβ 
clearance from the brain. The BBB has a key role in controlling the composition of interstitial 
fluid (ISF) and is described in further detail in 1.1.3.4. The lipoprotein receptor related 
proteins, such as LRP1, and  ATP-binding cassette transporters, such as ABCB1, mediate 
the transcytosis of Aβ across the BBB 20. Both LRP1 and ABCB1 have been shown to be 
reduced in AD 21 contributing to the accumulation of Aβ in the brain. Additional receptors, 
including ABCA1, can facilitate Aβ efflux in a APOE dependent manner with with ApoE2 and 
E3 forming complexes with Aβ more efficiently than E4 
https://alzres.biomedcentral.com/articles/10.1186/alzrt187. Soluble transports, such as 
sLRP, bind to Aβ in the plasma preventing it from entering the ISF 21. Bulk flow transport of 
ISF to the CSF and through the arachnoid villi into the blood stream provides another route 
of Aβ clearance.  
The proteasome and lysosome are known to mediate proteolysis. The proteasome is a 
protease complex that degrades proteins that have been tagged with ubiquitin polymers 22. 
In AD, ubiquitin tags are known to accumulate in both Aβ plaques and NFT. Proteasome 
activity is known to be reduced in the hippocampus in AD brain compared to control and Aβ 
has been shown to inhibit proteasome function 23. Lysosomal degradation commonly 
degrades extracellular and cell surface proteins. Proteins are internalised by endocytosis 
and degraded within the lysosome, a double membrane vesicle containing proteases and 
acid hydrolyses (such as phosphatases) 22. Dysfunction in lysosome autophagy has been 
reported in numerous studies and includes the presence of endosomes with undigested 
contents in AD 24.  
In addition to the above processes, specific enzymes may degrade Aβ. However, the exact 
contribution of these enzymes and their effect on Aβ level in the human brain are yet to be 
established. These include endothelin-converting enzyme (ECE) and angiotensin converting 
enzyme (ACE) 22. 
Increased permeability of the BBB can lead to infiltration of Aβ and other molecules from the 
blood as discussed further in section 1.1.3.4 25. In addition, transporters on the BBB can be 
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involved in uptake of Aβ into the brain. The receptor for advanced glycation end products 
(RAGE) transports Aβ from the blood across the BBB into the brain 26. The level of RAGE is 
determined by the level of its ligands and RAGE levels on blood vessels and have been 
shown to be elevated in AD27. Consequently, RAGE has become a therapeutic target 20, 27. 
1.1.1.1.2 Tau 
In addition to Aβ plaques, intraneuronal NFTs are a second pathological hallmark of AD 
(Figure 1-2B). These are made up of paired helical filaments composed of 
hyperphosphorylated microtubule associated binding protein tau (MAPT) 28 29. NFT 
pathology spreads through the brain in a predictable manner, as documented by Braak and 
Braak 30, leading to the use of ‘Braak staging’ to indicate disease progression. NFTs are 
present in the entorhinal region and subiculum in stages I-II, also involve the limbic region 
and adjacent inferior temporal neocortex in stages III-IV, and the neocortex in stages V-VI. 
Braak stages correlate well with the progression of AD symptoms, which indicates the 
importance of NTF in AD pathogenesis. In stages I-II, there is no clinical manifestation of 
disease. In stages III-IV symptoms include short term memory loss, lack of spatial 
awareness,  
When NFT have progressed to the neocortex in stages V-VI the symptoms include a decline 
in the ability to communicate and changes in mood and behaviour 31. 
The presence of tau pathology alone can cause other neurodegenerative disorders 
emphasising the involvement of tau in neurodegeneration. Together with AD these are 
collectively known as tauopathies. Tauopathies include several forms of frontotemporal lobe 
degeneration (FTD-tau), corticobasal degeneration and progressive supranuclear palsy 32. 
1.1.1.1.3 Cerebrovascular pathology 
The deposition of Aβ in blood vessel walls is known as CAA (Figure 1-2C). CAA is present in 
over 90% of patients with AD 33 and approximately 33% of elderly people who do not have 
AD 33. CAA is often asymptomatic, though can present as intracranial haemorrhage and 
dementia 34. The severity of CAA varies considerably, with advanced CAA being present in 
approximately 25% of AD patients 35. Most of the Aβ deposited in the vasculature is Aβ1-40 
rather than Aβ1-42. There are rare forms of heritable CAA in which mutations in the APP gene 
cause preferential build-up of Aβ in blood vessels leading to cerebral haemorrhage. In one 
study, Dutch type hereditary CAA dementia was predicted by the amount of severely 
amyloid laden vessels as opposed to severity of other AD pathologies 35. 
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Cerebral microbleeds are a hallmark of CAA and are present in higher numbers in AD when 
compared to the general population and other forms of dementia 35. Moderate to severe CAA 
is associated with impaired cognition in the elderly even with controlling for other pathologies 
36. CAA is frequently present in AD with PSEN1 and Arctic APP mutations 37 and there is 
evidence that CAA in AD is correlated with more severe cognitive impairment than those 
with AD but no CAA 38 39 40. In patients with CAA the vascular smooth muscle layer of 
arteries and arterioles tends to degenerate which probably contributes to the risk of rupture 
of the vessel wall and intracerebral bleeding. It is also increasingly recognised that 
ischaemic regions are common in CAA 41. In AD microbleeds are associated with increased 
severity of dementia but it is not clear whether this is because they contribute directly or are 
simply a marker of severe CAA. There is evidence that Aβ contributes to the production of 
reactive oxygen species (ROS) in the vasculature, which can interfere with vascular 
signalling and damage proteins, lipids and DNA 42. The extent of CAA has been reported to 
predict longitudinal episodic memory decline in presymptomatic autosomal dominant AD and 
global cognitive decline in symptomatic AD 43. 
1.1.1.2 Genetics 
Familial AD (FAD) is directly caused by heterozygous dominant mutations and makes up 
fewer than 5% of all AD cases 44. FAD-causing mutations have been identified in the genes 
encoding APP (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2). Although these full-
penetrance disease causing mutations are rare, they provide insight into the mechanisms of 
sporadic AD.  
Mutations in the gene encoding APP lead to the deposition of Aβ by favouring the 
processing of APP by β and γ secretase rather than α secretase. This results in the 
Figure 1-2 AD pathology. [A] Extracellular Aβ plaques immunolabelled for Aβ. [B] 
Intraneuronal neurofibrillary tangles immunolabelled for tau. [C] Deposition of Aβ in the walls 
of cerebrocortical and leptomeningeal blood vessels as indicated by the red arrows. Figure 
courtesy of the South West Dementia Brain Bank (SWDBB). 
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formation of more Aβ1-40 and Aβ1-42 or a shift in the proportion of Aβ1-42 production compared 
Aβ1-40 17, 45. To date, over 40 pathogenic mutations of APP have been identified 46 47. 
Mutations in PSEN1 and PSEN2 account for up to 80% of FAD 44. Presenilin genes 1 and 2 
code for the catalytic component of the γ-secretase complex 48 discussed in 1.1.1.1.1. The 
majority of mutations are found within the PSEN1 gene with 205 pathogenic mutations 
identified to date. 13 pathogenic mutations have been identified within the PSEN2 gene 46. 
Mutations in PSEN1 and PSEN2 alter γ-secretase cleavage of APP, resulting in 
overproduction of Aβ1-42 which forms plaques more readily than Aβ1-40 45 49. 
Numerous other genetic risk factors have been identified by genome-wide association 
studies (GWAS). Genetic risk factors are variants in genes common in the population that 
can increase or decrease an individual’s risk of developing a disease. GWAS studies are 
conducted using data form tens of thousands of individuals 50. The AlzGene database is an 
open access resource that collates potential AD susceptibility genes and performs 
systematic meta-analysis with available data 51. 
The gene encoding apolipoprotein E (apoE) is the highest ranked in the database with 
numerous case-controlled studies conducted across ethnic groups. ApoE is produced in the 
brain by neurons and astrocytes. It has roles in mobilisation of cholesterol during neuronal 
growth and after injury 44. There are three main isoforms of apoE: apoE2, apoE3, and apoE4 
encoded by three alleles of the APOE gene: APOEε2, APOEε3 and APOEε4. Many studies 
have shown an association between the ε4 allele and an increased risk of developing late 
onset AD. The presence of an apoE4 allele is thought to accelerate disease development for 
a number of reasons, one of which may be causing increased deposition of Aβ by 
modulating its protein metabolism, aggregation, and deposition 52. APOEε4 increases the 
risk of AD in a gene-dose dependent manner: 20% of non-carriers have AD, ~45% of 
heterozygotes develop AD and over 90% of those homozygous for APOEε4 develop AD52, 53. 
Since the discovery of APOE, further risk genes have been identified including those 
involved with inflammation (e.g. CLU, ABCA7) and synaptic functioning (e.g. PICALM, 
CD33) 50. Next generation sequencing can sequence whole genomes at high throughput 
leading to the discovery of rare genetic variants 50. TREM2 has been identified with an effect 
size similar to that of APOE ε4 in association with late-onset Alzheimer’s disease. TREM2 is 
expressed on microglia and is thought to have a role in immune response 54. GWAS and 
next generation sequencing are powerful tools for identifying risk genes, though the 
challenge of locating the variants directly involved in AD pathogenesis remains.  
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1.1.1.3 Amyloid cascade hypothesis 
The amyloid cascade hypothesis was first proposed in 1992 16, and updated in 2002 17 and 
2016 55. This is the leading hypothesis for the development of and, as a result, has become 
the focus of much AD research. The hypothesis states that the deposition of Aβ peptide is 
the cause of AD. It is then hypothesised that NFTs, cell loss, vascular damage and dementia 
following as a direct result of Aβ deposition. A driver behind the amyloid hypothesis is that 
mutations in the APP and PSEN genes cause AD, present with amyloid plaques and 
intraneuronal NFTs 56. In contrast, mutations in MAPT cause a tauopathy but no amyloid 
plaques. This indicates that APP, and therefore Aβ, is further upstream in disease 
pathogenesis  32.  
1.1.2 Vascular dementia 
VaD is dementia that results from damage caused by reduced oxygenation of the brain as a 
consequence of systemic or cerebral vascular disease. VaD encompasses a group of 
conditions that together make up the 2nd largest cause of dementia 57. The term vascular 
cognitive impairment (VCI) has more recently been used to describe a broader range of 
cognitive impairment associated with cerebrovascular disease, ranging from vascular 
cognitive impairment, no dementia (VCIND)/mild VCI to VaD as the most severe form.  
There are several subtypes of VCI that each possess distinct clinical and pathological 
features. Subtypes of VaD include: cortical VaD (multi-infarct dementia, post-stroke VaD), 
subcortical VaD (small-vessel dementia, Binswanger’s disease, subcortical ischaemic vessel 
disease) and strategic infarct dementia 58.  
Reduction in blood flow leads to reduced oxygenation of the brain. The combination of 
reduced oxygen levels and impaired clearance of H+ ions causes neurons and glial cells to 
degenerate, leading to the onset of symptoms. Clinical signs of VaD vary according to the 
subtype of VCI responsible, though symptoms can include memory impairment, 
dysexecutive syndrome, communication difficulties and a range of psychological symptoms. 
VaD is commonly diagnosed according to the NINDS-AIREN criteria 59. The clinical history 
and examination, including assessment of cardiac risk factors, measurement of blood 
pressure and other aspects of cardiovascular function, are combined with results from 
cognitive testing to reach a diagnosis. 
There are currently no drug treatments licenced for use specifically in VaD. Typically, 
treatment plans focus on controlling cardiovascular risk factors, such as diabetes, cigarette 
smoking and high blood pressure 6. Treating VaD with AChE inhibitors and memantine has 




There are a limited number of autosomal dominant gene mutations that can cause VaD. 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL) is the most common form of inherited stroke and VaD. Patients with CADASIL 
exhibit similar symptoms and neuropathology to those with SVD but have an earlier age of 
onset. The mutation for CADASIL occurs in the gene encoding the Notch3 receptor on the 
smooth muscle of blood vessels61. These mutations alter the extracellular domain of the 
Notch3 receptor which causes accumulation of the Notch3 cleavage product in small 
arteries. Mice engineered to express CADASIL mutations have been used as a model of 
VaD 62.  
1.1.2.2 Neuropathology 
Atherosclerosis, small vessel disease (SVD) and CAA are the three main pathologies the 
contribute to VCI and VaD (hereafter the abbreviation VaD is used to encompass both VCI 
and VaD). Atherosclerosis effects large to medium blood vessels that supply blood to the 
brain, such as those of the circle of Willis. Atherosclerotic plaques form in blood vessels due 
to the deposition of cholesterol, and can thombose, fibrose, calcify or expand by 
inflammation and/or haemorrhage to narrow the vessel lumen. This directly reduces blood 
flow 63 and can also lead to embolism or dissection. 
SVD is the most common cause of pathology underlying VaD 64. SVD encompasses 
degenerative changes in the vessel wall of arterioles, capillaries and venuoles 65. Arterioles 
are affected by arteriolosclerosis where deposition of cholesterol can lead to narrowing of 
vessel lumen and hardening of vessel walls. In addition, capillary damage is probably an 
under-recognised contributor to SVD in dementia 66. SVD manifests in the subcortical white 
matter, leaving cortical vessels unaffected 63. CAA has been described above (1.1.1.1.2) and 
presents in approximately 10% of VaD cases 64.  
Atherosclerosis, SVD and CAA can all lead to destructive lesions within the brain, including 
infarcts, white matter lesions and haemorrhages. Atherosclerosis is commonly associated 
with large infarcts. SVD can produce multiple pathologies including white matter infarcts 
(typically lacunar infarcts) and intracerebral haemorrhages, often deep within the basal 
ganglia. CAA predominantly causes more superficial lobar haemorrhages 63. 
Diagnosis of VaD is challenging due to the diverse cerebrovascular pathologies that can be 
associated with the disease and the absence of specific neuropathological findings 64. The 
diagnosis of ‘pure’ VaD is made when a spectrum of vascular abnormalities are present 
without significant coexistent neurodegenerative pathologies in a person with dementia. 
However, this diagnosis of VaD by exclusion captures only a minority of people whose 
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dementia is associated with vascular brain damage 64, the contribution of which is probably 
markedly under-recognised. 
1.1.3 Cerebrovascular aspects of AD 
Atherosclerosis was observed in Alois Alzheimer’s first report of AD and vascular 
abnormalities are once again a focus of attention in AD research 67. There is growing 
evidence that vascular dysfunction has a role to play in the pathogenesis of AD.  
1.1.3.1 Risk factors 
Numerous epidemiological studies have highlighted links between cardiovascular factors 
and the development of dementia. Risk factors for cardiac disease are also risk factors for 
dementia, these include hypertension, tobacco smoking, type 2 diabetes and stroke 68. Extra 
weight midlife has been correlated with earlier onset of dementia independent of other 
cardiovascular risk factors such as diabetes, hypotension and stroke 69. Those with cardiac 
risk factors also exhibited more severe tau pathology and CAA accumulation 70. Together 
with epidemiological studies, combined GWAS and pathway analysis has identified genetic 
links between cardiovascular disease pathways and AD 71. 
1.1.3.2 Cerebral blood flow 
Reduction in cerebral blood flow (CBF) is a defining pathological process in VaD and is 
thought to contribute to the pathology and exacerbate clinical manifestations of AD 72. CBF is 
regulated by local neuronal activity and metabolism through a process known as 
neurovascular coupling. The pial and intracerebral arteries and probably also the capillaries 
control the local increase in CBF that occurs during brain activation – known as functional 
hyperaemia.  
Reduced CBF results in a decrease in oxygen concentration in the brain and a chronic 
reduction in perfusion can result in cell death. Mild hypoperfusion negatively affects protein 
synthesis, required for long-term potentiation (LTP) and therefore alters synaptic plasticity 
and memory formation 42. More severe CBF reduction can affect adenosine triphosphate 
(ATP) synthesis reducing the ability of neurons to form action potentials 73. 
Blood flow and oxygenation are reduced in the cerebral cortex and underlying white matter 
in AD 74. This has been shown through imaging studies using arterial spin labelling 75, 76 and 
via measuring fluorodeoxyglucose (FDG) uptake in the brain as a measure of blood flow 
(FDG is taken up by neurons in amounts directly proportion to their blood supply, but not 
then metabolised by glycolysis) 77. Hypoperfusion has also been shown in post-mortem brain 
tissue, using molecular markers, including VEGF 78, 79. CBF is reduced before cognitive 
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decline or brain atrophy 74, 80 and is associated with biochemical and MRI evidence of tissue 
damage 81, 82. 
Reduced CBF and cerebrovascular dysfunction can increase the accumulation of toxic brain 
metabolites including Aβ 83 84. This has been attributed to reduced clearance combined with 
increased APP production 85 via the γ secretase pathway 42 86 and HIF1α-mediated 
transcriptional increase in β-secretase expression 87. 
1.1.3.3 Vasoconstriction 
Together with CAA and SVD, the narrowing of blood vessels in AD appears to be 
compounded by an increase in molecular factors that cause vasoconstriction. Aβ itself, in 
addition to its role in causing CAA, can lead to vasoconstriction. This finding has been 
replicated in murine models overexpressing APP 88, 89. Endothelin 1 (EDNI) is a potent 
vasoconstrictor; in post-mortem human brain the levels of EDNI was found to be elevated in 
AD compared to controls 79, 90. Angiotensin II (AngII) is another vasoconstrictor whose levels 
are significantly elevated in the post-mortem AD brain 91. Nitric oxide produced by 
endothelial cells can signal smooth muscle to relax, therefore mediating vasodilation of blood 
vessels. In AD, nitric oxide signalling is impaired by Aβ, this has been shown in vitro 92 and in 
vivo 93. Finally, there is a reduction in cholinergic innervation of cerebral vessels which is 
likely to cause vasoconstriction. ACh is a potent vasodilator, so a reduction in the availability 
of this ligand would result in vasoconstriction and reduced CBF. The use of AChE inhibitors 
to treat AD by prolonging the action of ACh may indeed provide therapeutic benefit by its 
action on the cerebral vasculature 94, 95. 
1.1.3.4 Blood-brain barrier 
The BBB is a formed by specialised endothelial cells that line the blood vessels at the 
interface of the circulatory system and the CNS. The cells are joined by tight junctions to 
form an interface that limits the entry of red blood cells, leukocytes and components of 
plasma to the brain and regulates the entry of nutrients and metabolites. Pericytes, 
astrocytes and neurons, together with endothelial cells work to control blood flow, maintain 
the integrity of the BBB and regulate the clearance of metabolites, including potentially toxic 
molecules such as Aβ 73. The maintenance of an intact BBB is essential for healthy neuronal 
function. The BBB can be disrupted by a number of pathological conditions including stroke, 
certain pathogens and AD as well as an increase in angiogenic factors such as VEGF. The 
dysfunction and breakdown of the BBB allows infiltration of immune cells, large molecules 
such as fibrinogen and ions, and affects clearance from the brain 96. The results can include 
neuroinflammation, neuronal dysfunction, and eventually, neurodegeneration.  
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BBB breakdown has been demonstrated in several post mortem studies of AD 37. Magnetic 
resonance imaging (MRI) studies have demonstrated BBB permeability in cognitively normal 
individuals at risk of AD 97, AD patients 98, 99 and carriers of APOEe4 98, 100. The levels of tight 
junction and adherens proteins are known to decrease in AD and the age-dependent loss of 
pericytes in mice has been shown to lead to BBB dysfunction, neurodegeneration and 
cognitive decline 73. AD patients and animal models have also shown reduced Aβ clearance 
from the brain 73, 101. 
1.1.3.5 Blood vessel density and angiogenesis 
There is strong evidence that capillary density decreases with age in animal and human 
brain 102. Studies have also reported a decrease in capillary density in AD. This includes 
decreases of up to 16% with age matched controls 102. 
It has been hypothesised that AD is caused by an increase in blood vessel density at least in 
the early stage of disease. In one study the length of blood vessels was measured in the 
hippocampal regions of control, AD, VaD and post-stroke post mortem tissue 103. The length 
density of vessels in the CA1 region of the hippocampus was found increased in AD 
compared to control whereas the vessel diameter was reduced in AD and VaD samples 103. 
This implies that there may be increased angiogenesis in response to reduced CBF in AD 
though this increase could be a result of tissue atrophy in the hippocampus in AD. The 
decrease vessel diameter is likely to be due to increased vasoconstriction in AD and VaD as 
described in 1.1.3.3. Despite a possible increase in vessel density, blood vessels in AD and 
VaD appear less effective at perfusing brain tissue. 
Another study of post-mortem tissue showed that though overall brain mass was reduced 
capillary density was not reduced in AD compared to control 104. However, there was an 
increase in string capillaries, in AD compared to control groups indicating that 
cerebrovascular may be dysfunctional in AD. String capillaries are caused by a collapse of 
functional capillaries following reduced CBF and are not able to carry blood flow 105.  
1.2 VEGF 
The VEGF superfamily consists of 7 members with structural and functional similarities but 
different physiological functions. In mammals, the VEGF family comprises four homologues 
(VEGF-A, -B, -C and -D) and placental growth factor (PlGF)106. Structurally similar VEGF-E 
is found in parapoxvirus and VEGF-F exists in snake venom 107. VEGF-A, -B and –C and 
PlGF have been described in the human nervous system. Each form of VEGF can bind to 
and activate tyrosine kinase receptors (VEGFR1, VEGFR2 and VEGFR3) and numerous co-
receptors. This thesis focuses on VEGF-A and two of its tyrosine kinase receptors, VEGFR1 
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and VEGFR2. The interactions between the VEGF-A, -B and -C and their tyrosine kinase 
receptors summarised in Figure 1-3. 
1.2.1 VEGF-A 
VEGF-A, hereafter referred to as VEGF, is a homodimeric glycoprotein comprised of two 
subunits to form a protein of approximately 40 kDa 107. VEGF expression is induced by 
hypoxia. Hypoxia allows stabilisation of hypoxia inducible factors (HIFs) which bind to the 
hypoxia response element on the VEGF-A promotor resulting in VEGF transcription 107.  
Transcription of the human VEGF-A gene results in the production of 9 mRNA isoforms: 111, 
121, 145, 148, 162, 165, 183, 189 and 206 108. These are formed by the alternate splicing of 
exons 6 and 7 with the numbers representing the number of amino acids in the resulting 
protein 109. Isoform 121 is freely diffusible while 186 and 206 are nearly completely 
sequestered in the extracellular matrix. VEGF165 has intermediate properties with 50% freely 
diffusible and 50% in the extracellular matrix 109. The most commonly expressed isoforms 
are 121, 165, 189 with VEGF165 being the most well studied 110 111. There are two families of 
VEGF-A isoforms: VEGFxxxa and VEGFxxxb. VEGFxxxb is formed by the alternate splicing of 
terminal exon 8 of VEGF-A and is described in more detail in 1.2.1.2 112, 113.  
Figure 1-3 The interaction between VEGF-A, -B and C and their tyrosine kinase receptors in 
the nervous system. VEGF-A binds to VEGFR1 and VEGFR2, as well as the soluble form of 
VEGFR1, sVEGFR1. VEGF-A weakly binds to sVEGFR2. VEGF-B binds only to VEGFR1 and 
sVEGFR1. VEGF-C binds to VEGFR2, sVEGFR2 and VEGFR3. 
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VEGF acts through its receptors on the cell surface and soluble receptors in the cytoplasm 
as well as via co-receptors. These include tyrosine kinase receptors VEGFR1 and VEGFR2 
(shown in Figure 1-3) and co-receptors, such as neuropilin 1 (NRP1) and 2 (NRP2). In all 
VEGF-A variants exons 2–5 determine the specificity for VEGFRs while exons 6 and/or 7 
and 8 determine co-receptor binding. VEGFs can simultaneously bind two distinct receptors 
such as VEGFR2 and co-receptors, such as neuropilins, even when those receptors are 
expressed separately on adjacent cells 114. 
VEGF-A is by far the most thoroughly investigated subtype of VEGF in health and disease. 
First discovered as a lymphatic factor 115, VEGF is most well known in relation to 
angiogenesis. Expressed in development, it is vital for the correct formation of the vascular 
system as illustrated by the finding that heterozygous VEGF knock-outs die in utero 116, 117. 
VEGF and its receptors have also been heavily studied in pathological angiogenesis, 
particularly in relation to tumour development 118-120. More recently new roles for VEGF within 
the nervous system have emerged. VEGF is involved in neuroprotection and neurogenesis 
in the hippocampus. VEGF is also a modulator of inflammation and astrocyte proliferation 
121. 
1.2.1.1 Other VEGFxxx isoforms 
1.2.1.2 VEGFxxxb 
This VEGF subtype is formed from a splice variant that causes a change in the 6 terminal 
amino acids of the protein. As a result, the VEGFxxxb family has the same number of amino 
acids as VEGFxxxa but has a different biological role. Due to the difference of only the 6 
terminal amino acids, detection can prove difficult 112, leading to debate over the existence of 
VEGFxxxb isoforms 111. To date three members of the VEGFxxxb family have been identified: 
VEGF165b, VEGF121b and VEGF186b 122-124. 
VEGF165b isoforms have anti-angiogenic actions, opposing the actions of VEGF165a 112, 113 
and investigation has revealed VEGF165b phosphorylates VEGFR2 in a different way to 
VEGF165a 109. The ratio of these subtypes may prove important in disease as indicated by 
one study that measured VEGF165a and VEGF165b expression level in human lung biopsies 
and found significant changes in subtypes between control and disease tissue 109. There has 
been one published investigation of the VEGFxxxa and VEGFxxxb subtype levels and 
distribution in the CNS 125. VEGFR165b was identified by immunohistochemistry and strongly 
expressed by neurons in the hippocampus and expressed in a small number of neurons 
throughout the cortex 125. VEGFR165b was estimated to make up to 45% of total VEGF in the 




To complicate the VEGF story further, another variant was identified by Eswarappa et al 
(2014) 126. VEGF-Ax was first identified in mammalian endothelial cells, including human 
umbilical vein endothelial cells (HUVECs), and immunofluorescence confirmed VEGF-Ax 
present in human brain [75]. VEGF-Ax has also been shown to be altered in disease states 
[75].  
The VEGF-Ax (‘x’ standing for extension) variant has a unique 22 amino acid C-terminus 
extension in comparison to VEGF165. VEGF-Ax is formed by programmed translational read-
through of VEGFA mRNA. In normal translation, the stop codon prevents translation of any 
sequence following it. In programmed translational read-though, a cis-acting sequence lies 
downstream of the stop codon and ‘programmes’ read-through, distinguishing the process 
from translational error. In the case of VEGF-Ax, an RNA segment following the stop codon 
encodes the peptide extension of VEGF-A and acts as a cis-acting regulatory element 
driving the post-translational read-through 126. 
VEGF-Ax was initially reported to have an anti-angiogenic effect 126, though a recent report 
from Xin et al (2016) contradicted this finding 127. In work conducted on endothelial cells, 
VEGF-Ax administration was reported to reduce migration, proliferation and tube formation. 
This was reported to be due to VEGF-Ax binding to VEGFR2 at a similar affinity to VEGF but 
not to the co-receptor NRP1. It was also found to activate the non-canonical pathway of 
VEGFR2 signalling, a finding leading to the hypothesis that it acts as a decoy ligand 126, 128. 
In the later study, VEGF-Ax was found to stimulate endothelial cell migration, angiogenesis 
and permeability and induce VEGFR2 receptor phosphorylation 128. In agreement with 
Eswarappa et al. (2014), VEGF-Ax was found to be less potent than VEGF, consistent with 
its inability to bind to NRP1126. Further work is needed to establish the function of this 
isoform in the brain.  
1.2.1.4 VEGF-B 
VEGF-B binds only to VEGFR1 and NRP1 106. Two isoforms of VEGF-B have been 
described in humans, VEGF-B167 and VEGF-B186, formed by alternative splicing of the gene, 
VEGFB, 129. Unlike VEGF, VEGFB knock-out mice are born healthy, indicating that VEGF-B 
is not essential for development under normal conditions 129. VEGF-B does not optimally 
rotate VEGFR1, like PlGF, so is a weaker activator of signalling 130. VEGF-B may be more 
relevant to angiogenesis under pathological conditions 106. VEGF-B was found to have a 
detrimental effect in a mouse model of stroke. VEGF-B expression increased infarct volume 
by up to 40% when the middle cerebral artery was ligated in mice 131. 
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Although it probably only has a minor role in angiogenesis, it is thought that VEGF-B may 
have a more important role in the nervous system function. VEGF-B is highly expressed in 
murine CNS development, where VEGF-B mRNA levels were higher than VEGF-A 132. 
VEGF-B has been identified in cortical neurons, spinal motor neurons and retinal ganglion 
cells 129. VEGF-B has a role in adult neurogenesis. VEGF-B deficient mice were given 
VEGF-B and neurogenesis returned to wild type levels 133. VEGF-B is also neurotrophic, 
promoting the survival of neurons by acting on VEGFR1. ALS mutant mice lacking VEGF-B 
experience more severe motor neuron neurodegeneration 134.  
1.2.1.5 VEGF-C 
VEGF-C has a major role in lymphogenesis 135 but also has roles in the nervous system 
including angiogenesis, neuronal and oligodendrocyte development 136, 137. VEGF-C acts via 
VEGFR2, VEGFR3 135 and coreceptor, NRP2 106. The sVEGFR2 isoform is an endogenous 
antagonist for VEGF-C actions, binding and limiting the bioavailability of the ligand 106. 
VEGF-C, acting through VEGFR3, is essential for lymphogenesis but is also required for 
coordinating tip cell sprouting in new blood vessels. VEGF-C is produced by macrophages 
and promotes vessel sprouting via VEGFR3 138.  
In the nervous system VEGF-C regulates neural cell development via VEGFR3 138. VEGF-C 
also regulates expansion of oligodendrocyte precursor cells (OPCs) and neural progenitors 
136. Mice deficient in VEGF-C have selective loss of OPCs from optic nerve 136.  
1.2.2 VEGF receptors 
1.2.2.1 VEGFR1 
VEGFR1 is able to bind VEGF-A, VEGF-B (Figure 1-3) and PlGF 139. Membrane-bound 
VEGFR1 (mbVEGFR1) has an extracellular domain with 7-immunoglobulin like loops, a 
short transmembrane domain and an intracellular tyrosine kinase domain. VEGFR1 is mostly 
present as a homodimer. VEGFR heterodimers have been discovered, though their 
physiological function remains unknown 129. VEGFR1 shares 40.3% total sequence 
homology with VEGFR2. Despite the kinase domain being the most highly conserved 
between receptors, the VEGFR1 kinase is impaired 125140126. The level of phosphorylation 
catalysed by VEGFR1 tyrosine kinase is low and only detectable in models that overexpress 
the receptor 107. VEGFR1 is expressed in response to hypoxia as the promotor region 
contains a 40bp hypoxia response element, including the HIF binding site. 
VEGFR1 was initially thought to be expressed only on vascular endothelium but has now 
been identified throughout the body 109. In the vascular system VEGFR1 has a direct role in 
endothelial cell migration 106. In the brain VEGFR1 expression has been observed in cultured 
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microglia 141, by immunohistochemistry in microglia in human brain 142 and in developing and 
adult neurons 110. There is debate over the expression of VEGFR1 by astrocytes (Chapter 
3).  
VEGFR1 was hypothesised to act as a decoy receptor to prevent the over activation of 
VEGFR2. This was based on evidence that VEGFR1 lacking a tyrosine kinase domain is 
sufficient for normal development and angiogenesis 143 and VEGFR1 possesses a higher 
binding affinity for VEGF than VEGFR2 129. This view has been challenged as VEGFR1 
appears important in postnatal angiogenesis, neuroprotection and immune cell migration. It 
has been demonstrated that VEGFR1 and VEGFR2 both play distinct roles in signal 
transduction in endothelial cell models 144. VEGFR1 is upregulated in certain pathological 
conditions such as hypoxia and malignancy, so much so that it may become the dominant 
signal transducer 145.  
The VEGFR1 gene, FLT1, produces at least 9 splice isoforms that transcribe proteins with 
different cellular localisations and properties. VEGFR1 splice isoforms can be membrane 
bound (mbVEGFR1), soluble (sVEGFR1) and intracellular (iVEGFR1), as summarised in  
Table 1-1 and Figure 1-4. sVEGFR1 is described in detail below (1.2.2.1.1). Four isoforms of 
iVEGFR1 have been identified. iVEGFR1 isoforms possess the intracellular domains 
including one or two kinase regions and the c terminal tail. They were first identified in 
cancer cell lines and can activate Src signalling pathways 146. There have been no 
investigations into iVEGFR1 in the nervous system to date.  
1.2.2.1.1 sVEGFR1 
sVEGFR1 receptor negatively regulates VEGF binding 147. sVEGFR1 has the highest 
binding affinity for VEGF of any of its receptors and accounts for more than half of vascular 
endothelial bound VEGF receptor sites 148. It should be noted that many studies focus on 
VEGF-A as the only ligand for sVEGFR1 but sVEGFR1 is also able to bind VEGF-B and 
PlGF which are also present in the nervous system 149.  
sVEGFR1 isoforms exist in monomeric (110) and dimeric forms (220 kDa)149 both of which 
are also detectable when bound to VEGF resulting in a band at higher molecular weights 
(~140 and ~240 kDa respectively) 147, 150, 151. To date four soluble isoforms of VEGFR1 have 
been reported. sVEGFR1 isoforms have Ig-like domains but do not possess any 
transmembrane and cytoplasmic regions (Figure 1-4). Changes in nomenclature have made 
identification of isoforms in the literature challenging. The sVEGFR1 isoforms described are 
summarised in Figure 1-4 and  
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Table 1-1. sFlt_v1 was discovered first by Kendall et al (1993)147 and is commonly referred 
to as sVEGFR1. sFlt_v2, otherwise known as sFlt-14 or sFlt1_e15a, was discovered by 
Thomas et al. (2007) 152. sFlt_v2 has a predicted molecular weight of 82 kDa and is 
observed around 135 kDa but has been reported at other molecular weights from 95-135 
kDa due to varying glycosylation states 153-155. sFlt1_v2 has been found expressed up to 
600x more than other sVEGFR1 subtypes in placenta 156. sFlt_v3 differs from sFlt_v2 by 
alternate splicing of exon 15 leading to its alternative name, sFlt_e15b 153, 157, 158. sFlt_v4 was 
first discovered by Jin et al. (2008) 159 and then confirmed by Thomas et al. (2009)160. 
sFlt_v4 possesses a distinct c-terminal sequence159. Overall the regulation of sVEGFR1 
isoforms appears to be tissue and disease specific with the molecular details still being 
uncovered 151, 161.  
In addition to alternative splicing there is increasing evidence of sVEGFR1 production via 
proteolytic cleavage. First reported by Cai et al. (2006) in endothelial cells 162 cleavage of 
mbVEGFR1 released an 80 kDa c-terminal fragment intracellularly, the cleavage was found 
to be dependent on γ-secretase 163, 164. Cleavage is dependent on the VEGFR1 c-terminal 
remaining intact and VEGFR1 being present as a homodimer rather than a heterodimer with 
VEGFR2 165. This cleaved version was found in the conditioned media of cells at 130 kDa 164, 
165. The cleaved sVEGFR1 was shown to have the same antagonist action as the splice 
variant of VEGFR1 164. The cleavage and intracellular trafficking of receptor tyrosine kinases 
via proteolytic cleavage has now been reported in at least 10 receptor tyrosine kinase 
subfamilies and has been reviewed in further detail 166.  
When measuring the level of sVEGFR1, the relative abundance of sVEGFR1 appears to be 
tissue- and condition-specific. In HUVECs, sVEGFR1 transcripts have been reported to be 
1.5–2.5-fold more abundant than VEGFR1. In cytotrophoblasts, a cell type specific to the 
placenta, sVEGFR1 transcripts are 250-fold more abundant than VEGFR1 160. Lack of 
consistency in reporting sVEGFR1 protein level has been documented by Wu et al. (2010) 
149. The variability in reported sVEGFR1 levels may be due to differing protocols and sample 
processing as well as tissue heterogeneity 149. Relative abundance of sVEGFR1 in the 





Figure 1-4 VEGFR1 and sVEGFR1 protein and splice variants. mbVEGFR1 is a dimer with 
extracellular immunoglobulin (Ig)-like domains and intracellular tyrosine kinase domains. 
sVEGFR1 can be found as a dimer or a monomer. There are 4 splice variants that result in the 
production of four protein products with different c-terminal lengths and sequences. All 
sVEGFR1 isoforms contain exons 1-13. sFlt1_v1 consists of additional intron 13. sFlt1_v2 
consists of addition sequence in exon 14 and 15. sFlt1_v3 consists of additional sequence 
from exon 14 and 15. sFlt1_v4 consists of additional sequence from intron 14. Figure adapted 
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Table 1-1 VEGFR1 isoforms. The VEGFR1 gene produces at least 9 splice isoforms that transcribe proteins with different cellular localisations and 
properties. The table presents the membrane bound isoform, 5 soluble isoforms and 4 intracellular isoforms. Aliases for each isoform are 
presented. NCBI nucleotide and protein reference sequence numbers are provided where available. Primers used for qPCR and antibody used in 




VEGFR2 is also known as kinase domain receptor (KDR) and previously as fetal liver kinase 
1 (Flk1). Both VEGF and VEGF-C act on VEGFR2 (Table 1-2) but it is the effects of VEGF-A 
that are the most thoroughly studied in the nervous system. Like VEGFR1, VEGFR2 is 
formed of a 7-immunoglobulin extracellular domain and predominantly forms homodimers 
129. VEGF binds to the extracellular domain of VEGFR2 with an affinity approximately 10-fold 
lower than that of VEGFR1. Ligand binding results in receptor dimerization and 
phosphorylation. VEGFR2 has a highly active kinase region VEGFR2 able to activate 
numerous downstream pathways, described in more detail in section 1.2.2.3 168 107. The 
VEGFR2 promotor is not directly regulated by hypoxia but by VEGF binding. 
VEGFR2 is known to form heterodimers with VEGFR1 and VEGFR3 130, 169. Signalling of 
heterodimers is still being elucidated and the extent of heterodimerisation in the nervous 
system is not known 130.  
VEGFR2 was first identified as a major regulator of angiogenesis 170 and is now known to 
stimulate migration, proliferation and survival of various neural cell types as well as 
mediating vascular permeability 129, 168. Disruption of the VEGFR2 gene in development does 
not impair nervous system development or viability, suggesting that it is not essential for 
neuronal or glial development 110.  
1.2.2.2.1 sVEGFR2 
A soluble form of VEGFR2, sVEGFR2, has been discovered in humans. sVEGFR2 has a 
poor affinity for VEGF-A, although it binds with a higher affinity to VEGF-C. Unlike the 
complex splice variants of sVEGFR1, only two isoforms of sVEGFR2 have been identified 
and are detailed in Table 1-2. sVEGF2 is thought trap VEGF-C in the cytoplasm acting as a 
negative regulator for lymphogenesis 106. This mechanism could also regulate VEGF-C 
activity in the CNS. sVEGFR2 has been reported as being present on astrocytes 171, though 





Table 1-2 VEGFR2 isoforms. The VEGFR2 gene produces at least 3 splice isoforms. The table presents the membrane bound isoform and 2 soluble 
isoforms. Aliases for each isoform are presented. NCBI nucleotide and protein reference sequence numbers are provided where available. Primers 
used for qPCR and antibody used in this work are provided. Predicted and observed molecular weights are provided. 
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1.2.2.3 Downstream signalling 
The binding of VEGF to VEGFR2 results in the activation of intracellular signalling pathways. 
Numerous phosphorylation sites have been identified on VEGFR2 kinase domains, though 
only 6 have been fully validated in the full-length receptor 174. Phosphorylation at these sites 
triggers pathways that control endothelial survival, permeability, migration, and proliferation. 
Downstream pathways are summarised in Figure 1-5.  
Figure 1-5 VEGFR2 signalling. VEGFR2 receptor phosphorylation activates numerous 
downstream targets, including kinases, enzymes and transcription factors, that mediate cell 
survival, permeability, migration and proliferation.  
Non-VEGF ligands and mechanical forces such a shear stress can activate VEGFR2. These 
form the non-canonical pathway of VEGFR2 activation. These ligands activate the 
cytoplasmic tyrosine kinase Src which phosphorylates downstream VEGFR2 and initiates 
downstream signalling 130. As discussed in 1.2.2.1, iVEGFR1 can also activate Src 
signalling.  
1.2.2.4 VEGFR3 
VEGFR3 is also known as Fms-related tyrosine kinase 4 (FLT4). In contrast to VEGFR1 and 
VEGFR2, VEGF is not a ligand for VEGFR3. VEGF-C and VEGF-D bind to VEGFR3, the 
main role of which is to moderate lymphogenesis. VEGFR3 is expressed by blood and 
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lymphatic endothelial cells in development. VEGFR3 knock-out mice display defective blood 
vessel formation leading to embryonic lethality before the formation of the lymphatic system 
175. In adults VEGFR3 expression is usually confined to lymphatic endothelial cells, 176 
though the receptor can be re-expressed on vascular endothelium in certain situations. 
VEGFR3 has been found in vascular endothelium in tumour formation in human tissue 177 
and wound healing 178. VEGFR3 upregulation has also been shown to mediate angiogenesis 
in the absence of VEGF-VEGFR2 signalling in the retina via a notch-dependent mechanism 
179.  
VEGFR3 has been reported in cerebral vascular cells, neurons and astrocytes. The deletion 
of VEGFR3 from endothelial cells in the cerebral vasculature resulted in excessive sprouting 
and angiogenesis in the mouse hindbrain, indicating a role in angiogenesis, at least in 
development. VEGFR3 was found expressed in neurons and astrocytes via in situ 
hybridisation and double immunohistochemistry 180, 181 as well as by neuronal progenitors 136 
and oligodendrocyte precursors 181. In the developing nervous system VEGFR3 is reported 
to be present in the subventricular zone (SVZ), hippocampal gyrus, olfactory bulbs and 
cortex. Further investigation of VEGFR3 in the SVZ resulted in discovery of its role in 
neurogenesis on neural stem cells and astrocytes mediated by VEGF-C in mice 137.  
In contrast to the study of VEGFR2, much of VEGFR3 signalling is still being elucidated 130, 
176. NRP1 and NRP2 are both involved with VEGFR3 signalling at least in the lymphatic 
system 176. VEGF189a, VEGF-C and VEGF-D have been shown to modulate signalling of 
VEGFR3 positive receptors, which are thought to be VEGFR2-VEGFR3 heterodimers 130. 
VEGFR3 has also been reported to bind with VEGFR2 and vascular endothelial cadherin 
(VE-cadherin) to make a mechanosensory complex that responds to shear stress on 
endothelial cells 182, 183. 
1.2.2.5 Co-receptors 
1.2.2.5.1 Neuropilins 
NRP1 and NRP2 were originally discovered as receptors for semaphorins. They were later 
found to be co-receptors for VEGF-A, -B, -C, -D and PlGF 184. The receptors are single 
membrane-spanning glycoproteins with 3 extracellular domains: A, B and C. On NRP1, 
semaphorins bind to both domains A and B; members of the VEGF family only bind to B. 
Extracellular domain C is required for oligomerisation with VEGFR2. NRP1 and NRP2 bind 
VEGF165a, possibly VEGF189a but not VEGF121a 110. NRP1 has a high affinity for VEGFR1 and 
binds to VEGF-B and PlGF. NRP2 can bind to VEGF-C and PlGF 106, 130. 
Neuropilins enhance VEGF signalling by acting as co-receptors with VEGFRs. NRP1 and 
VEGFR2 co-localise in the presence of VEGF to enhance VEGFR2 phosphorylation and 
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signalling 129. Motifs on VEGFA exon 7 and 8 bind to NRP1 and NRP2, although with a 50 
fold stronger affinity to NRP1 130. Enhanced VEGF165a-mediated proliferation and migration 
was noted when NRP1 and VEGFR2 were co-expressed in the same cells 109. 
NRP1 is expressed on the endothelium of arteries. The deletion of NRP1 in development 
causes various vascular defects including impaired formation of the cerebral vasculature 110 
110. NRP2 is expressed on the endothelium of venous and lymphatic vessels. Following the 
deletion of NRP2 in development, embryos are viable 129.  
NRP1 can bind to VEGF without VEGFR2 and sequester it. In retinal neurons VEGF binds to 
VEGFR2 and NRP1 but in hindbrain neurons VEGFRs are not expressed and VEGF is 
sequestered by NRP1 130. VEGF can also signal directly through NRP1 without VEGFR2 138. 
The branchiomotor neuron cell bodies in the mouse brainstem are the only known neuronal 
cell type where NRP1 has been identified as the main receptor for VEGF 110 138. In addition 
to the membrane-bound NRP receptors, a soluble form of NRP1 (sNRP1) that binds VEGF 
has been identified in vivo 185 but there has been no investigation of this subtype in the CNS.  
Both NRP1 and NRP2 have been detected on adult neurons. NRP1 was co-expressed with 
VEGF on motor neurons and in axons of peripheral cells 186. NRP1 is upregulated on 
neurons and endothelial cells after CNS ischaemia 110. It has been difficult to determine the 
importance of NRP1 and 2 in VEGF signalling in the adult nervous system as they also act 
as receptors for the semaphorins. 
In a transgenic mouse model of AD, in situ hybridisation showed moderate intensity of NRP1 
expression in subcortical regions such as entorhinal, somatosensory and frontal cortices as 
well as hippocampal of transgenic mice and controls 187. As the mice aged, NRP1 was 
reported to be upregulated in the entorhinal cortex. Double immunofluorescence on VEGF 
and NRP1 protein showed them colocalised in endothelial cells and microglia in transgenic 
mice. NRP1 reported upregulated following middle cerebral artery occlusion and acute optic 
nerve injury 187. 
1.2.2.5.2 Heparan sulphate proteoglycans 
The heparan sulphate proteoglycans (HSPGs) are another group of proteins that act as co-
receptors for VEGF. HSPGs bind to heparin growth factors on the plasma membrane or in 
extracellular matrix. HSPGs, such as perlecan, can prolong the action of VEGFR2 signalling 
130. Other HSPGs, such as glypican, may have dual roles, both controlling VEGF localisation 




Angiogenesis is the process by which new blood vessels are formed from existing vessels. 
Adult vessels rarely form new branches but can respond to environmental cues such as 
hypoxia. Angiogenesis is highly regulated and controlled by several growth factors, of which 
VEGF is of major importance. VEGF is a major mediator of angiogenesis in the adult central 
nervous system. Sprouting angiogenesis is the predominant form of angiogenesis in adults 
and is described below 188. 
A hypoxic environment leads to the stabilisation of hypoxia inducible factors (HIFs). HIFs are 
regulated by oxygen-sensing domains. HIFs are regulators of angiogenesis due to their 
ability to activate multiple genes that mediate short and long-term adaptation to hypoxia 189. 
HIF consists of an α subunit and a β subunit. The α subunit can be one of three subtypes; 
HIF1α, HIF2α or HIF3α, any of which can combine with a constant HIF1β subunit. HIF1 
activates the transcription of VEGF 190 and PDGF 189. HIF-1α and HIF-2α are both able to 
induce VEGF expression by binding to the hypoxia response element (HRE) preceding the 
VEGF coding region. HIF2α stabilisation upregulates VEGFR1 188. 
Angiogenesis in response to hypoxia is presented in Figure 1-6. Upon VEGF stimulation, 
endothelial cells degrade the basement membrane and pericytes detach. This allows 
endothelial cells to migrate. VEGF/Notch signalling selects tip and stalk cells, and filopodia 
guide tip cells by sensing cues in the local environment 188. Tip cells fuse (not shown in 
Figure 1-6) and notch signalling leads to tip cell stabilisation. This is followed by lumen 
formation and the cells remodel in response to blood flow. Pericyte recruitment is stimulated 
by PDGF release and leads to vessel stabilisation and maturation. Successful angiogenesis 




1.2.4 VEGF in disease 
Disruption to angiogenesis can lead to disease. Aberrant angiogenesis has been heavily 
investigated in tumour formation and diabetic retinopathy, while reduced angiogenesis has a 
role in preeclampsia, diabetic neuropathy, stroke and amyloid lateral sclerosis (ALS) 191.  
Focusing on the nervous system, ALS is the first neurodegenerative disease to show clear 
involvement of VEGF and insufficient angiogenesis in disease pathogenesis. ALS is caused 
by the degeneration of motor neurons in the spinal cord, brainstem, and motor cortex 192. 
Oosthuyse et al (2001), showed that the deletion of the hypoxia response element in the 
VEGF-A promotor region led to motor neuron degeneration in mice 186. 60% of mice 
homozygous for the mutation died before birth and the remaining 40% displayed 
physiological and neuropathological signs of motor neuron degeneration 186. In humans, 
polymorphisms in the promoter region of the VEGF gene cause reduced VEGF expression 
which results in increased risk of developing ALS 193. Two main hypothesis were put forward 
to explain the role of VEGF in motor neuron degeneration: either there is reduced 
neurotrophic support from VEGF, or there is reduced vascular support due to a lack of VEGF 
which makes motor neurons more vulnerable to ischaemic insult 121. 
Figure 1-6 Angiogenesis in response to hypoxia. 1. A hypoxic environment leads to the 
stabilisation of HIF1 and the transcription of numerous proteins, including VEGF. VEGF 
stimulates endothelial cells to degrade the basement membrane and cause pericytes to 
detach. 2. VEGF acts via VEGFR2 to stimulate tip cell growth. 3. Tube formation occurs. 4. 
Vessel size is regulated by cross talk between VEGFR2 and Notch signalling. 5. PDGF 
stimulates pericyte attachment via its receptor PDGFR. Once the tissue is reperfused and 
adequately oxygenated, HIF is no longer stabilised and VEGF levels decrease.  
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Supporting the theory that the neurodegeneration is due to chronic hypoxia, mutant mice 
experienced lower baseline neural blood flow and had decreased capillary lumen size in 
skeletal muscle 186. Overexpression of VEGFR2 on motor neurons protected cells from 
SOD1 mutant protein (implicated in familial ALS) in vivo, although it is not clear if the effect 
was due to neuronal or glial actions 194. VEGF was regarded as a promising therapeutic 
target, and intracerebroventricularly delivered recombinant human VEGF165 reached a phase 
II clinical trial in ALS patients 195.  
1.3 VEGF in dementia 
1.3.1 VEGF as a biomarker 
VEGF has previously been identified as a potential AD biomarker. Higher VEGF levels were 
found in the plasma of AD patients when compared to control 196, while lower levels were 
observed in AD patient serum 197. VEGF levels in cerebrospinal fluid (CSF) have been 
reported increased 198 and unchanged 199 200 compared to control. VEGF was suggested as 
a prospective AD biomarker as levels of VEGF correlated with the MMSE scores in AD, but 
not with MMSE scores in other neurodegenerative diseases 199. VEGF levels were measured 
for the first time in VaD where they were found unchanged compared to control and AD 
CSF200. The levels of other members of the VEGF family and VEGF receptors have not been 
investigated in cognitively impaired subjects 37.  
1.3.2 VEGFA polymorphisms 
Due to the detrimental effect of VEGF disruption in ALS, polymorphisms in the promotor 
regions of VEGFA have been investigated in several types of dementia. A polymorphism is a 
variant in the gene which is common in the population. Variants in the gene can increase or 
decrease the risk of disease. 
VEGF promotor polymorphisms were identified as risk factors for VaD in one study 201. The 
study identified three variants after comparing VEGFA in 207 VaD and 207 controls. One 
polymorphism, -7C/T, in the 5- prime untranslated region (5’UTR) was associated with 
increased VaD risk. This polymorphism also interacted with two other variants in the 
promoter region and the three-prime untranslated region (3’UTR) to increase VaD risk 201. 
This study needs validating in other populations but suggests that VEGF could influence 
dementia risk. A VEGF promotor polymorphism was also identified as a risk factor in another 
form of dementia, frontotemporal dementia (FTD) [129]. 
In AD, there has been a debate in the literature over two VEGF promotor polymorphisms 
and relation to risk. Of the several polymorphisms described, -2578C/A and -1154G/A were 
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most commonly identified in studies on AD. Polymorphisms were previously reported to 
affect the activity and responsiveness of the promoter region and consequent expression of 
VEGF 202.  
Several studies have found evidence both for 196, 203, 204 and against 204 205 206 the association 
of these polymorphisms with disease. Two meta-analysis concluded that there was no 
overall link between the identified polymorphisms and AD 207, 208 though the polymorphisms 
may be associated with AD risk in an ApoE-dependent manner. There was a link identified 
between ApoE status and a risk variant for AD (-2578C/A polymorphism) and also a 
protective variant (-1154G/A). Caveats to the meta-analysis results, detailed in Liu et al. 
2013 208, include small sample sizes and the heterogeneous methods used between studies 
which may be masking effects. Overall it is hypothesised that any changes in the VEGF 
promoter activity will be minor 186.  
1.3.3 VEGF and BBB dysfunction 
VEGF is a known permeability factor. As BBB increased permeability has a probable 
detrimental effect in AD (1.1.3.4), the interaction between VEGF and this structure is an 
important consideration in the disease. VEGF derived from astrocytes was shown to 
increase BBB permeability in mice [29]. In the same study, VEGF induced VEGFR2 
signalling on endothelial cells resulting in disrupted expression of junction-forming proteins 
and BBB breakdown [29]. Thus, increased VEGF in the brain may have detrimental effects 
on the BBB in AD.  
The recognition of VEGF as a potent angiogenic factor has led to investigations into its 
possible therapeutic applications. However, the permeability effects of VEGF on the BBB 
may offset any potential benefit of VEGF treatment in the nervous system 209.  
1.3.4 VEGF in neurons and glia 
As has been noted, VEGF is expressed not just by endothelial cells but also by neuronal 
populations and glia.  
Most VEGF research in the nervous system has been conducted on neuronal populations. 
VEGF is expressed by neurons and has been specifically identified in CA1 pyramidal 
neurons in the hippocampus, in the olfactory bulb in pyramidal cells of the cortex and 
Purkinje cells of the cerebellum. VEGF is a neurogenic factor, though its exact role in the 
sub-processes of neurogenesis are yet to be elucidated. VEGF maintains the stem cell niche 
in the dentate gyrus and SVZ through its role in angiogenesis and glial cell proliferation. 
VEGF stimulates the migration of neuroblasts from their niche to a remote site. From the 
SVZ, neuroblasts travel along a vascular scaffold produced by VEGF-secreting astrocytes 
31 
 
which enhances migration. VEGF also has a role in neuroblast differentiation. The inhibition 
of VEGF signalling impairs maturation of olfactory bulb neurons derived from the SVZ 210 and 
application of VEGF enhanced neurite growth and survival in explanted neuronal cultures 
194. 
There is evidence that VEGF can modulate LTP, independent of its role in angiogenesis and 
neurogenesis. LTP describes the increase in synaptic strength that occurs after repeated 
stimulation of a synapse and is thought to be the mechanism behind learning and memory. 
VEGF upregulation increased neurogenesis, angiogenesis and LTP in the dentate gyrus of 
the adult mouse hippocampus 211. Blocking VEGF prevented LTP and impaired memory 
whilst there was no reduction in perfusion or neurogenesis in the mouse 211. This could be 
attributed to stimulatory and inhibitory effects of VEGF on ion channels surrounding the 
synapse, possibly due to the differing signal pathways of VEGFR1 and VEGFR2 210. 
Despite the abundance of work on the neuronal population, it is astrocytes that are the 
biggest producers of VEGF in the brain 212. Astrocytes are known to regulate angiogenesis in 
the CNS 213 119. VEGF-A induces astrocyte proliferation 121 194. In microglia, VEGF induces 
proliferation and increases chemotaxis 141 142.  
Pericytes are glial cells found surrounding capillaries in the brain, they have a key role in 
capillary blood flow and a key role in BBB maintenance. VEGF is known to be expressed in 
pericytes and they are reported to express both VEGFR1 and VEGFR2214, 215. VEGFR2 has 
also been shown to form heterodimers with platelet-derived growth factor receptor (PDGFR), 
in immature vasculature 216.  
VEGFR1 has a direct role in endothelial cell migration 106. VEGFR1 expression has been 
observed on cultured microglia 141, and by immunohistochemistry, on microglia in human 
brain 142 and on developing and adult neurons 194. There is debate over the expression of 
VEGFR1 on astrocytes (Chapter 3).  
1.3.5 VEGF in post-mortem human brain 
Examination of post-mortem AD brain has identified increased VEGF levels compared to 
age matched controls 212. More recently VEGF level was reported to be significantly 
increased in the parahippocampus in AD brain tissue compared to controls 78. In the same 
study an increase in VEGF was observed in regions of VaD brains but this was not 
significant. As there is known to be a reduction in blood flow in the AD brain it was 
hypothesised that VEGF is increased in response to chronically reduce tissue oxygenation. 
Thomas et al. (2015) used von Willebrand factor (vWF) as a surrogate measure of 
microvessel density and reported that levels of this factor were decreased in the 
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parahippocampal and frontal lobes despite increased levels of VEGF 78. This indicates that 
despite high levels of VEGF, angiogenesis in the AD brain is not increased, potentially 
interfering with the ability of the brain to compensate for cerebral hypoperfusion. 
There is substantial literature to support VEGF upregulation in conditions of acute ischemia 
in the brain - both in animal models and in human stroke. VEGF levels remain upregulated 
for up to 7 days after an ischaemic incident in the human brain 217 and in AD upregulation 
may be a permanent state. The effect of acute hypoxia on VEGFRs have also been studied, 
using animal models and explants, but little is known of the changes in VEGFRs in AD. 
One study does highlight increased microvessel density in transgenic AD mice and a small 
cohort of AD brains (n=4) when compared to control 218. The study measured the level of 
CD105, also known as endolin, by western blot and by IHC and found it increased in AD 218. 
However, the study was in a small cohort and endolin is induced by hypoxia so may not be a 
marker of new blood vessel formation219 and has been shown as a marker of microglia 
activity. The group also measured laminin by IHC which has in turn been shown to increase 
in AD 220 and may be subject to morphological changes that are known to occur to capillaries 
in AD 221. 
1.3.6 VEGF and AD pathology 
It has been proposed that Aβ acts as a ‘molecular sink’ for VEGF. VEGF was found to bind 
to Aβ with the same affinity as it binds to its own receptors and has been found sequestered 
in Aβ plaques 222. There is also evidence that Aβ induces expression of VEGF in vitro 223: 
Normal adult human astrocytes showed increased production of VEGF when exposed to Aβ 
in normoxic conditions. This provides evidence that increased VEGF concentration in AD 
brain may not be due to hypoxia only but may also be elevated as a direct effect of Aβ. 
There is also evidence that Aβ can directly activate HIF1α in vitro 224 though this has been 
disputed 225. The ability of Aβ to activate HIF1α, a transcription factor able to upregulate 
multiple genes including VEGF, would lead to a further increase in VEGF levels in the brain. 
Though increases in VEGF are beneficial for the formation of new blood vessels, chronic 
VEGF increases may lead to undesirable effects such as an increase in BBB permeability as 




Figure 1-7 Hypothesised effect of Aβ on VEGFR1 and VEGFR2 on endothelial cells in AD. In 
hypoxia increases in the number of VEGFR1 receptors and presence of VEGFR2 enable 
angiogenesis. In AD, with the presence of Aβ1-42, VEGF is bound to Aβ plaques reducing 
bioavailability of the ligand. Aβ1-42 may also bind to VEGFR2, which will prevent receptor 
activation by VEGF.  
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1.4 Hypothesis and aims 
1.4.1 Hypothesis 
There is disruption of VEGF receptor expression or function in AD. 
This follows on from previous findings from our research group showing that brain tissue is 
hypoperfused in AD using  molecular markers. Levels of vasoconstrictors such as endothelin 
1 (EDN1) 90, 226, ACE and AngII are elevated in the AD brain compared to control 91, 227. 
Increases in these molecules can cause vasoconstriction and therefore contribute to 
cerebral hypoperfusion. VEGF, a marker for hypoxia, was found upregulated in AD, and VaD 
brain, by our group61, 67. Following investigation in relation to microvessel density, it was 
found that although microvessel density increased with increasing VEGF in VaD, this was 
not the case in AD78.  
Despite high levels of VEGF microvessel density in the AD brain is not increased and the 
brain is unable to compensate for cerebral hypoperfusion. Disruption to the VEGF receptor 
system via alteration in receptor level, direct interaction with AD pathology or disruption of 
downstream signalling may explain the lack of VEGF induced angiogenesis. 
1.4.2 Aims 
[1] To examine the cellular localisation of VEGFRs in post-mortem parietal lobe tissue. 
[2] To measure the levels of VEGFR1 and VEGFR2 mRNA in the post mortem control and 
AD parietal lobe. 
[3] To measure the levels of VEGFR1 and VEGFR2 protein in the post mortem control, AD 
and VaD parietal lobe. 




Chapter 2 Materials and Methods 
2.1 Materials 
The details of chemical, equipment, software, common solutions, commercial kits and 
antibodies used can be found in Appendix 1-8. 
2.2 Human brain tissue 
2.2.1  Tissue acquisition 
Tissue was obtained from the Human Tissue Authority-licensed South West Dementia Brain 
Bank (SWDBB), University of Bristol, Southmead Hospital, UK. All work was conducted with 
local research ethics committee approval.  
Brains were removed within 72 hours of death. Brains were cut midsagittally and the left 
hemisphere sliced coronally and frozen at -80°C. The right hemisphere was placed in 10% 
buffered formalin for a minimum of 3 weeks. Blocks of frontal, mid-temporal, mid-parietal and 
occipital regions, midbrain, pons, cerebellum, vermis, medulla, basal ganglia and any 
macroscopically visible lesions were then cut and processed in a tissue processor before 
being embedded in paraffin wax. All brains had undergone routine histological assessment. 
Sections of tissue from each of the brain regions detailed above were stained with 
haemotoxylin and eosin (H&E) and immunolabelled with Aβ, tau and α-synuclein antibodies 
to allow the cellular morphology, Aβ plaques, neurofibrillary tangles, and Lewy body 
pathology to be examined by a neuropathologist.  
AD was diagnosed post-mortem by assessment of Aβ plaque and neurofibrillary tangle 
density in combination with information from clinical records indicating presence or absence 
of dementia, according to the CERAD criteria228 and also by the neurofibrillary tangle Braak 
stage method. As described in Chapter 1, it is rare to have a definitive diagnosis of AD prior 
to death due to the heterogeneity of dementia symptoms and the expense of neuroimaging. 
The CERAD criteria are a standardised, validated measures for the assessment of 
Alzheimer’s disease (AD) 229. This l assessment includes reviewing of clinical documentation 
and neuropathological examination of NFT density. Braak stages provide a purely 
neuropathological assessment of NFT progression. Briefly, NFTs begin in the transentorhinal 
region in stage I and are present in the entorhinal region and subiculum in stage II. NFTs 
then involve the limbic region and adjacent inferior temporal neocortex in stages III-IV. 
Finally NFTs are present all layers of the occipital and frontal neocortex in stages V-VI 30. All 
AD brains studied had a CERAD diagnosis of probable or definite AD with a Braak stage of 
III to VI. Control brains from the SWDBB were all from donors with no clinical history of 
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dementia and at post-mortem diagnosis there was no evidence of neuropathological 
abnormalities, limited or no plaques, and a Braak stage of III or less. 
Sections of cortical tissue were also examined to determine the severity of cerebral amyloid 
angiopathy (CAA) and graded using a method based on that of Olichney et al 230 and Ellis 
231. A score of 0 corresponded to vessels devoid of amyloid, a score of 1 to scattered 
deposition of amyloid in a few leptomeningeal or cortical blood vessels, a score of 2 to more 
widespread deposition of amyloid in vessels, and a score of 3 to severe and widespread 
amyloid deposition. 
The severity of small vessel disease (SVD) was scored in frontal, temporal, parietal and 
more recently the occipital regions of the brain. Paraffin embedded tissue was used to 
assess SVD on a 4-point semi-quantitative scale. SVD severity was rated on the following 
scale: 0 = normal vessel wall thickness, 1 = slightly increased thickness, 2 = moderately 
increased thickness, 3 = markedly increased thickness such that for many arterioles the 
diameter of the lumen was <50% of the outer diameter of the blood vessel 230, 231. CAA score 
was provided for the parietal cortex and white matter of control, AD and VaD cases. 
Frozen brain tissue was use for RNA extraction and protein studies. Formalin fixed paraffin 
embedded tissue (FFPE) tissue was used for immunohistochemistry and 
immunofluorescence.  
2.2.2  Cohort selection 
Control, AD and VaD cohorts were used. Tissue was taken from the parietal cortex and 
white matter case summarise in Table 2-1. 
Parietal cortex and white matter Control AD VaD 
N 36 50 19 
Age (years) Range 58 - 95 57 - 93 67 - 97 
Mean ± SD 80.1 ± 8.7 77.5 ± 8.1 82.9 ± 7.3 
Gender Female 11 26 9 
Male 25 24 10 
Post-mortem delay 
(hours) 
Range 3 - 67 4 - 85 20 - 85 
Mean ± SD 32.5 ± 16.3 31.6 ± 19.0 47.6 ± 19.0 
 
Table 2-1 Summary of the neuropathological and demographic features of control, AD and 
VaD. Details of cases are listed in Appendix 9 
FFPE sections of control and AD frontal lobe were used for VEGFR1 and VEGFR2 
immunohistochemistry. Details of cases can be found in the Appendix 10. 
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2.2.3 Brain tissue homogenisation 
One hundred mg of tissue was dissected from the desired region into a 2ml screw top tube 
with 5 x 2.3 mm ceramic beads (Stratech Scientific) and 1ml of desired lysis buffer. The 
tissue was homogenised at 6000rpm using the automated homogeniser (Precellys 24) for 2 
x 15 seconds. Samples were placed in the 4°C centrifuge for 15 minutes at 17000 g. 
Supernatant was removed and transferred to a new 1.5 ml tube and stored at -80˚C. 
2.3 Protein quantification 
Total protein concentrations of cell or tissue homogenates were determined using the Total 
protein kit (Sigma) according to the manufacturer’s instructions. Samples were thawed and 
diluted in 0.85% NaCl. Human brain homogenates were diluted 1:20 and cell lysate was 
diluted 1:5. Brilliant blue dye was diluted 1:5 in distilled water and 250 μl dye solution was 
then added to wells of a clear 96-well microplate for each reaction. 5 μl of diluted sample 
was added to the dye solution in duplicate followed by duplicates of blanks (5 μl of 0.85% 
NaCl) and protein standards (5 μl of 0.3 mg/ml; supplied). The samples were incubated for 2 
minutes before absorbance readings were taken. The results were blank corrected, and the 
protein concentration of samples was calculated, adjusting for the dilution factor. 
2.4 Western Blot  
2.4.1 Gel electrophoresis and transfer 
 12% Resolving gel (ml) Stacking gel (ml) 
Milli-Q water 3.3 6.8 
30% Acrylamide 4.0 1.7 
1.5M Tris pH 8.8 2.5 - 
1.0M Tris pH 6.8 - 1.25 
10% SDS 0.1 0.1 
10% APS 0.1 0.1 
TEMED 0.004 0.01 
Total 10 10 
Table 2-2 Composition of 12% resolving gel and stacking gels used for western blotting. 
Precast 7.5% and graduated 4-20% gels (Bio-Rad Laboratories) were used and 12% SDS 
gels were prepared as described in Table 2-2. Gels were positioned within the gasket and 
placed in the module tank (Mini-PROTEAN 3; Bio-Rad Laboratories) with 1x SDS running 
buffer. Cell lysate or tissue homogenate samples (30 μg), recombinant standard (1 ng) and 
ladder (5 μl) were loaded into the wells of the gel and the module was attached to the power 
supply. Separation of the denatured proteins by electrophoresis took place at 150V for 60 
minutes. The proteins were transferred to nitrocellulose membrane using an electrophoretic 
transfer cell (Mini Trans-Blot; Bio-Rad Laboratories). The gel, with the sheet of nitrocellulose 
(ThermoFisher Scientific) positioned on top, was arranged between two sheets of blotting 
paper and two fibre pads within the gel holder cassette. The cassette was positioned into the 
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transfer cell tank on ice with 1 L of pre-cooled 1x blotting buffer and an ice pack to keep the 
system cool during the protein transfer. The gels were blotted at 100V for 1 hour at room 
temperature. 
2.4.2 Protein detection 
All incubations took place at room temperature on a shaking platform unless otherwise 
stated. The transfer cell was dismantled and the membrane briefly washed with TBS-T. The 
membrane was incubated in blocking buffer for at least 1 hour or overnight at 4˚C. The 
membrane was washed in TBS-T (3 x 10 minutes) then incubated with primary antibody at 
an assay-dependent dilution/incubation time in appropriate antibody buffer solution. The 
membrane was washed again in TBS-T (3 x 10 minutes) and incubated with peroxidase-
labelled secondary antibody for 1 hour, then washed in TBS-T (3 x 10 minutes). ECL 
western blotting substrate (ThermoFisher Scientific) were added to the membrane according 
to the manufacturer’s instructions; a 1:1 dilution of reagents 1 and 2, for 3-5 minutes. 
Membranes were imaged using a chemiluminescent imager (Bio-Rad Laboratories) with 
ImageLab software (BioRad Laboratories). 
To re-probe the membrane antibodies were ‘stripped’ from the membrane after imaging. 
Membranes were washed with TBS-T then incubated with stripping buffer (ThermoFisher 
Scientific) for 10 minutes. The membranes were then washed with TBS-T (3 x 10 minutes) 
before proceeding to the blocking stage of the protein detection protocol. 
2.5 Dot Blot 
All incubations were at room temperature unless otherwise stated. 
Sample homogenates and homogenate standards were diluted to the desired concentration 
in TBS. The dot blot manifold (BioRad Laboratories) containing nitrocellulose membrane was 
assembled according to manufacturer’s instructions and vacuum tightened. With vacuum 
switched off and manifold exposed to air 100 µl of sample was added in triplicate to wells 
and left to filter through membrane for 1 hour. Serial dilutions of a homogenate standard 
were used to create a 7-point standard curve for each dot blot. 100 µl of TBS was added to 
blanks and unused wells. The manifold was disassembled and membrane briefly washed in 
TBS-T and placed in desired blocking solution for 1 hour. Primary antibodies were incubated 
overnight at 4˚C. Peroxidase-labelled secondary antibody was applied for 1 hour. Dot blots 
were developed with HRP substrate as for western blotting (2.4). The background adjusted 
volume was calculated using ImageLab software and relative values were each sample were 
calculated by interpolating from the standard curve. 
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2.6 Sandwich enzyme-linked immunosorbant assay 
Enzyme-linked immunosorbant assays (ELISA) were completed as per manufacturer’s 
instructions (R&D Systems, Abcam). All incubations were at room temperature unless 
otherwise stated. 
Clear 96 well plates (R&D Systems) were coated with capture antibody and left overnight. 
Wells were drained and tapped dry then filled with wash buffer, this was repeated 5 times. 
Wells were incubated with 200 µl of blocking buffer for 1 hour. Blocking buffer was drained 
and wells washed as previously. Recombinant standard and samples were diluted in PBS 
and 50 µl added to each well in duplicate. Blanks were filled with PBS. Samples were 
incubated for 2 hours then wells drained and washed. 100 µl of detection antibody was 
added to each well and incubated for 2 hours. After draining and washing, 100 µl of 
streptavidin-HRP was added to each well and incubated away from direct light for 20 
minutes. Following washing, 100 µl substrate solution added to each well and incubated 
away from direct light for 20 minutes. 50 µl of 2N sulphuric acid (stop solution) was added 
and the optical density determined immediately using a 450 nm filter on the plate reader. 
Readings were blank corrected and standard curve constructed and the protein 
concentration for each sample interpolated from the standard curve.  
2.7 Direct enzyme-linked immunosorbant assay 
Fifty µl of standard and sample were added to each well of a clear 96 well plate (R&D 
Systems) and incubated for two hours. The plate was washed 5 times with 0.05% PBS-T 
and tapped dry after the final wash. Each well was incubated with 100 μl of detection 
antibody for 2 hours. The plate was washed as previously described, and incubated with 100 
μl of biotinylated antibody in PBS, for 20 minutes and protected from light. After further 
washing, 100 μl of HRP-labelled streptavidin diluted in PBS was loaded to each well and 
incubated for another 20 minutes and protected from light. A final wash stage was performed 
and each well was incubated with 100 μl substrate (C2 kits) in the absence of light to 
visualise the captured antigen. The reaction was stopped using 50 μl of 2N sulphuric acid 
and the optical density was measured using a plate reader at 450 nm. Readings were blank 
corrected and a 7-point curve was constructed. Sample values were determined by 
interpolated. Samples were measured in duplicate on each plate and corrected for the total 
protein concentration of each sample. 
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2.8 Adjustment for total protein concentration 
Protein levels for each sample were adjusted for the total protein concentration of the 
sample. Total protein concentration was measured as described in 2.3. Adjustment for 
protein level was calculated using Equation 2-1. 
𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺 𝒕𝒕𝒕𝒕𝒕𝒕𝑺𝑺𝑺𝑺 𝑺𝑺𝒑𝒑𝒕𝒕𝒕𝒕𝑺𝑺𝒑𝒑𝒑𝒑 𝒄𝒄𝒕𝒕𝒑𝒑𝒄𝒄𝑺𝑺𝒑𝒑𝒕𝒕𝒑𝒑𝑺𝑺𝒕𝒕𝒑𝒑𝒕𝒕𝒑𝒑
𝑴𝑴𝑺𝑺𝑺𝑺𝒑𝒑 𝒕𝒕𝒕𝒕𝒕𝒕𝑺𝑺𝑺𝑺 𝑺𝑺𝒑𝒑𝒕𝒕𝒕𝒕𝑺𝑺𝒑𝒑𝒑𝒑 𝒄𝒄𝒕𝒕𝒑𝒑𝒄𝒄𝑺𝑺𝒑𝒑𝒕𝒕𝒑𝒑𝑺𝑺𝒕𝒕𝒑𝒑𝒕𝒕𝒑𝒑
 ×  𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺 𝒕𝒕𝑺𝑺𝒑𝒑𝒕𝒕𝑺𝑺𝒕𝒕 𝑺𝑺𝒑𝒑𝒕𝒕𝒕𝒕𝑺𝑺𝒑𝒑𝒑𝒑 =  𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝒕𝒕𝑺𝑺𝑨𝑨 𝒗𝒗𝑺𝑺𝑺𝑺𝑨𝑨𝑺𝑺 
Equation 2-1 Adjustment for total protein concentration. 
2.9 Immunohistochemistry  
2.9.1 Immunoperoxidase staining of paraffin embedded tissue 
Sections 7 µm in thickness were cut from paraffin blocks containing desired brain regions 
using a microtome and mounted on to charged microscope slides prior to the start of this 
study. 
Slides were incubated overnight in a 60°C oven dewaxed in clearene (2 x 5 minutes) and 
dehydrated in 100% ethanol (2 x 3 minutes). Endogenous peroxidase was blocked by 
incubation with 3% hydrogen peroxide in methanol for 30 minutes, followed by a 10 minute 
wash under running water. Sections underwent the antigen retrieval pre-treatment required 
for the primary antibody before being washed under running water for 10 minutes, 
equilibrated in PBS and circled with a wax pen. Sections were blocked with 20% normal 
horse serum for 20 minutes and slides drained before application of primary antibody in 5% 
BSA, which was left to incubate overnight at 4°C. Sections were washed in two changes of 
PBS (2 x 3 minutes) and biotinylated universal antibody (Vector Laboratories) applied and 
left to incubate for 20 minutes. Sections were washed in two changes of PBS (2 x 3 
minutes), VectaElite ABC complex (Vector Laboratories) was prepared 30 minutes prior and 
applied and sections left to incubate for 20 minutes. Sections were then washed in two 
changes of PBS (2 x 3 minutes), DAB (Vector Laboratories) applied and left to incubate for 
7-10 minutes, and subsequently washed under running water for 10 minutes. Sections were 
immersed in copper sulphate DAB enhancer for 4 minutes, washed under running water for 
5 minutes, counterstained in Gills haematoxylin (Leica) for 5-30 seconds for nuclei staining, 
and washed under running water for at least 10 minutes. Finally, sections were dehydrated 




2.9.2 Double immunoperoxidase staining of paraffin embedded tissue 
Sections were immunolabelled for the first antigen with DAB as described in section x. After 
sections had been immersed in copper sulphate and washed in water, they were incubated 
in 20% normal horse serum for 20 minutes. Sections were then incubated overnight with 
antibody against the second antigen. Sections were washed in two changes of PBS and 
biotinylated universal antibody was applied for 20 minutes. Sections were washed in two 
changes of PBS, then VectaElite ABC complex, which had been prepared and left to sit for 
30 minutes, was applied for 20 minutes. Sections were washed in two changes of PBS, 
incubated for 5-10 minutes in VIP substrate kit and washed in running water for 10 minutes. 
Sections were counterstained with Gills haematoxylin, and washed under running water for 
at least 10 minutes, before being dehydrated, cleared and mounted as for single staining as 
above (2.9.1). 
2.9.3 Antigen retrieval pre-treatments 
2.9.3.1 Citrate buffer treatment 
Sections were immersed in citrate buffer and microwaved for 5 minutes until boiling. 
Sections were left to stand at room temperature for 5 minutes then returned to the 
microwave for a further 5 minutes. Sections were cooled in running water for 10 minutes. 
2.9.3.2 EDTA buffer treatment 
Sections were immersed in EDTA buffer and microwaved for 10 minutes until boiling. 
Sections were cooled in running water for 10 minutes. 
2.10  Double immunofluorescence staining of paraffin embedded tissue 
Sections 7 µm in thickness were cut from paraffin blocks containing desired brain regions 
using a rotary microtome and mounted on to charged microscope slides. 
Slides were incubated overnight in a 60°C oven dewaxed in clearene (2 x 5 minutes) and 
dehydrated in 100% ethanol (2 x 3 minutes). Sections were washed 3x in PBS. 
Autofluorescence blocking pre-treatment was applied if necessary. Sections underwent the 
antigen retrieval pre-treatment required for the primary antibody before being equilibrated in 
PBS and circled with a PAP pen. Sections were blocked with 10% normal goat serum (NGS) 
for 30 minutes and slides drained before application of primary antibody in 10% NGS, which 
was left to incubate overnight at room temperature. Sections were washed in three changes 
of PBS (3 x 3 minutes) and a direct secondary fluorophore applied and left to incubate for 30 
minutes. Sections were washed in three changes of PBS (3 x 3 minutes) and treatment to 
quench autofluorescence was applied if necessary. Sections were washed in three changes 
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of PBS (3 x 3 minutes) and mounted in Vectorstain medium with DAPI and sealed with nail 
varnish. Sections were viewed and imaged on a fluorescent microscope. 
2.10.1 Autofluorescence quenching 
2.10.1.1 Copper sulphate pre-treatment 
Copper sulphate was used to reduce lipofuscin-like fluorescence 232. Copper sulphate was 
applied after the first wash step for 1 hour at room temperature.  
2.10.1.2 Sudan black post-treatment 
Sudan black was used as a post-treatment to reduce auto fluorescence 232-234. Sudan black 
solution was applied following secondary antibody incubation and left for 15 minutes at room 
temperature. 
2.11  RNA Extraction 
2.11.1  Frozen human brain tissue 
Certified RNAse free pipette tips and Eppendorf tubes were used. 2ml screw top 
homogenisation tubes were autoclaved to minimise contamination.  
One hundred mg of tissue was dissected from the desired region and put in a 2ml screw top 
tube with 5 x 2.3 mm ceramic beads and 750 μl TRIzol reagent (ThermoFisher Scientific). 
The tissue was homogenised at 6000 rpm using the Precellys 24 automated homogeniser 
(Bertin Technologies) for 2 x 15 seconds and left to settle on ice. In a fume hood, 160 μl 
chloroform was added and the sample vortexed for 15 seconds. Samples were then 
incubated for 3 minutes and then centrifuged at 17,000 g for 15 minutes at 4°C for phase 
separation. The aqueous phase was transferred to a 1.5 ml tube to which 500 μl of 
isopropanol was added. The preparation was mixed by inversion and incubated for 10 
minutes to precipitate the RNA. The sample was then centrifuged at 17,000 g for 10 minutes 
at 4°C, the supernatant removed, and the resulting RNA pellet washed by inversion with 800 
μl 70% ethanol. The pellet was re-formed by centrifugation at 9000 rpm for 5 minutes at 4°C, 
supernatant removed and left to air-dry. The pellet was then re-suspended in 30 μl RNase-
free distilled water and aliquoted into 2 15 μl samples. Samples were stored at -80°C for 
future use.  
2.11.2  DNase-1 treatment 
To eliminate any genomic DNA, 0.6 μl MgCl2 (ThermoFisher Scientific) and 2 μl DNase-I 
(Roche) were added to a 15 μl aliquot of RNA. This was incubated for 1 hour at 37°C 
followed by inactivation at 90°C for 5 minutes. The samples were spun down by short 
centrifugation then incubated on ice or transferred to the -80°C freezer for future use. 
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2.11.3 Quantification of RNA 
RNA concentration was determined using a RiboGreen RNA quantitation kit (Invitrogen). A 
standard curve was generated in the range of 1-1000 ng/ml, diluting the working standard in 
TE buffer to a final volume of 100 μl in the plate Nunc black 96-well untreated plate, and a 
blank of 100 μl TE buffer. RNA stock was diluted 1 in 20,000 in TE buffer to a concentration 
within the standard range to a final volume of 100 μl. RiboGreen fluorescent dye was diluted 
1 in 200 in TE buffer, and 100 μl added to each well. The plate reader was programmed to 
shake the plate for 30 seconds to aid mixing before taking fluorescence readings with filters 
set to excite at 485 nm and read emission at 520 nm. 
2.11.4 Generation of cDNA 
For each sample, 10 μg of RNA diluted in 50 μl of RNase-free distilled water. This was 
added to 50 μl of the high capacity cDNA reverse transcription kit (ThermoFisher Scientific). 
The adapted protocol is detailed in Table 2-3. The samples were then incubated 25°C for 10 
minutes, followed by 37°C for 2 hours and inactivation at 85°C for 5 seconds in a thermal 
cycler. cDNA was stored at -80°C until use. 
Component Vol per reaction tube (µl) 
10x RT buffer 10 
10x Random primers 10 
Reverse Transcriptase 5 
25x dNTP mixture 4 
H2O 21 
Final volume 50 
Table 2-3 High capacity cDNA kit with adapted protocol. Up to 10 ug of RNA combined with 
RNase free H2O and added to the Master Mix. 
2.11.5 Quantification of cDNA 
cDNA concentration was determined by using a PicoGreen DNA quantitation kit (Invitrogen). 
A standard curve was generated in the range of 1-1000 ng/ml, diluting the working standard 
in TE buffer to a final volume of 100 μl in the black 96-well untreated plate, and a blank of 
100 μl TE buffer. cDNA stock was diluted 1 in 100 with TE buffer to a concentration within 
the standard range to a final volume of 100 μl. PicoGreen fluorescent dye was diluted 1 in 
200 in TE buffer, and 100 μl added to each well. The plate reader was programmed to shake 
the plate for 30 seconds to aid mixing before taking readings with correct filters set to excite 
at 485 nm and read emission at 520 nm. 
Subsequently the use of Picogreen dye was found to be an ineffectual measure of ssDNA 
levels. Despite the used of cDNA quantification to load PCR reactions this will not adversely 
affect interpreted results. Measurement of RNA ensured a set quantity was converted to 
cDNA. Volumes loaded from cDNA varied between samples. Despite variation the PCR 
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reaction was not overloaded as detailed by cycle threshold (CT) values which fell between 
the range of 20 and 39 across all targets and there was no correlation between cDNA 
volume added to reaction and resulting CT (Appendix 11). In addition, the 2-ΔΔCt method for 
relative quantification of gene expression was used to calculate fold change in gene 
expression. The CT of the endogenous control is subtracted the gene of interest for each 
sample to normalises the samples for the volume of cDNA or RNA added235. 
2.12 Quantitative PCR 
Samples were plated on 0.1 ml Fast plates (Thermofisher Scientific) with each well 
containing, 10 µl of fast advanced master mix (Thermofisher Scientific), 1 µl of primer (Table 
2-4) and 10 ng of cDNA made up to a total volume of 20 µl with RNase free water. Samples 
were run in triplicate for each gene probed. Each plate contained non-template controls for 
genes probed. Samples were incubated according to Taqman fast conditions set out in 
Figure 2-1. 
Table 2-4 Details of qPCR primers used (ThermoFisher Scientific). Primer maps are displayed 
in Appendix 13 
Name Alias Gene 
symbol 










ALDH1L1 Hs00201836_m1 94 Chr.3: 125822408 - 125899485 
β-Actin BRWS1, PS1TP5BP1 ACTB Hs01060665_g1 115 





























Gene expression for each sample was calculated compared to control using the 2-ΔΔCt 
method for relative quantification of gene expression developed by Livak et al 235. In this 
study one disease group (AD) was compared to one control group (C). The cycle threshold 
(CT) of the gene of interest for each sample was first normalised to an endogenous control in 
the same sample (ΔCt). The genes of interest in this study were FLT1 (VEGFR1) and KDR 
(VEGFR2). The ACTB gene for β-actin was chosen as a reference gene expressed in all cell 
types. Three reference genes were chosen to account for expression of the genes of interest 
on multiple cell types in brain tissue. These were ALDH1L1 (expressed on astrocytes), 
PECAM1 (expressed on endothelium) and RBFOX3 (expressed on neurons). The difference 
in gene expression between control and disease groups was then calculated via the 2-ΔΔCt 
method detailed in Equation 2-2. 
 Fold change = 2‐ΔΔCt 
CT target gene – CT reference gene = ΔCt  
ΔCT disease case – mean value of control ΔCT  = ΔΔCt  
Equation 2-2 The 2-ΔΔCt method for calculating relative gene expression.  
Figure 2-1 Plot of qPCR cycle conditions for all primers. 
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The geometric mean of control and disease group 2-ΔΔCt values was subsequently 
established to allow comparison between the cohorts. Relative change in gene expression in 
each disease case is compared to the average of control values.  
2.13 Primary cell culture 
All cell culture experiments were conducted in a class II biological safety cabinet (MDH 
InterMed) at room temperature and the cultures were maintained in a 5 % CO2 humidified 
incubator at 37 ºC (Sanyo Electric co.). Cells were cultured in tissue culture treated 
plasticware (Greiner). 70% isopropanol was used to clean out safety hood before and after 
each use to prevent infection of cultures. The dH2O and PBS was autoclaved prior to used. 
Cell medium was stored at 4 ºC and were pre-warmed to room temperature prior to use.  
2.13.1 Initiating primary cell culture 
Complete cell medium was prepared. Cells we removed from liquid nitrogen or -150 °C and 
thawed in a 37 ºC water bath. The ampule was removed and contents were transferred to a 
T75 containing culture medium. The flask was placed in the incubator overnight and media 
changed the next day to remove any residual DMSO.  
2.13.2 Subculture of primary cells 
The media was changed every 3 days until 70% confluent then every day until the culture 
was 90% confluent when cultures were passaged. The existing media was removed and 
remaining cells were washed with PBS and 2 ml of trypsin-EDTA solution (Sigma) was 
applied. The flask was placed in in the 37 ºC incubator for 3 minutes. The flasks were gently 
agitated to detach the cells, they were harvested and added to a 15 ml falcon tube 
containing fresh media. 50 µl was removed for cell quantification (2.13.3). Cells were then 
pelleted with centrifugation at 200 g for 4 minutes at room temperature in a bench top 
centrifuge (ThermoFisher Scientific). The media was aspirated, cell pellet re-suspended in 
fresh media and plated as required. Cells were seeded at a density of 6000 cells/cm2. 
2.13.3 Cell counting 
To determine the number of living cells present in a sample, trypan blue exclusion was 
performed with a level of less than 10% cell death considered acceptable. A 50μl aliquot 
of the cell suspension was taken and mixed with an equal volume of trypan blue dye. 
50μl of the 1:1 mixture was added into both grids of a haemocytometer (Hawksley). 
Dead cells appear blue as the die permeates the cell membrane while live cells remain.  
Cell viability was calculated by counting live cells and total cells (live and dead) in grids 
of the haemocytometer using an inverted phase contrast microscope (Nikon). Equation 
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2-3 was used to establish % viability. A % viability of 80% or over was considered 
acceptable.  
𝑵𝑵𝑨𝑨𝑺𝑺𝑵𝑵𝑺𝑺𝒑𝒑 𝒕𝒕𝒐𝒐 𝒗𝒗𝒑𝒑𝑺𝑺𝑵𝑵𝑺𝑺𝑺𝑺 𝒄𝒄𝑺𝑺𝑺𝑺𝑺𝑺𝑨𝑨
𝑻𝑻𝒕𝒕𝒕𝒕𝑺𝑺𝑺𝑺 𝒑𝒑𝑨𝑨𝑺𝑺𝑵𝑵𝑺𝑺𝒑𝒑 𝒕𝒕𝒐𝒐 𝒄𝒄𝑺𝑺𝑺𝑺𝑺𝑺𝑨𝑨
(𝑺𝑺𝒑𝒑𝒗𝒗𝑺𝑺 𝑺𝑺𝒑𝒑𝑨𝑨 𝑨𝑨𝑺𝑺𝑺𝑺𝑨𝑨)
 ×  𝟏𝟏𝟏𝟏𝟏𝟏 = % 𝑽𝑽𝒑𝒑𝑺𝑺𝑵𝑵𝒑𝒑𝑺𝑺𝒑𝒑𝒕𝒕𝑽𝑽 
Equation 2-3 Cell viability 
Cell number was established by counting the live cells (>100 cells to increase accuracy) in 
grids of the haemocytometer. Equation 2-4 was used to calculate the viable cells/ml.  
𝑵𝑵𝑨𝑨𝑺𝑺𝑵𝑵𝑺𝑺𝒑𝒑 𝒕𝒕𝒐𝒐 𝒗𝒗𝒑𝒑𝑺𝑺𝑵𝑵𝑺𝑺𝑺𝑺 𝒄𝒄𝑺𝑺𝑺𝑺𝑺𝑺𝑨𝑨
𝑵𝑵𝑨𝑨𝑺𝑺𝑵𝑵𝑺𝑺𝒑𝒑 𝒕𝒕𝒐𝒐 𝑨𝑨𝒔𝒔𝑨𝑨𝑺𝑺𝒑𝒑𝑺𝑺𝑨𝑨 𝒄𝒄𝒕𝒕𝑨𝑨𝒑𝒑𝒕𝒕𝑺𝑺𝑨𝑨
 ×  𝟐𝟐 (𝑫𝑫𝒑𝒑𝑺𝑺𝑨𝑨𝒕𝒕𝒑𝒑𝒕𝒕𝒑𝒑 𝒐𝒐𝑺𝑺𝒄𝒄𝒕𝒕𝒕𝒕𝒑𝒑)  ×  𝟏𝟏𝟏𝟏𝟒𝟒  = 𝒄𝒄𝑺𝑺𝑺𝑺𝑺𝑺𝑨𝑨/𝑺𝑺𝑺𝑺 
Equation 2-4 Cell number 
2.13.4 Human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (HUVEC) primary cell were grown by the Lung 
Research Group, Southmead Hospital, University of Bristol, UK. Lysates were provided for 
use as positive control for antibody characterisation.  
2.13.5 Human brain microvascular endothelial cells 
Human brain microvascular endothelial cells (HBMEC) were obtained from ScienCell 
(#1000) and maintained using endothelial cell growth media (ScienCell, #1001). Cells were 
maintained in accordance with ScienCell guidelines. Serum-free medium was prepared by 
adding endothelial cell growth supplement and penicillin/streptomycin solution. Flasks were 
coated in fibronectin (ScienCell) at a concentration of 2 μg/cm2 in Ca2+ and Mg2+-free PBS 
(Sigma) and placed in the 37 ºC incubator overnight. Fibronectin solution was removed and 
flasks washed twice with dH2O prior to use.  
2.13.6 Human brain vascular pericytes 
Human brain microvascular endothelial cells (HBVP) were obtained from ScienCell (#1200) 
and maintained using pericyte medium (ScienCell, #1201). Complete medium was prepared 
by adding all supplements and refrigerated until use. Serum-free medium was prepared by 
adding pericyte growth supplement and penicillin/streptomycin solution. Flasks were coated 
in poly-l-lysine (ScienCell) at a concentration of 2 μg/cm2 in dH2O and placed in the 37 ºC 
incubator overnight. Poly-L-lysine solution was removed and flasks washed twice with dH2O 
prior to use.  
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2.13.7 Long-term storage of cells 
Cell lines and primary cells were stored in the presence of the cryoprotector DMSO. Cells 
were grown in T75 tissue culture flasks until 90 % confluent and processed as described for 
routine maintenance. In the last step, instead of re-suspending the pellets in fresh media, the 
cells were re-suspended in a mixture of 10 % DMSO and 90 % FBS and allowed to freeze at 
a controlled rate alcohol-free cell freezing container (Biocision) at -80 °C. After 24 hours 
cryovials were transferred into liquid nitrogen or -150 °C storage for future use. 
2.13.8 Aβ preparation 
Aβ1-40 (Anaspec, AS-24236) and Aβ1-42 (Anaspec, AS-24224) were lyophilised in 35% 
acetonitrile-H2O. 
2.13.9 Hypoxic chamber 
The hypoxic chamber (SCI-tive, Baker Ruskinn) was set to 2% O2 and 5% CO2 and a 
temperature of 37°C. O2, and CO2 levels were maintained with compressed O2, air and 
nitrogen. The station was humified with dH2O. 
2.14 Statistical approaches 
The statistical analyses were performed using GraphPad Prism (GraphPad Software). The 
D'Agostino-Pearson omnibus K2 normality test 236 was used to indicate if data sets were of 
normal distribution. A null hypothesis is that all the values were sampled from a Gaussian 
distribution. A p value of < 0.05 indicates the data is not normally distributed, > 0.05 
indicates the data set is normally distributed. Normality tests were not used to determine 
sample distribution in isolation as they are susceptible to outliers and small sample sizes. 
The data was plotted to observe the distribution and the presence of outliers and lognormal 
distributions was considered before choosing an appropriate statistical test.  
Normally distributed data sets were compared using the unpaired, two tailed t-test. The null 
hypothesis for this test is that there is no difference in the means of the groups being 
compared. For a p-value of <0.05, the null hypothesis is rejected and the difference between 
the means of the two data sets being compared was deemed significantly different.  
One-way ANOVA was used to compare three or more unmatched groups with normal 
distributions. The null hypothesis for this test is that the means of all groups are same. If the 
p-value was <0.05 the null hypothesis was rejected and groups were deemed to have 
different means. This does not mean all groups had different means but at least one group 
differed from the others. If the one-way ANOVA reported a significant difference either the 
Dunnett test or the Tukey-Kramer multiple comparisons test were used as post-hoc tests, 
depending on experimental setup. The Dunnett test was used to compare every group to a 
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mean, usually control, value. The null hypothesis is that test is that the means of both groups 
are same. The Dunnett test does not report an exact p value but provides a list of significant 
or not significant decisions for each pair analysed (>0.05, <0.05, <0.01, or <0.001). If a p-
value was <0.05 the null hypothesis was rejected and the mean of two data groups was 
deemed significantly different. The Tukey-Kramer test compares the mean of one group with 
every other group and allows for unequal sample sizes and has the same null hypothesis 
and assumptions at the Dunnett test. 
Pearson’s correlation was used to assess linear correlation in normally distributed data sets. 
The correlation coefficient, r, reports the direction and magnitude of the correlation with 1 a 
perfect positive correlation, -1 a perfect negative correlation and 0 denoting no correlation. 
The null hypothesis is that the data were sampled from a population where there is no 
correlation between the two variables. If a p-value was <0.05 the null hypothesis was 
rejected and the two data sets was deemed significantly correlated. 
Non-normally distributed data sets were compared using non-parametric tests. The Mann-
Whitney test was used to establish the difference between two groups. Values are ranked 
from low to high regardless of group. The null hypothesis is that the distributions of both 
groups are identical. If a p-value was <0.05 the null hypothesis was rejected and the 
distribution of the two data sets was deemed significantly different. 
The Kruskal-Wallis test was used to establish the difference between three or more 
unmatched groups. Values are ranked from low to high regardless of group. The null 
hypothesis is the distributions of all groups are identical. If a p-value was <0.05 the null 
hypothesis was rejected and the distribution of the data sets was deemed significantly 
different. Dunn’s multiple comparisons test was used if Kruskal-Wallis reported a significant 
difference. The Dunn’s test compares the sum of ranks in two groups with the expected 
average, dependent on number of samples and groups. The null hypothesis is that 
distributions are identical for each pair. The Dunn’s test does not report an exact p value. 
Spearman’s correlation was used to assess rank order correlation in non-normally 
distributed data sets. The null hypothesis is that the data were sampled from a population 
where there is no correlation between the two variables. If a p-value was <0.05 the null 
hypothesis was rejected and the two data sets was deemed significantly correlated and the r 




Chapter 3 VEGFR1 
3.1 Introduction 
VEGF is a pro-angiogenic factor 117, 237 upregulated in response to hypoxia 238, 239 (1.2.1). 
VEGF primarily acts on two tyrosine kinase receptors in the nervous system, VEGFR1 and 
VEGFR2. VEGF is vital for angiogenesis and mediates its effects via receptors expressed on 
the endothelial cell surface. VEGFR2 mediates most of the actions of VEGF and is a major 
regulator of angiogenesis 170. VEGFR2 to mediates endothelial cell proliferation, migration, 
permeability and survival 107, 129, 168 resulting in the formation and maintenance of blood 
vessels. This results in increased blood flow and reduction in hypoxia. The role of VEGFR2 
in the nervous system and AD will be covered in more detail in Chapter 4. 
VEGFR1 has broadly been viewed as a negative regulator of VEGF, however important 
roles for the receptor are being elucidated in the adult CNS. sVEGFR1 isoforms are 
produced by alternate splicing and possess no kinase region (1.2.2.1.1). sVEGFR1 isoforms 
act as negative regulators of VEGF action by sequestering VEGF in the extracellular matrix 
143, 148. The membrane bound VEGFR1 (mbVEGFR1) has a high affinity for VEGF 148 but 
limited kinase activity 240. mbVEGFR1 transduces signals for endothelial cell proliferation and 
permeability and is important in the regulation of postnatal angiogenesis 120, 241, 242. VEGFR1 
has been reported as being expressed on neurons and has a role in neuroprotection 243, 244 
and neurogenesis 245 in the adult brain. VEGFR1 expression is upregulated in hypoxic 
conditions 145, 246-249. CBF is reduced in AD resulting in cerebral hypoperfusion and hypoxia. 
There have been conflicting reports of VEGFR1 localisation on astrocytes and microglia. 
VEGFR1 has been identified on microglia in ischaemic rat brain 250 and in control and AD 
post mortem study 142. There is also evidence for a role of VEGFR1 in microglial migration 
141, 142. However, in other rat and porcine models of hypoxia, VEGFR1 expression was not 
seen on microglia 251-253. VEGFR1 has also been reported on rat astrocytes in hypoxic 
models 142, 172, 251, 254-256 though was not observed in all animal models 252, 253, 257 or in human 
brain 142. The level of VEGFR1 in tissue of critical importance as a negative regulator of 
VEGF function. In animal models of hypoxia elevated levels of VEGFR1 mRNA 142, 252-254, 256, 
258 and protein 250, 253, 257 have been reported in the brain.  
Despite increases in VEGF 72, 198, 212 it has previously been reported that there is no increase 
in microvessel density in the AD brain 78. There are several possible explanations for this 
disparity including alteration in VEGFR location, level and downstream activation. VEGFR1 
has a prominent anti-angiogenic role and is of importance in the understanding of 
dysregulated angiogenesis in AD. There have been few studies addressing VEGFR1 
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distribution in human brain. An increase in VEGFR1 due to hypoxia or in combination with 
other changes, may result in reduced angiogenesis in AD. 
Frontal lobe was used as it provides a large area of tissue for examination of grey and white 
matter. Parietal lobe was used for all investigation on non-fixed tissue due to its relative 
abundance in post-mortem brains. 
Results presented in this chapter on the cellular localisation of VEGFR1 and the level of 
VEGFR1 in human brain tissue were recently published 259. 
3.1.1 Hypothesis 
[1] VEGFR1 will be located on endothelial cells, microglia and neurons and not astrocytes in 
the frontal lobe. VEGFR1 has not been identified on astrocytes in human studies and several 
animal models, and physiological function for VEGFR1 on astrocytes is yet to be identified.  
[2] Hypoxia directly regulates the transcription of VEGFR1, therefore the level of VEGFR1 
mRNA will be increased in the AD brain compared to age matched control in the parietal 
cortex.  
[3] Hypoxia directly regulates the transcription of VEGFR1, which can to regulate the protein 
level. The level of VEGFR1 protein will be increased in the AD brain compared to age 
matched control in the parietal cortex. 
3.1.2 Aims 
[1] Examine the cellular localisation and cerebral distribution of VEGFR1 in AD and control 
post-mortem frontal lobe using immunostaining.  
[2] Measure the level of VEGFR1 mRNA in parietal cortex from AD compared with controls 
by qPCR. 
[3] Measure the VEGFR1 protein level in parietal cortex from AD compared with controls by 
ELISA and western blot. 
3.2 VEGFR1 localisation 
Due to debate in the literature over the localisation of VEGFR1 in the glial population (3.1) it 
was important to establish the cellular location of the receptor in the AD brain.  
3.2.1 Methods 
3.2.1.1 Study cohort 
Control and AD cases were neuropathologically confirmed as described in Chapter 2 and 
detailed in Table 3-1. The neuropathological and demographic features of control and AD 
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cases used for immunostaining are summarised in Table 3-2 and detailed here. Details of 
individual cases can be found in the Appendix 9. FFPE frontal lobe was used to investigate 
VEGFR1 localisation and was sectioned as described in Chapter 2 prior to the start of this 
study.  
Parietal cortex and white matter Control AD 
N 36 50 
Age (years) Range 58 - 95 57 - 93 
Mean ± SD 80.1 ± 8.7 77.5 ± 8.1 
Gender Female 11 26 
Male 25 24 
Post-mortem delay 
(hours) 
Range 3 – 67 4 - 85 
Mean ± SD 32.5 ± 16.3 31.6 ± 19.0 
Table 3-1 Summary of the neuropathological and demographic features of control and AD 
cohorts used in mRNA and protein analysis 
Frontal cortex Control AD 
N 4 5 
Age (years) Range 75-85 60-97 
Mean ± SD 79.0 ± 4.5 80.2 ± 15.0 
Gender Female 1 2 
Male 3 3 
Post-mortem delay 
(hours) 
Range 23-92 24-65 
Mean ± SD 48.4 ± 30.9 37.3 ± 16.5 
Table 3-2 Summary of the neuropathological and demographic features of control and AD 
cohorts used in immunolabelling studies. See Appendix 10 for individual case details.  
Parietal cortex from control cases was used to perform western blotting and the cohort used 
is detailed in 3.4.1.1. 
3.2.1.2 Western blot 
Total protein concentration for tissue homogenates was calculated as described in 2.2.3. 
Western blotting was carried out as described in 2.4. Samples were run on 4-20% precast 
gels. The membrane was blocked with 3% BSA-TBST for 1 hour and incubated overnight at 
4°C with anti-VEGFR1 antibody at a concentration of 1:2000 in 3% BSA-TBST. β-Actin was 
used as a loading control at 1:5000 in 5% milk-TBST. Human umbilical vein endothelial cell 
(HUVEC) lysates express both VEGFR1 and VEGFR2 and were used as a positive control. 
Recombinant VEGFR1 and VEGFR2 (R&D) were used to confirm the specificity of the 
antibody. 
3.2.1.3 Immunohistochemistry 
Immunohistochemistry was performed as described in 2.9.1. The antibody was titred to 
determine the optimal concentration and tested with both EDTA and citrate buffer pre-
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treatment to enhance straining as described in 2.9.3. Sections were pre-treated with citrate 
buffer prior to immunolabelling with anti-VEGFR1 Ab32152 at 1:200. A no-primary control 
was included to account for any non-specific binding of the secondary antibody. Antibody 
diluent was applied, followed by secondary antibody incubation and detection as described. 
An immunoglobulin control was performed to ensure staining was not caused by non-specific 
interactions of immunoglobulin in the tissue. Sections were incubated with an 
immunoglobulin of the same isoform, species and concentration as the primary antibody. 
Secondary antibody incubation and detection were carried out as described in section 2.9.1. 
In this case rabbit IgG was used at a concentration of 2 µg/ml and incubated for 1 hour at 
RT. 
3.2.1.4 Double immunofluorescence and immunohistochemistry 
VEGFR1 co-localisation in glial cells was investigated by double immunohistochemistry 
(2.9.2) and double immunofluorescence (2.10). 
Distribution of VEGFR1 was investigated using anti-VEGFR1 Ab32152 at 1:200. Antibodies 
against glial fibrillary acidic protein (GFAP), an astrocyte marker, and HLA-RD, a class II 
major histocompatibility antigen known to be a marker of microglia and macrophages, were 
both used at a concentration of 1:200. Sections were pre-treated with citrate buffer prior to 
immunolabelling with the first antibody. VEGF receptors were labelled first and bound 
antibody visualised with DAB (brown) and glial cells were labelled second and visualised 
using VIP (purple). AD tissue was used as it contains an increased number of GFAP positive 
astrocytes and areas of immune cell activation in comparison to control brain tissue. 
3.2.2 Results 
3.2.2.1 Validation of VEGFR1 antibody specificity 
The antibody used was raised to the N terminus of VEGFR1 detecting only membrane 
bound and soluble forms. Western blot confirmed the presence of mbVEGFR1 in parietal 
cortex at 180 kDa (Figure 3-1). This molecular weight corresponded to the 180 kDa 
observed in the HUVEC lysate used as a positive control. sVEGFR1 isoforms were observed 
between 90 kDa and 135 kDa in parietal cortex homogenate. The antibody was shown to be 
specific to VEGFR1 recombinant protein at 220 kDa corresponding to the predicted weight of 
a sVEGFR1 homodimer 147, 150, 151. No cross-reactivity was observed with VEGFR2 (210 kDa 
and 230 kDa). 
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Figure 3-1 Western blot validation of VEGFR1 antibody in parietal cortex homogenate. HUVEC 
lysate was used as a positive control as HUVECs express both VEGFR1 (R1) and VEGFR2 (R2). 
VEGFR1 was observed at 180 kDa corresponding to HUVEC lysate. sVEGFR1 isoforms are 
also observed from 80 - 135 kDa in brain homogenate. The antibody was shown to be specific 




3.2.2.2 Localisation of VEGFR1 in control and AD brain 
Immunohistochemistry was performed to elucidate the cellular localisation of VEGFR1 in AD 
and control frontal cortex. No labelling was observed on negative (no primary antibody) or 
IgG controls (Figure 3-2). 
Figure 3-2 Negative control signal in sections of human frontal lobe. [A] No-VEGFR1-primary-








Intense immunolabelling of VEGFR1 can be seen in the grey matter of the frontal cortex with 
white matter labelled much less intensely (Figure 3-3). VEGFR1 was clearly identified within 
the neuropil and neurons of the grey matter with some neuronal populations showing 
particularly intense staining (Figure 3-4A, B). VEGFR1 labelling was also observed in the 
endothelium of capillaries and arterioles (Figure 3-4C, D). 
 
Figure 3-3 VEGFR1 IHC of control [A] and AD [B] frontal lobe. Strong immunopositivity is 
observed in the cortex compared to the white matter in control [A] and AD [B]. VEGFR2 IHC of 
control [C] and AD [D] frontal lobe is shown for comparison. In [C] there is some artefactual 
signal but that in general the labelling is weaker and not specific to the cerebral cortex. A more 




Figure 3-4 VEGFR1 labelling of control and AD frontal lobe. VEGFR1 antibody labelled the 
neuropil and neurons in the grey matter in control [A] and AD [B]. Approximately 100% of the 
neuropil was immunopositive for VEGFR1, with the pyramidal neurons displaying intense 
immunopositivity. VEGFR1 labelling was seen in capillaries and arterioles in control [C] and 
AD [D]. This was seen on 100% of capillaries and arterioles in C and AD. Scale bars = 100 µm. 
3.2.2.3 Glial localisation of VEGFR1 in AD brain 
To look for possible cellular localisation of VEGFR1 on glial cells double immunolabelling 
was performed. Double immunofluorescence using two fluorophores stimulated at different 
wavelengths was attempted. High levels of background fluorescence were observed and 
persisted despite the adjustment of primary antibody concentration and the use of pre- and 
post-treatments to reduce autofluorescence (Appendix 12). Double immunoperoxidase 
labelling was therefore used as an alternative.  
Double immunolabelling of VEGFR1 (brown) with GFAP, an astrocyte marker, and HLA-DR, 
a microglial marker, (purple) is shown in Figure 3-5. VEGFR1 was again readily detectable, 
by immunohistochemistry, in the neuropil of the parietal cortex in AD (Figure 3-5A) and 
control brains, with most intense immunolabelling of neuronal cell bodies (Figure 3-5B, C). 
There was minimal co-localisation with GFAP-positive astrocytes (Figure 3-5B) or HLA-DR-







Figure 3-5 Cellular localisation of VEGFR1 in human parietal cortex. The examples shown are 
from an AD brain. [A] Double-labelling of VEGFR1 (brown) and GFAP (purple) shows VEGFR1 
to be present in the cerebral cortex (double-headed arrow) but not the underlying white matter. 
Scale bar = 2 mm. [B] At higher magnification VEGFR1 is detectable within neurons and 
neuropil, with minimal labelling of GFAP-positive astrocytes. Scale bar = 50 µm. [C] Double-
labelling of VEGFR1 (brown) and HLA-DR (purple) shows minimal VEGFR1 immunopositivity in 
HLA-DR-positive microglia. Scale bar = 50 µm. 
3.3 VEGFR1 mRNA level in control and Alzheimer’s disease 
The aim of this work was to measure the VEGFR1 mRNA level in the parietal cortex of 
control and AD.  
3.3.1 Methods 
3.3.1.1 qPCR study cohort 
Parietal cortex from control and AD patients was used to investigate VEGFR1 mRNA 
expression. Control and AD cases were neuropathologically confirmed as described in 2.2. 
Control and disease subjects were age-matched and, where possible, matched for gender. 
All subjects had a post-mortem delay of less than 90 hours. The neuropathological and 
demographic features of control and AD cohorts are described in Table 3-3. 
Parietal cortex Control AD 
N 36 50 
Age (years) Range 58 - 95 57 - 93 
Mean ± SD 80.1 ± 8.7 77.5 ± 8.1 
Gender Female 11 26 
Male 25 24 
Post-mortem delay 
(hours) 
Range 3 - 67 4 - 85 
Mean ± SD 32.5 ± 16.3 31.6 ± 19.0 
Table 3-3 Summary of the neuropathological and demographic features of control and AD 
cohorts used for VEGFR1 mRNA analysis and protein analysis. Details of individual cases are 
listed in the Appendix 9. 
3.3.1.2 Selection of primers for VEGFR1 
Several sVEGFR1 isoforms can be produced by alternative splicing of the FLT1 gene as 
described in 1.2.2.1.1, and several were found to be present in human brain tissue (see 
3.2.1.2). The primer set was selected to measure mbVEGFR1 and sVEGFR1 mRNAs. The 
genomic map containing primer location can be found in Appendix 13. 
3.3.1.3 Selection of reference genes for relative quantification 
The use of appropriate reference genes is essential for the proper interpretation of qPCR 
results. The ideal reference gene should be expressed in the same cell types as the gene of 
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interest so that expression is not affected by changes in cellular composition of the tissue 
with disease. Reference gene selection in tissue can be confounded by the heterogeneity of 
cell type, and different cell types may be affected differently by disease, therefore selection 
of appropriate reference genes is extremely important. Multiple reference genes were used 
to help to distinguish between changes in the cellular expression of the gene of interest, and 
changes in mRNA levels caused by changes in cellular composition in AD. Reference genes 
were needed to account for total cell content and for the relative number of neurons and 
endothelial cells on which VEGFR1 is present. 
The gene encoding β-actin, ACTB, was used to adjust for total cell content. ACTB is a 
commonly used reference gene with stable expression across all cell types. It has been 
identified as an intermediately stable reference gene in hypoxic conditions 260 261 and stable 
in control and AD post-mortem human brain tissue 262. 
To establish whether changes in VEGFR1 expression might reflect loss of neurons in AD 
(3.2.2.2), a specific neuronal gene was used as one calibrator. In AD there is a decrease in 
the number of neurons in the brain. If the level of VEGFR1 mRNA was reduced in AD when 
calibrated to ACTB this could either be a result of the loss of neurons on which VEGFR1 is 
expressed or due an overall reduction in VEGFR1 mRNA expression. Calibration with 
reference to a neuronal marker helps to interpret any changes in VEGFR1 mRNA. Neuronal 
nuclei protein (NeuN), also known as neuronal specific splicing regulator, Fox-3 263, was 
selected as an established neuronal mRNA 264. 
Given the presence of VEGFR1 on endothelial cells in the brain (3.2.2.2), a specific 
endothelial cell gene transcript as a calibrator. The endothelial marker, platelet endothelial 
cell adhesion molecule (PECAM1), also known as cluster of differentiation 31 (CD31) 265, 266 
was used to investigate whether changes in VEGFR1 mRNA could be explained by altered 
endothelial cell content. 
3.3.1.4 qPCR 
RNA was extracted from fresh frozen parietal cortex as detailed in 2.11.1. cDNA was 
generated as described in 2.11.4, added to primers and master mix and made up to total 
volume with RNase free water. Samples were analysed in triplicate with non-template 
controls on each plate using the protocol detailed in 2.12. 
3.3.1.5 Statistical analysis  
The 2-ΔΔCt method was used to determine the fold difference between VEGFR1 and 
reference gene (ACTB, RBFOX3 and PECAM1) mRNA levels, as described in 2.12. Groups 
were tested for normality and were found to have a non-normal distribution, as expected 
from exponential values. The geometric mean and 95% confidence interval were calculated 
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for each group. Mann Whitney test was used for comparisons between individual sample 2-
ΔΔCt values in control and AD groups. 
3.3.2 Results 
3.3.2.1 Expression of reference genes in control and AD 
Reference genes were validated prior to investigating genes of interest. There was no 
significant difference in the CT values of ACTB, encoding β-actin, between control and AD 
samples (Figure 3-6). 
ACTB was shown to be stable in control and AD samples and is expressed at similar levels 
in all cell types. RBFOX3 is expressed in neuronal cells and PECAM1 in endothelial cells. 
The fold change of RBFOX3 and PECAM1 in AD was calculated relative to the mean level in 
control tissue using ACTB as the calibrator and results shown in Figure 3-7. There was no 
significant difference in the fold change of RBFOX3 between control and AD (~1.1-fold 
higher, p= 0.436). There was a significant ~1.6-fold increase in PECAM1 in AD samples 
compared to control (p= 0.021). A significant fold increase in PECAM1 could indicate an 
increase cell type expressing PECAM1 in the AD brain compared to control.  
  
Figure 3-6 ACTB CT values were measured by qPCR in human parietal cortex. There was no 
significant difference in mean CT value when control and AD samples were compared. The 




Figure 3-7 RBFOX3 and PECAM1 mRNA levels were measured by qPCR in parietal cortex. Fold 
difference in RBFOX3 and PECAM1 mRNA was calculated via the 2-ΔΔCt method using ACTB as 
a calibrator gene and compared to mean levels in control tissue. There was no significant 
difference between the fold change of RBFOX3 between control and AD (p= 0.439). There was 
a significant increase in the fold change of PECAM1 in AD samples compared to control (p= 
0.021). This indicates an increase in the number of cells expressing PECAM1. The geometric 
mean and 95% confidence intervals of the 2-ΔΔCt values are shown for each group on a log2 
scale. Horizontal line indicates 2-ΔΔCt fold change of 1 assigned to control samples, increases 
or decreases from this line in disease subjects indicate corresponding fold changes in gene 
expression in disease. C: n= 31, AD: n= 47. * p<0.05. 
3.3.2.2 VEGFR1 mRNA levels in AD and control brain 
In relation to expression of ACTB, that of VEGFR1 was significantly increased in AD 
compared to controls of 2.4-fold (p= 0.014). As would be expected from the previous results 
(see 3.3.2.1), VEGFR1 was also significantly increased in relation to RBFOX3, by ~2.2-fold 
in AD compared to controls (p= 0.014). The level of VEGFR1 relative to PECAM1 was not 
significantly increased in AD compared with controls (p= 0.114). It should be noted, 
however, that my immunohistochemical findings indicated that most of VEGFR1 in the brain 




Figure 3-8 VEGFR1 mRNA levels measured by qPCR in homogenates of parietal cortex. The 
fold difference relative to the mean in control tissue was calculated for each sample by the 2-
ΔΔCt method. Significant increases were observed with ACTB (β-actin) (p= 0.014) and RBFOX3 
(neuronal marker) (p= 0.014) as calibrators, but not when VEGFR1 mRNA was calibrated to 
PECAM1 (endothelial cell marker) (p= 0.114). The geometric mean and 95% confidence 




3.4 VEGFR1 protein level in control and Alzheimer’s disease 
The aim of this work was to measure VEGFR1 protein level in control and AD parietal cortex. 
3.4.1 Methods 
3.4.1.1 Protein level study cohort 
Fresh frozen parietal cortex and white matter from control and AD patients was used to 
investigate VEGFR1 protein expression. Control and disease subjects were age-matched 
and, where possible, matched for gender. All subjects had a post-mortem delay of less than 
90 hours. The demographic features of the control and AD cohort are summarised in Table 
3-3. 
3.4.1.2 VEGFR1 sandwich enzyme-linked immunosorbent assay 
Human total VEGFR1 (FLT1) duoset IC ELISA kit was used to measure VEGFR1 protein 
level in human brain homogenate. Frozen brain samples were homogenised as detailed in 
2.2.3 using the manufacturers recommended NP-40 based lysis buffer with phosphatase 
and protease inhibitors (Lysis buffer #9). The assay was carried out according to 
manufacturer’s instructions summarised in 2.6. Readings were blank corrected and a 7-point 
curve was constructed using VEGFR1 recombinant standards. A 4-parameter logistic curve 
fit was applied and sample values interpolated. 50 µl of standard and sample were added to 
each well. Samples were measured in duplicate on each plate. 
3.4.1.3 Spike, recovery and linearity testing 
The ELISA kit had been validated for use on cell culture supernatant, serum and plasma 
samples by the supplier. To validate the ELISA kit for use on human brain tissue, 
homogenates were spiked with recombinant protein, and recovery and linearity testing was 
performed. 2000 pg/ml of VEGFR1 recombinant protein was used to ‘spike’ neat brain tissue 
homogenate, to make the spiked sample, and control diluent (PBS), to make the control 
spike. The spiked sample, unspiked sample and control spike were mixed thoroughly and 
serial dilutions performed. Percentage recovery and linearity were calculated using Equation 
3-1 and Equation 3-2. Spiked values should return an increase in signal compared with the 
unspiked sample dependent on the amount of recombinant protein added. Values outside 
the accepted range indicate interference by one or more substances in the sample matrix. 
Samples homogenised in different buffers were tested (SDS and Triton X-100) and spike 
testing was repeated once. Percentage recovery and linearity did not fall within the 







×  100 
Equation 3-1 Percentage recovery for spiked sample 
% 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 (1: 𝐸𝐸) =
𝑂𝑂𝑂𝑂𝑂𝑂𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑂𝑂 𝑅𝑅𝑣𝑣𝑣𝑣𝑣𝑣𝑅𝑅 𝑅𝑅𝑜𝑜 1 𝑈𝑈𝑈𝑈 𝐸𝐸 𝑂𝑂𝑈𝑈𝑣𝑣𝑣𝑣𝐸𝐸𝑈𝑈𝑅𝑅𝑈𝑈
𝐸𝐸𝐸𝐸𝑈𝑈𝑅𝑅𝑅𝑅𝐸𝐸𝑅𝑅𝑂𝑂 𝑅𝑅𝑣𝑣𝑣𝑣𝑣𝑣𝑅𝑅 ÷ 𝐸𝐸
×  100  




Spiked Unspiked Control 
Neat 6.2 - - 
1:2 137.8 132.1 91.5 
1:4 135.6 155.2 125.8 
Table 3-4 Percentage recovery and linearity of brain tissue homogenate on VEGFR1 ELISA. 
Spiked samples were treated with 2000 pg/mL of VEGFR1 recombinant protein and diluted. 
Unspiked samples contained brain homogenate only. Percentage recovery and linearity of 
brain homogenates did not fall within the manufacturer’s acceptable range of 80-120%. Control 
samples contain PBS diluent spiked with 2000 pg/mL of VEGFR1 and remained within the 
accepted range. 
3.4.1.4 VEGFR1 dot blot 
Dot blots were performed on cortex samples from control and AD cortex detailed in 3.4.1.1. 
Western blot displayed low levels of VEGFR1 in white matter which was confirmed by 
minimal immunolabelling of the white matter observed by IHC (3.2.1.3).  
Observed: Spiked sample value 
Unspiked: Unspiked sample value 
Expected: Amount spiked into sample  
x: dilution factor 
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Dot blotting for VEGFR1 was carried out as described in 2.5. Serial dilutions of homogenate 
standard were prepared using a 1:100 starting dilution in TBS. Homogenate samples were 
diluted at a concentration of 1:1000 in TBS. Following sample incubation for 1 hour the 
membrane was blocked with 5% BSA-TBST. VEGFR1 Ab32152 was used at a 
concentration of 1:2000 in 5% BSA-TBST and applied overnight at 4˚C. Secondary antibody 
was applied and membranes were developed and analysed using BioRad ImageLab 
software. A representative dot blot is shown in Figure 3-9 which shows the standard curve 
used to calculate relative units and the samples in triplicate. The background adjusted 
volume was calculated for each dot and relative values for each sample were calculated by 
interpolating from the 4-parameter logistic curve fit standard curve. A 7-point standard curve 
was created for each blot. Coefficient of variation (CoV) was performed between samples on 
each blot to calculate intra-assay reliability. Each sample was measured on two membranes 
and inter-assay reliability calculated by CoV. Any samples outside of the acceptable range 
were repeated. Values were corrected for the total protein concentration of the sample. 
Figure 3-9 Representative VEGFR1 dot blot. Blank and 7-point homogenate standard were run 
in triplicate. High standard was a 1:100 concentration of homogenate. The corresponding 
relative units for the homogenate standard are listed. Homogenates were diluted at a 
concentration of 1:1000 and assayed in triplicate. Coefficient of variation (CoV) was calculated 





3.4.2.1 VEGFR1 protein level in control and AD cortex 
An ELISA provides an accurate way to measure VEGFR1 protein levels in tissue 
homogenate. A commercially available Human VEGFR1 ELISA kit (R&D Systems) was used 
to develop an ELISA on brain tissue. Spike and recovery experiments demonstrated poor 
percentage recovery and linearity in human brain samples suggesting that a factor in the 
brain homogenate was interfering with the measurement. As a result, dot blotting with a 
validated antibody was used to assess VEGFR1 protein level in control and AD tissue 
samples. 
Figure 3-10. VEGFR1 protein level was significantly lower in AD than control brains (p= 0.02). 
Median ± interquartile range is displayed. C: n= 34, AD: n= 44. * p< 0.05. 
The level of VEGFR1 was measured in the parietal cortex of AD and control brains. The 
median level of VEGFR1 was significantly lower in AD than control brains (p= 0.02) although 




3.5 Proportion of VEGFR1 and sVEGFR1 in control and Alzheimer’s 
disease 
To follow the measurement of total VEGFR1 in the cortex, the level of sVEGFR1 in relation 
to membrane bound VEGFR1 was investigated. The aim of this work was to measure the 
proportion of sVEGFR1 in control and AD parietal cortex.  
3.5.1 Methods 
3.5.1.1 Western blot 
The western blotting for VEGFR1 as described in 3.2.1.2. Control samples and disease 
samples were selected at random from the parietal cortex cohort described in 3.4.1.1. The 
cases used were not age-matched and are detailed in Appendix 14. 
3.5.1.2 Calculation of mbVEGFR1:sVEGFR1 ratio 
sVEGFR1 isoforms have been identified and described in 3.2.2.1. Membranes were 
developed and analysed using BioRad ImageLab software. Western blot lanes and samples 
bands were selected. Molecular weights of sample bands were calculated with the ‘MW 
Analysis Tool’ using protein ladder(s) as a reference. Analysis table reports the volume of 
the intensities within band boundaries. These volumes were used to calculate the ratio of 
mbVEGFR1 to the sum of its soluble forms. 




Equation 3-3 mbVEGFR1: sVEGFR1 ratio 
3.5.1.3 Calculation of normalised densitometry of mbVEGFR1 and sVEGFR1 
The densitometry of mbVEGFR1 and the sum of sVEGFR1 isoforms was normalised to β-
actin. Membranes were analysed using BioRad ImageLab software as described in 3.5.1.2. 
The reported intensities for mbVEGFR1 and sVEGFR1 isoforms in were divided by the 
reported intensity of the β-actin band. 
mbVEGFR1: membrane bound VEGFR1 (reported intensity) 




3.5.2.1 mbVEGFR1:sVEGFR1 in control and AD parietal cortex 
Western blots with antibody to the N terminus of VEGFR1 were used to quantify membrane 
bound and soluble forms of VEGFR1 (Figure 3-11). mbVEGFR1 migrates at 180 kDa and 
sVEGFR1 isoforms range from 90-135 kDa. mbVEGFR1:sVEGFR1 was significantly lower 
in AD than controls (p= 0.046, Figure 3-12A). There was a significant decrease in 
mbVEGFR1 in AD compared to control when normalised to β-actin (p= 0.0057, Figure 
3-12B). No difference was observed in sVEGFR1 between control and AD when normalised 
to β-actin (Figure 3-12C). Uncropped blots are displayed in Appendix 15.  
Figure 3-11 VEGFR1 western blots on control and AD parietal cortex homogenates.  
mbVEGFR1 was observed at 180 kDa. sVEGFR1 isoforms were observed between 80-135 kDa. 




Figure 3-12 Densitometry of VEGFR1 western blots. [A] Scatterplot showing 
mbVEGFR1:sVEGFR1 in control and AD parietal cortex, as determined from integrated area-
density measurement of the western blot bands. The ratio was significantly lower in the AD 
brains (p= 0.046). [B] mbVEGFR1 normalised to β-actin. There was a significant reduction in 
mbVEGFR1 in AD compared to control. [C] The sum densities of sVEGFR1 isoforms 
normalised to β-actin. Median ± interquartile range is displayed. C: n= 12, AD: n= 12. ** p < 
0.01. 
3.6 Discussion 
The aim of this work was to determine the cellular distribution and levels of VEGFR1 mRNA 
and protein in human post-mortem cerebral cortex in AD and controls. 
The localisation of VEGFR1 was investigated by IHC in control and AD brain. The 
expression of VEGFR1 by neurons is in keeping with previous evidence of its involvement in 
neuroprotection 243, 244 and neurogenesis 245. It is also in accord with the roles of VEGF in 
neurogenesis, neuronal migration and synaptic plasticity 121, 210, 211, 267, 268. VEGFR1 was 
previously reported to be present on primary rat cultured microglia 141, in rat brain following 
middle cerebral artery occlusion 250 and in human control and AD brain 142. In contrast, 
VEGFR1 was not seen on microglia in other rat and porcine models of hypoxia 251-253. 
VEGFR1 immunopositivity within microglia was not seen in either AD or control brains in this 
study, contrary to the findings of Ryu et al (2009) who identified VEGFR1 in microglia in 
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control and AD brain tissue 142. The cohort used in this study was of modest and would 
benefit from expansion to confirm VEGFR1 localisation on microglia. Other reasons for the 
disparity could include their use of a different VEGFR1 antibody whose specificity was not 
confirmed, and a different fixation protocol. The same study identified VEGFR1 on microglia 
and a subset of astrocytes in a mouse model of AD 142. In the present study VEGFR1 was 
not observed on astrocytes in human frontal lobe. VEGFR1 was previously reported on 
astrocytes in fetal and early postnatal cortical rat explants 172, on a subset of reactive 
astrocytes in a rat model of CNS trauma 256 and in a rat model of hypoxia 255. Expression of 
VEGFR1 mRNA was also reported in rat astrocytes after addition of VEGF 254 but not in 
animal models of trauma and hypoxia 252, 253, 257 or transgenic AD mice 142. Animal models of 
hypoxia use differing experimental designs, making comparison difficult. It is also possible 
that there may be species or developmental differences in VEGFR1 expression. As there is 
evidence that VEGFR1 is expressed at low levels in astrocytes in normal CNS 250, it would 
be of benefit to conduct further studies on unfixed frozen tissue to assess VEGFR1 co-
localisation both in the healthy adult brain and in AD. 
The level of VEGFR1 mRNA was measured by qPCR in human parietal cortex. It was 
hypothesised that there would be an increase in VEGFR1 mRNA expression in AD. A 
reduction in CBF leads to reduced tissue oxygenation in AD and might be expected to 
upregulate VEGFR1 transcription 145, 246, 247 via hypoxia-inducible factor 1 (HIF1α) 269. 
In this study, there was a significant increase in VEGFR1 mRNA level in AD parietal cortex 
when calibrated against a control mRNA expressed in all cell types. VEGFR1 mRNA was 
also increased in relation to a neuronal transcript not affected by AD, in keeping with an 
increase in neuronal expression of VEGFR1 in AD. This finding is consistent with previous 
studies which have identified significant upregulation of VEGFR1 in neuronal populations in 
animal models and cell models of acute cerebral hypoxia 252, 254, 256. AD is a 
neurodegenerative disease and it might be expected that there would be neuronal loss in 
disease compared to controls 270. However, the level of the calibrator neuronal transcript was 
unchanged within the samples analysed. It would be useful to run a panel of neuronal 
markers in post mortem human tissue to assess stability with in control and disease.  
VEGFR1 was also increased but not significantly in relation to an endothelial calibrator 
mRNA, the level of which was itself elevated in AD. The elevation of VEGFR1 mRNA in 
endothelial cells was expected, due to its increased expression in hypoxic conditions and 
important role as a regulator of angiogenesis 144, 271. Since this study, the endothelial marker, 
PECAM1, has been found to be expressed by monocytes and neutrophil populations, and to 
be elevated in response to blood brain barrier disruption which may lead to its increased 
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expression in AD 272. In future studies, it would be worth using the gene encoding von 
Willebrand factor (vWF) as a more specific endothelial cell reference gene. 
In future qPCR studies it would be useful to use multiple reference genes for each cell type. 
In particular it would be beneficial to include an additional reference gene that would control 
for all cell types to accompany ACTB, for example, 18S rRNA or 28S rRNA shown to be 
stable under hypoxic conditions 260 261 and CYC1 found to be stable in post mortem brain 
tissue 262. This would ensure that changes in the gene of interest were attributed to disease 
state and not due to changes in the reference gene. 
Quantification of mRNA provided an indicator of VEGFR1 gene expression in the brain but 
proteins are subject to regulation at the translational and posttranslational level. To assess 
VEGFR1 protein level, VEGFR1 protein was measured by dot blot in the same samples. It 
was hypothesised that VEGFR1 protein would be increased in AD compared to controls in 
consequence of the elevation of VEGFR1 mRNA, as established by qPCR. Contrary to this, 
a reduction was seen in total VEGFR1 level in AD. This may reflect post-translational 
modifications or possible increased protein degradation in disease. There has been little 
investigation into VEGFR1 internalisation and degradation though VEGFR2 expression has 
been shown to be tightly regulated 130. 
Ikeda et al (2011) previously demonstrated downregulation of VEGFR1 in human 
microvascular endothelial cells, cultured under hypoxic conditions for 48 hours 273. The 
reduction in total VEGFR1 was attributed to a reduction in sVEGFR1 mRNA and protein, 
while the level of membrane bound VEGFR1 remained unchanged 273. Under conditions of 
chronic hypoxia the downregulation of sVEGFR1 may be physiologically beneficial, as 
sVEGFR1 isoforms are negative regulators of angiogenesis. Increased sVEGFR1 in AD 
could inhibit angiogenesis and reductions in sVEGFR1 isoforms could result in increased 
vessel formation to combat reduced oxygenation. To investigate this possibility western blots 
were used to assess the proportion of mbVEGFR1 and sVEGFR1 in control and disease 
parietal cortex. In contrast to the hypothesis, the ratio of mbVEGFR1 to sVEGFR1 was 
decreased in AD compared to control. When further investigated, the level of mbVEGFR1 
was found to be reduced in AD compared to control and there was no difference in 
sVEGFR1 level. This indicates an increase in the proportion of sVEGFR1 isoforms which 
may contribute to impaired angiogenesis despite the chronic hypoperfusion. There is 
evidence that VEGF can induce the expression of sVEGFR1 expression without effecting 
mbVEGFR1 transcription via a VEGF-A responsive element in intron 13 274. This direct 
regulation of sVEGFR1 splicing may explain the pattern of VEGFR1 expression in AD. 
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Soluble forms of VEGFR1 are yet to be investigated in the nervous system but have been 
found to be biologically important in cancer research and preeclampsia 275-277. To expand on 
the present work, future studies could include the measurement of mRNA level of soluble 
isoforms via qPCR and development of a sVEGFR1 specific ELISA in the control and AD 
brain to analyse changes in sVEGFR1 levels in a larger cohort. 
In future, it would be beneficial to conduct the mRNA and protein analysis on VaD samples 
to gain insight into possible changes in VEGFR1 expression in disease. This would provide 
further insight into the VEGF system in hypoxic disease and allow comparison with AD. 
Angiogenesis may be active in very early AD although structural abnormalities have been 
reported in several studies 278-281 and there is no reported increase in microvessel density in 
AD 78. Reduction in total VEGFR1 and mbVEGFR1 despite transcriptional upregulation may 
indicate a physiological adjustment to chronic hypoperfusion but an increase in the 




Chapter 4 VEGFR2 
4.1 Introduction 
VEGFR2 (KDR, Flk-1) is a major regulator of angiogenesis in health and disease and is the 
main signal transducer for VEGF 107, 129, 168, 170. In the adult nervous system VEGFR2 also 
mediates neurogenesis 267, LTP 211, neuronal survival 268, astrocyte migration 282 and 
proliferation 283, 284 (1.2.2.2). VEGFR2 level is regulated by VEGF binding 285, 286 and by HIF-
2α 287. VEGFR2 activation can occur by the binding of its canonical ligands VEGF, VEGF-C, 
VEGF-D and by non-canonical activation via shear stress, gremlins, galectins, lactate and 
low density lipoproteins (LDLs) 130. Co-receptors, NRP1 and NRP2 and HSPGs, can also 
mediate the activation of VEGFR2. Receptor activation is regulated by internalisation and 
degradation, and the activity of protein tyrosine phosphatases (PTPs) 130, 288. PTPs are 
enzymes that remove phosphate groups from phosphorylated tyrosine kinase residues and 
therefore regulate receptor function via altering the duration and extent of phosphorylation. 
Several PTPs act on VEGFR2 and there is evidence that some PTPs act on specific VEGFR 
phosphotyrosines 130, 174. 
CBF is reduced in AD more than can be accounted for by a reduction in metabolic demand, 
and this results in cerebral hypoxia. Few studies have addressed VEGFR2 localisation in the 
human brain although there have been several published studies considering its distribution 
in models of brain ischaemia. VEGFR2 has been shown to be present on endothelial cells 
and neurons 129, 134; however, there is debate in the literature as to whether the receptor is 
localised on glial cells. 
In human post-mortem studies VEGFR2 has been observed on astrocytes in the developing 
brain 289, 290. In contrast, VEGFR2 was not observed on astrocytes in a large cohort, human 
post-mortem study of white matter lesions 291. Looking to animal literature for clarification, 
models of trauma and hypoxia in the nervous system are similarly contradictory. VEGFR2 
has been identified on primary rat astrocytes 284, in a subset of GFAP-positive astrocytes in 
the normal and aged rat brain 292 and on astrocytes in mouse hippocampus 293. Astrocytes 
immunopositive for VEGFR2 were reported in rats treated with an endothelin receptor type B 
receptor agonist 294. VEGFR2 immunoreactivity was also reported on glial cells and 
endothelial cells in a rat study of transient and permanent brain ischaemia. However, double 
immunolabelling to confirm cellular localisation was not carried out 250. In contrast, VEGFR2 
was not identified on astrocytes in the rat brain after direct VEGF infusion 254 or brain trauma 
255, nor was it identified on astrocytes in pigs after hypoxia preconditioning or transient 
ischaemia253. There have been conflicting reports of the presence of VEGFR2 on microglia 
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in animal studies 141, 251, 295. Human post-mortem studies also provide conflicting evidence as 
VEGFR2 has previously been reported on activated microglia in a study of white matter 
lesions in normal aged brains 291 but was not identified in a study of temporal cortex and 
white matter in control or epilepsy cases 296. In vivo models of acute ischaemia have 
identified VEGFR2 mRNA in microglia by qPCR 251 but not in vitro by examination of mRNA 
or protein in murine microglia 141. There have been no studies that have shown that VEGFR2 
modulates microglial function, although there is evidence in favour of VEGFR1 as a mediator 
of microglial migration and proliferation 141. From the evidence so far, it was not entirely clear 
whether microglia would express VEGFR2 in the human brain tissue in this study.  
Since cerebral hypoperfusion and hypoxia are part of AD pathology, and as VEGF signalling, 
via VEGFR2, controls vascular sufficiency by angiogenesis, it is important to look not only at 
the level of VEGF in AD brain but also to correlate this with expression of the receptor. 
VEGFR2 expression is regulated by VEGF 285, 286 and there is evidence that VEGFR2 is 
directly upregulated by HIF-2α 287. VEGFR2 mRNA has been shown to be upregulated by 
hypoxia in human lung 248 and injured rat brain 254. VEGFR2 mRNA was shown to be stable 
or downregulated in human umbilical vein endothelial cells (HUVECs) 297 and in other in vitro 
primary endothelial cell models of hypoxia 298, and no change was seen in VEGFR2 mRNA, 
measured by northern blot, in mouse brain after exposure to hypoxic conditions for 6 hours 
258. I hypothesised that VEGFR2 would be increased in AD, compared to controls, due to the 
relative cerebral hypoxia in AD and elevated VEGF level.  
Studies of VEGFR2 protein expression in animal models of brain ischemia and in vitro 
models of nervous system hypoxia have yielded conflicting results. In some, VEGFR2 
protein has been reported as upregulated in response to hypoxia in vitro 299, 300, rat 301, 
porcine 253 and primate 302 models. In other studies, VEGFR2 was reported unchanged in a 
mouse model 258 or reduced by 70% in primary endothelial cells exposed to hypoxia 298. It is 
hypothesised that VEGFR2 will increase in AD, compared to control, in accordance with a 
mRNA increase and evidence of VEGFR2 elevation in animal models.  
In addition, the level of VEGFR2 activation is also of interest in both AD and VaD. The 
binding of VEGF results in receptor dimerization and autophosphorylation of the highly active 
VEGFR2 receptor kinase region 174 to give phosphorylated VEGFR2 (p-VEGFR2). At least 
19 phosphorylation sites have been characterised on VEGFR2 303. Of the tyrosine residues 
present in the VEGFR2 intracellular domain, those known to play a major role are Tyr 
(tyrosine, Y) 951/996 303, Tyr1054/9 107 and Tyr1175 130, 303. Tyr1054/9 are required for 
maximum kinase activity 107 and mutation analysis has shown Tyr996 is essential for 
receptor activation 304, 305. Mutagenesis of Tyr1175 has the same phenotypic effect as 
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VEGFR2 knock out and is crucial for PLCγ activation 130. The level of VEGF induced p-
VEGFR2 at Tyr996 and Tyr1175 were reported to be reduced in human coronary artery 
primary endothelial cells when exposed to hypoxia in correlation with a reduction in VEGFR2 
expression 298. 
Disruption of VEGFR2 location, level or downstream signalling could contribute to reduced 
angiogenesis in AD despite elevated VEGF level 78. The presence of Aβ in AD brain may 
also have an impact on VEGFR2 bioavailability and signalling. Aβ1-42 has been reported to 
be anti-angiogenic 306, 307 and is able to bind to VEGFR2 and block receptor phosphorylation 
at Tyr996 in vitro 308. To assess the impact of Aβ on VEGFR1 and VEGFR2 protein, white 
matter was used as an internal control and VaD used as a disease control in which there is 
hypoperfusion but Aβ pathology is absent. There have been no studies assessing VEGFR2 
localisation in AD and the level of VEGFR2 in post-mortem human brain is yet to be 
investigated by qPCR or protein measurement. 
Results presented in this chapter on the cellular localisation of VEGFR2 and the level of 
VEGFR2 in human brain tissue were recently published 259. 
4.1.1 Hypotheses 
[1] VEGFR2 will be located on endothelial cells, astrocytes and neurons. VEGFR2 has been 
identified on astrocytes in human studies and several animal models,  
[2] VEGF directly regulates the transcription of VEGFR2, therefore the level of VEGFR2 
mRNA will be increased in the AD parietal cortex compared to control. 
[3] Hypoxia directly regulates the transcription of VEGFR1, which can regulate the protein 
level. Therefore the level of VEGFR2 protein will be increased in AD and VaD parietal cortex 
and white matter compared to control. 
[4] Following that VEGFR2 protein level and VEGF protein level are elevated in the AD and 
VaD brain. As hypothesised in [3] above, if the level of the VEGFR2 is increased, it is 
hypothesised that the level of phosphorylation of VEGFR2 will be increased in VaD and AD 
compared to control.  
4.1.2 Aims 
[1] To examine the cellular localisation and distribution of VEGFR2 protein in control and AD 
post-mortem frontal lobe tissue by immunohistochemistry. 
[2] To measure the level of VEGFR2 mRNA in parietal cortex from AD compared with brain 
tissue from controls by qPCR. 
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[3] To measure the level of VEGFR2 protein level in parietal cortex and white matter from 
control, AD and VaD by ELISA.  
[4] To measure VEGFR2 phosphorylation in control, AD and VaD parietal cortex and white 
matter by ELISA. 
4.2 VEGFR2 localisation 
The aim of this work was to examine the localisation of VEGFR2 in human brain. There have 
been conflicting reports of VEGFR2 localisation on glial cells in the literature and identifying 
the location of VEGFR2 will help to further understand its role in disease.  
4.2.1 Methods 
4.2.1.1 Study cohort 
Control and AD cases were neuropathologically confirmed as described in 2.2. The 
neuropathological and demographic features of control and AD cases used for 
immunostaining are summarised in 3.2.1.1 and details of individual cases can be found in 
the Appendix 10. FFPE frontal lobe, sectioned prior to the start of this study, was used to 
investigate VEGFR2 localisation. Frozen parietal cortex from control cases was used to 
perform western blotting and the cohort used is detailed in 4.3.1.1 
4.2.1.2 Western blot 
Total protein concentration for tissue homogenates was calculated as described in 2.3. 
Western blotting was carried out as described in 2.4. Samples were run on 7.5% precast 
gels. The membrane was blocked with 5% BSA-TBST for 1 hour and incubated overnight at 
4°C with anti-VEGFR2 antibody at a concentration of 1:1000 in 3% BSA-TBST. β-Actin was 
used as a loading control at 1:5000 in 5% milk-TBST. HUVEC lysates express both VEGFR1 
and VEGFR2 and were used as a positive control. 
4.2.1.3 Immunohistochemistry 
Immunohistochemistry was performed as described in 2.9.1. The antibody was titred to 
determine the optimal concentration and tested with both EDTA and citrate buffer pre-
treatment to enhance straining as described in 2.9.3. Sections were pre-treated with citrate 
buffer prior to immunolabelling with anti-VEGFR2 antibody at 1:200. A no primary control 
was carried out to account for any non-specific binding of the secondary antibody. Antibody 
diluent was applied, followed by secondary antibody incubation and detection. An 
immunoglobulin control was performed to ensure staining was not caused by non-specific 
interactions of immunoglobulin in the tissue. Sections were incubated with an 
immunoglobulin of the same isoform, species and concentration as the primary antibody 
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then secondary antibody incubation and detection was carried out. In this case anti-rabbit 
IgG was used at a concentration of 260 ng/ml and incubated or 1 hour at RT.  
4.2.1.4 Double immunofluorescence and immunohistochemistry 
VEGFR2 co-localisation in glial cells was investigated by double immunohistochemistry 
(2.9.2) and double immunofluorescence (2.10). 
Distribution of VEGFR2 was investigated using anti-VEGFR2 antibody at 1:200. Antibodies 
against GFAP, an astrocyte marker, and HLA-RD, a microglia and macrophage marker, 
were both used at a concentration of 1:200. Sections were pre-treated with citrate buffer 
prior to immunolabelling with the first antibody. VEGF receptors were labelled first and 
visualised with DAB (brown). Glial cells were labelled second and visualised with VIP 
(purple). AD tissue was used to provide areas of immune cell activation, often not present in 
control brain tissue. 
4.2.2 Results 
4.2.2.1 Validation of VEGFR2 antibody specificity 
Western blot confirmed the presence of VEGFR2 in human brain homogenate. Bands in 
human brain homogenate were present at the predicted molecular weight of VEGFR2 (210 
and 230 kDa) corresponding to the bands in HUVEC lysate used as a positive control. The 
230 kDa band is the glycosylated mature form of the receptor and the 210 kDa band 
corresponds to the non-glycosylated mature form of the receptor 309, 310. There was no cross-
reactivity with VEGFR1 as no bands were seen at the predicted molecular weight of 





4.2.2.2 Localisation of VEGFR2 in control brain and AD brain 
Immunohistochemistry was performed to elucidate the cellular localisation of each of 
VEGFR2 in AD and control cortex. No labelling was observed on negative (no primary 
antibody) or IgG controls (Figure 4-2).  
Macroscopically VEGFR2 appeared uniform in intensity across grey and white matter and no 
difference was observed between control and AD cases (Figure 4-3). VEGFR2 antibody 
labelled some but not all neurons in the grey matter (Figure 4-4A, B). VEGFR2 
immunopositivity was identified on glial cells in the white matter of both control and AD cases 
(Figure 4-4C, D). VEGFR2 labelled the endothelium of capillaries and tunica media of 
arterioles on control and AD cases (Figure 4-4E and F). 
  
Figure 4-1 Western blot validation of specificity of VEGFR2 antibody in parietal cortex. HUVEC 
lysate was used as a positive control, as the cells express both VEGFR1 and VEGFR2. Bands 
in human brain homogenate were labelled at the predicted molecular weight of VEGFR2 (210 




Figure 4-2 Negative controls on human frontal lobe. [A] No-VEGFR2-primary antibody control. 






Figure 4-3 VEGFR2 IHC of control and AD frontal lobe. A uniform pattern of labelling was seen 
across grey and white matter. No difference was observed between control [C] and AD [D]. In 
[C] there is some artefactual signal but that in general the labelling is weaker and not specific to 
the cerebral cortex. VEGFR1 IHC of control [A] and AD [B] frontal lobe is shown for comparison. 
Strong immunopositivity is observed in the cortex compared to the white matter in control and 




Figure 4-4 VEGFR2 antibody labelling of control and AD frontal lobe. VEGFR2 labelling was 
seen in the endothelium of capillaries and venules (arrowhead) in control [A] and AD [B]. 
Approximately 100% the capillaries and arterioles were immunopositively for VEGFR2 in C and 
AD. VEGFR2 antibody weakly labelled scattered neurons (arrowheads) in the grey matter in 
control [C] and AD [D]. Approximately 10% of neurones in the cortex could be visualised with 
VEGFR2 immunopositivity. VEGFR2 immunopositivity was identified on glial cells (arrows) in 
the white matter of control [E] and AD [F]. Approximately 70% of astrocytes were positively 
identified by VEGFR2 immunopositivity. Scale bars = 100µm. 
4.2.2.3 Glial localisation of VEGFR2 in AD brain 
To assess cellular localisation of VEGFR2 on glial cells double immunolabelling was 
performed. Double immunofluorescence was first attempted. High levels of background 
fluorescence were observed and persisted despite the adjustment of primary antibody 
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concentration and the use of pre- and post-treatments to reduce autofluorescence (Appendix 
16). Double immunoperoxidase labelling was used as an alternative.  
Double-labelling of VEGFR2 (brown) and either GFAP, an astrocyte marker, or HLA-DR, a 
microglial marker, (purple) in AD and control brains (Figure 4-5). VEGFR2 immunolabelling 
was present select neuronal cell bodies but not the surrounding neuropil (Figure 4-5A). In 
endothelial cells, VEGFR2 labelled the cytoplasmic membranes (Figure 4-5A, C) and tunica 
media of larger blood vessels (Figure 4-5A). VEGFR2 was colocalised with GFAP-positive 
astrocytes in the white matter and deep cortex (Figure 4-5A, B). VEGFR2 was not detected 







Figure 4-5 Cellular localisation of VEGFR2 in human parietal cortex. [A] Double-labelling of 
VEGFR2 (brown) and GFAP (purple) reveals VEGFR2 within endothelial cells, the tunica media 
of larger vessels, in neurons and GFAP-positive astrocytes. Bar = 100 µm. [B] This image 
shows more clearly the co-localisation of VEGFR2 with GFAP within astrocytes. Bar = 50 µm. 
[C] Double-labelling of VEGFR2 (brown) and HLA-DR (purple) does not show convincing co-
localisation of these antigens within microglia. A capillary shows a membranous pattern of 
VEGFR2 immunolabelling. Bar = 50 µm 
4.3 VEGFR2 mRNA level in control and Alzheimer’s disease  
The aim of this work was to measure the VEGFR2 mRNA level in the parietal cortex of 
control and AD. 
4.3.1 Methods 
4.3.1.1 qPCR study cohort 
Fresh frozen parietal cortex from control and AD patients was used to investigate VEGFR2 
mRNA expression. Control and disease subjects were age-matched and, where possible, 
matched for gender. All subjects had a post-mortem delay of less than 90 hours. The 
neuropathological and demographic features of control and AD cohorts are described in 
Table 3-3. 
4.3.1.2 Selection of primers for VEGFR2 
Alternate splicing of the kinase insert domain receptor (KDR) gene can produce membrane 
bound VEGFR2 and a soluble isoform known as sVEGFR2 (1.2.2.2.1). This study focuses 
on membrane bound VEGFR2 as the main mediator of VEGF action and the primer set was 
selected to measure membrane bound VEGFR2 only. The genomic map containing primer 
location can be found in Appendix 13. 
4.3.1.3 Selection of reference genes for relative quantification 
In this study VEGFR2 was expressed on neurons, endothelial cells and astrocytes in the 
control and AD brain (4.2.1.4). ACTB, encoding β-actin, was used to normalise for total cell 
content. RBFOX3, encoding NeuN, was used to normalise to the neuronal population and 
PECAM1, encoding platelet endothelial cell adhesion molecule (CD31) was used to 
normalise to the endothelial cell population. The rationale behind the selection of these 
reference genes is presented in 3.3.1.3.  
To normalise for the expression of VEGFR2 on astrocytes the astrocyte specific reference 
gene aldehyde dehydrogenase 1 family member L1 (ALDH1L1) was selected. In contrast to 
the traditional astrocytic marker, GFAP, ALDH1L1 has a wider pattern of astrocytic 




RNA was extracted from fresh frozen parietal cortex as detailed in 2.11.1. cDNA was 
generated as described in 2.11.4, added to primers and master mix and made up to total 
volume with RNase free water. Samples were analysed in triplicate with non-template 
controls on each plate using the protocol detailed in 2.11.5. 
4.3.1.5 Statistical analysis 
The 2-ΔΔCt method was used to determine the fold difference between VEGFR2 and 
reference genes (ACTB, RBFOX3, PECAM1 and ALDH1L1) as described in (2.12). Groups 
were tested for normality and were found to have a non-normal distribution, as expected with 
exponential values. The geometric mean was calculated for each group and has been 
displayed with a 95% confidence interval. Individual sample 2-ΔΔCt values were used to 
perform the Mann Whitney test for difference in distribution between control and AD groups. 
4.3.2 Results 
4.3.2.1 Expression of the reference genes in control and AD 
Reference genes were validated prior to investigating genes of interest. ACTB acted as a 
reference gene expressed at similar levels in all cell types. The stability of ACTB in control 
and AD brain is displayed in 3.3.2.1. RBFOX3 is expressed in neuronal cells, ALDH1L1 is 
expressed in astrocytes and PECAM1 in endothelial cells. The fold change in mRNA levels 
of RBFOX3, PECAM1 and ALDH1L1 was calculated relative to the mean level in control 
tissue using ACTB as the calibrator. There was no significant difference in the fold change of 
RBFOX3 between control and AD (~1.12-fold increase, p = 0.436) and there was a 
significant ~1.6-fold increase in PECAM1 (p = 0.021) as reported in 3.3.2.1. There was a 






Figure 4-6 RBFOX3, PECAM1 and ALDH1L1 mRNA levels were measured by qPCR in parietal 
cortex. Fold difference in RBFOX3, PECAM1 and ALDH1L1 mRNA was calculated via the 2-ΔΔCt 
method using ACTB as a calibrator gene and compared to mean levels in control tissue. There 
was a significant increase in the fold change of PECAM1 (p = 0.021) and ALDH1L1 (p< 0.0001) 
in AD samples compared to control. There was no significant difference between the fold 
change of RBFOX3 between control and AD. The geometric mean and 95% confidence 
intervals of the 2-ΔΔCt values are shown for each group on a log2 scale. Horizontal line indicates 
2-ΔΔCt fold change of 1 assigned to control samples, increases or decreases from this line in 
disease subjects indicate corresponding fold changes in gene expression in disease. C: n = 
31, AD: n = 47. * p < 0.05  *** p < 0.001 
4.3.2.2 VEGFR2 mRNA levels in control and AD brain 
VEGFR2 mRNA levels were calibrated against four reference genes displayed in Figure 4-7. 
Assessment of VEGFR2 mRNA with reference to ACTB showed a significant increase in AD 
compared to control (3.4-fold respectively, p= 0.0002). VEGFR2 mRNA with reference to 
RBFOX3 showed in a significant increase in AD compared to controls (~2.9-fold increase, p= 
0.0003). VEGFR2 calibrated against PECAM1 also displayed a significant increase in AD 
compared to control (~2.1-fold increase, p= 0.008). VEGFR2 mRNA with reference to 
ALDH1L1 showed a significant fold-increase in AD compared to controls (~1.8-fold increase, 




Figure 4-7 VEGFR2 mRNA levels measured by qPCR in homogenates of parietal cortex. The 
fold difference relative to the mean in control tissue was calculated for each sample by the 2-
ΔΔCt method, with ACTB (β-actin), RBFOX3 (neuronal), ALDH1L1 (astrocytic) and PECAM1 
(endothelial) as calibrators. The geometric mean and 95% confidence intervals of the 2-ΔΔCt 
values are shown for each group on a log2 scale. C: n = 32, AD: n = 46. * p<0.05  ** p<0.01  ***  p 
< 0.001 
4.4 VEGFR2 protein level in control, Alzheimer’s disease and vascular 
dementia 
The aim of this work was to measure total VEGFR2 and p-VEGFR2 protein level in control, 
AD and VaD parietal lobe. 
4.4.1 Methods 
4.4.1.1 VEGFR2 protein cohort selection 
VEGFR2 level was measured in the parietal cortex and white matter of control, AD and VaD 
cases. In addition to the parietal cortex, white matter of the same brains was used as an 
internal control. White matter in the AD brain is hypoperfused but contains little or no Aβ 72. 
VaD was used as a disease control. VaD is defined by hypoperfusion but with the absence 
of the Aβ and tau pathology present in AD (1.1.2). AD and VaD can display mixed pathology, 
VaD cases in this study were selected to have little or no AD pathology.  
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Parietal cortex and white matter Control AD VaD 
N 36 50 19 
Age (years) Range 58 - 95 57 - 93 67 - 97 
Mean ± SD 80.1 ± 8.7 77.5 ± 8.1 82.9 ± 7.3 
Gender Female 11 26 9 
Male 25 24 10 
Post-mortem delay 
(hours) 
Range 3 - 67 4 - 85 20 - 85 
Mean ± SD 32.5 ± 16.3 31.6 ± 19.0 47.6 ± 19.0 
Table 4-1 Summary of the neuropathological and demographic features of the control, AD and 
VaD cohorts used for VEGFR2 protein analysis. Demographic and neuropathological features 
of individual cases are listed in the Appendix 9. 
4.4.1.2 VEGFR2 sandwich enzyme-linked immunosorbent assay 
Human total VEGFR2 (KDR) duoset IC ELISA kit was used to measure VEGFR2 protein 
level in human brain tissue. Frozen brain samples were homogenised as detailed in 2.2.3 
using the manufacturers recommended NP-40 based lysis buffer with phosphatase and 
protease inhibitors (Lysis buffer #9). The assay was carried out according to manufacturer’s 
instructions summarised in 2.6. Readings were blank corrected and a 7-point curve was 
constructed from VEGFR2 recombinant standards. A 4-parameter logistic curve fit was 
applied, and sample values were interpolated. 
Fifty µl of standard and sample was added to each well. Samples were measured in 
duplicate on each plate and selected samples were measured on two plates to test 
interassay reliability. Additional controls were performed to ensure that no other factors were 
interfering with the accuracy of the assay. Capture antibody was replaced with PBS to test 
for VEGFR2 binding to the plate. Lysis buffer was used in place of sample to account for the 
interference of buffer components with measurement. Detection antibody and streptavidin 
HRP solution were each replaced with IC diluent #14 to account for any non-specific binding. 
All controls returned the same reading as blank values. The detection antibody was tested 
for specificity on human brain lysate by western blot and displayed bands at the predicted 
molecular weight for VEGFR2 (Appendix 17). 
4.4.1.2.1 Spike, recovery and linearity testing 
The ELISA kit had been validated for use on cell culture supernatant, serum and plasma 
samples by the supplier. To validate the ELISA kit for use on human brain tissue, 
homogenates were spiked with recombinant protein, and recovery and linearity testing was 
performed. 1000 pg/ml of VEGFR2 recombinant protein was added to ‘spike’ neat brain 
tissue homogenate and to control diluent (IC diluent 14) to make the control spike. The 
spiked sample, unspiked homogenate and control spike were mixed thoroughly and serial 
dilutions performed. Percentage recovery and linearity were calculated as described in 
90 
 
3.4.1.3. Percentage recovery and linearity with recombinant protein added were within the 
manufacturer’s acceptable range of 80-120% (Table 4-2). 
 
% Recovery 
Spiked Unspiked Control 
Neat 87.3 - - 
1:2 96.9 108.6 118.9 
1:4 93.6 115.7 113.9 
Table 4-2 Percentage recovery and linearity of brain tissue homogenate on VEGFR2 ELISA. 
Spiked samples were treated with 1000 pg/mL of VEGFR2 recombinant protein and diluted. 
Unspiked samples contained brain homogenate only. Percentage linearity was within the 
manufacturer’s acceptable range of 80-120%. Control samples contain IC diluent #14 spiked 
with 1000 pg/mL of VEGFR1 and remained within the accepted range. 
4.4.1.2.2 Interassay reliability  
The interassay reliability of the VEGFR2 ELISA was tested by measuring the same sample 
on two different plates. The coefficient of variation (CoV) was used to compare the mean 
values of the first plate to the second. The CoV was less than 5% for each of the samples 
tested showing that the assay is reliable (Table 4-3). 
MRC 
Identifier 
VEGFR2 (pg/ml) CoV (%) 
Plate 1 Plate 2 
BBN_9106 867.2 865.8 3.1 
BBN_9112 611 605.2 4.2 
BBN_4205 231.7 242.9 4.1 
BBN_9354 248.5 255.4 1.9 
Table 4-3 VEGFR2 ELISA interassay reliability. Homogenates from the same samples were 
measured on two different plates. CoV was performed to assess the relative variability of 
sample readings. CoV: coefficient of variation. 
4.4.1.3 p-VEGFR2 sandwich ELISA 
To measure the level of VEGFR2 phosphorylation in human brain tissue a p-VEGFR2 ELISA 
kit was tested. The ELISA was carried out in accordance with manufacturer’s instructions 
and as described in 2.6. The assay was not specific to one phosphorylation site but used a 
capture antibody specific to VEGFR2 and an anti-phosphor-tyrosine-HRP specific to 
phosphorylated tyrosine residues. Spike, recovery and linearity testing revealed recovery 
and linearity were outside the manufacture’s accepted range so the assay was not used 
(Appendix 18).  
4.4.1.4 p-VEGFR2 western blot 
Samples were run on a 4-20% precast gel. The membrane was blocked with 3% BSA-TBST 
for 1 hour and incubated overnight at 4°C with anti-p-VEGFR2 (Tyr 996) antibody at a 
91 
 
concentration of 1:200 in 3% BSA-TBST. β-Actin was used as a loading control at 1:5000 in 
5% milk-TBST. HUVEC lysates express both VEGFR1 and VEGFR2 and were used as a 
positive control. Western blots did not show a band at the predicted molecular weight for p-
VEGFR2 (150 kDa) in human brain tissue or cell lysate so the antibody was not used 
(Appendix 19). 
4.4.2 Results 
4.4.2.1 VEGFR2 protein level in control, AD and VaD cortex 
The level of VEGFR2 in the cortex and white matter of control, AD and VaD cases was 
measured by ELISA. There was no significant difference in the level of VEGFR2 between 
control, AD and VaD cases in the parietal cortex (Figure 4-8).  
Figure 4-8 VEGFR2 protein levels in parietal cortex measured by sandwich ELISA. No 
significant difference was observed between control and disease groups. Median ± 
interquartile range for each group are displayed. C: median = 328.8, interquartile range = 314.1, 
n= 36, AD: median 394.6, interquartile range: 491.1, n= 48, VaD: median = 400, interquartile 
range = 506.6, n= 19 
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4.4.2.2 VEGFR2 protein level in control, AD and VaD white matter 
A significant difference in median values was reported between groups (p= 0.037) (Control: 
Median = 151.7, Interquartile range = 127.4, AD: Median = 174.1, Interquartile range = 
113.5, VaD: Median = 131.0, Interquartile range = 102.6) and pairwise analysis revealed a 
significantly lower value for the VEGFR2 level in VaD compared to AD (p< 0.05, Figure 4-9).  
4.5 Discussion 
The aim of this work was to determine the cellular distribution and level of VEGFR2 mRNA in 
human post-mortem cerebral cortex in AD and controls. The cohort was expanded to include 
measurement of VEGFR2 protein level in the cortex and white matter of control, AD and 
VaD brains. 
The cellular localisation of VEGFR2 is clearly critical to its function in the brain but the 
literature includes conflicting accounts of VEGFR2 location, particularly on glia. The first aim 
of this study was to investigate this by visualisation of VEGFR2 by IHC in control and AD 
brain. VEGFR2 was not detectable on all neurons, an observation that has been noted in the 
literature 313. This labelling of some but not other neurons suggests possible neuronal 
subtype specificity, or the influence of localised microenvironmental factors. For example, 
VEGFR2 was identified on pyramidal neurons by Boer et al (2008) 296 and VEGFR2-positive 
neurons were increased in acute hypoxic conditions compared to control 302. VEGFR2 
localisation correlates with VEGF expression in the human brain 72, 212 and supports the role 
Figure 4-9 VEGFR2 protein levels in parietal white matter measured by sandwich ELISA. No 
difference was reported in VEGFR2 level between control and disease groups. A significantly 
lower value was observed for VaD compared with AD (p< 0.05). Median ± interquartile range for 
each group are displayed. C: median = 151.7, interquartile range: 127.4, n= 36, AD: median: 
174.1, interquartile range: 113.5, n= 50, VaD: median 131.0, interquartile range: 102.6, n= 19 
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of VEGFR2 as the mediator of VEGF in neurogenesis, neuronal migration and synaptic 
plasticity 121, 210, 211, 245, 267, 268, 293. 
In this study VEGFR2 was identified on astrocytes in control and AD brain. VEGFR2 was not 
identified on astrocytes in control subjects in a study on post mortem spinal cord, and was 
identified on GFAP-positive-astrocytes in only 2 out of 15 cases of ALS 313. This raises the 
possibility that the activation state of astrocytes may affect their expression of VEGFR2. No 
VEGFR2 immunopositivity was identified on microglia in control or AD brains in this study. 
This supports work by Boer et al 296 and provides further evidence that VEGFR1 rather than 
VEGFR2 is the main mediator of VEGF action on microglia.  
Following the completion of this work, a study of VEGFR2 immunohistochemical labelling 
was published, using the same anti-VEGFR2 antibody as used here, in human brain 171. The 
group looked at sections from the caudate and putamen of controls, those with a range of 
SVD severity, and CADASIL patients with a genetically determined form of SVD (1.1.2.1). 
The group identified sparse labelling of neurons in agreement with results reported here. 
VEGFR2 labelling was found on some but not all capillaries, and in vascular smooth muscle 
cells. In agreement with the results presented here, the group reported labelling of a subset 
of astrocytes and no labelling of microglia 171.  
The second aim of the present study was to measure the level of VEGFR2 mRNA in control 
and AD by qPCR. There was a significant increase in VEGFR2 mRNA in relation to β-actin 
mRNA in AD compared to control brains. To ensure that this was not simply due to an 
increase in the proportion of astrocytes or other VEGFR2-expressing cells within the tissue, I 
also assessed VEGFR2 mRNA level in relation to that of astrocyte-, endothelium- and 
neuron-specific mRNAs. This revealed an increase in VEGFR2 mRNA in relation to all of 
these cell type-specific mRNAs, indicating that the upregulation of VEGFR2 mRNA that I 
detected in AD is not an artefact of altered cellular composition of the tissue. It may be 
relevant that there is also significant upregulation of neuronal VEGFR2 mRNA in animal 
models of CNS trauma 256, in which, as in AD, there is also upregulation of VEGF, reactive 
astrocytosis and, at least temporarily, a potential disparity between metabolic demand and 
cerebral oxygenation. VEGFR2 was measured by qPCR in vitro and in vivo in mice and 
found to increase with hypoxia 283.  
Measuring mRNA levels is a useful indicator of VEGFR2 expression but proteins are also 
subject to translational and post-translational modification. The third aim of this study was to 
measure VEGFR2 total protein level in the same samples of parietal cortex, as well as white 




The level of VEGFR2 protein was not changed in AD or VaD compared to control cortex or 
white matter. In the white matter however, there was a 25% lower level of VEGFR2 in VaD 
than AD. I had expected that VEGFR2 would be increased in AD, in keeping with mRNA 
results, due to the relative hypoxia and associated increase in VEGF. Studies of VEGFR2 
expression in animal models of brain ischaemia and in vitro models of nervous system 
hypoxia have yielded conflicting results. An in vitro study by Waltenberger et al. (1996) on 
two endothelial cell types found that exposure to hypoxia initially upregulated VEGFR2 
protein, reaching a peak at 24 hours, but VEGFR2 expression then declined, becoming 
undetectable after 48 hours 297. In the same study, VEGFR2 mRNA level remained stable 
during hypoxic conditions. This indicates post-translational regulation of VEGFR2 in hypoxic 
conditions and suggests a possible explanation for the disparity between expression of the 
mRNA and protein in the present study. 
As expected, the level of VEGFR2 was lower in white matter than in cortex in control, AD 
and VaD brains. A reduction in VEGFR2 level in VaD in comparison to AD could be 
secondary to more pronounced hypoxic damage to astrocytes and/or endothelial cells in the 
white matter in VaD than in AD 102, 105 but further studies are needed to clarify the specific 
mechanisms underlying the differences.  
The fourth aim of this work was to measure the level of p-VEGFR2 in human brain tissue, 
but an effective method of measurement could not be optimised. The report of Aβ1-42 acting 
directly on VEGFR2 to block receptor phosphorylation at Tyr996 308 suggested that the 
presence of Aβ could have a direct effect on angiogenesis in AD. Future work to elucidate 
phosphorylation levels in human tissue would provide insight into receptor activation and the 
possible impact of Aβ on VEGFR2 function.  
The lack of difference in VEGFR2 level between control and AD brains is in keeping with the 
absence of any increase in microvessel density in AD, as previously reported 78. There was 
no difference in receptor localisation was between control and disease. Elevated VEGF 72, 78, 
198, 212, 314 seems unable to increase microvessel density in AD despite normal VEGFR2 level, 
suggesting that VEGFR2 signalling is defective in AD. Disruption of VEGFR2 ligand binding 
or alteration in downstream signalling could be responsible. Further work is needed to 




Chapter 5 VEGFR1 and VEGFR2 correlations with 
blood vessel density, hypoperfusion and Aβ 
5.1 Introduction 
The observation that prompted this work is that CBF is reduced in AD and associated with 
elevation of VEGF but without a corresponding increase in microvessel density. The aim was 
to investigate whether abnormalities in the VEGF-VEGFR system might be responsible for 
disrupted angiogenesis in AD. As part of this investigation, the levels of VEGFR1 and 
VEGFR2 were measured in the parietal lobe. This chapter covers further studies aimed at 
understanding the relevance of the differences observed in VEGFR1 and VEGFR2 between 
control and dementia brains, and describes the analysis of the relationship between these 
receptors and markers of cerebral hypoperfusion and AD pathology in controls, AD and VaD.  
vWF has previously been used as a surrogate measure of microvessel density in human 
post-mortem samples 72, 315, 316. Previously, this marker of microvessel density has been 
shown not to be changed in AD despite the increased VEGF 78. VEGF is a key regulator of 
angiogenesis and the main ligand for VEGFR1 and VEGFR2. Measurement of VEGF and 
vWF should provide information about responsiveness to angiogenic stimulation in the 
parietal lobe. I hypothesised that in AD there would be a negative relationship between 
VEGF and VWF as a consequence of abnormal expression of VEGFR1 and VEGFR2. I 
have also assessed whether the expression of VEGFR1 and VEGFR2 is altered by 
cerebrovascular pathology in AD and VaD. 
Cerebrovascular abnormalities are the defining pathological hallmarks of VaD and are 
observed in 90% of AD cases. The underlying pathologies include cerebral amyloid 
angiopathy (CAA) and small vessel disease (SVD). CAA is the deposition of Aβ in the 
cerebral blood vessels (1.1.1.1.3). CAA is present in up to 98% AD cases 317, 318 and can 
contribute to hypoperfusion and ischaemia in AD 230, 314, 319. 
CAA severity in the brain was measured 231 and compared with the levels of soluble and 
insoluble Aβ1-40, measured previously in the parietal cortex and white matter of the same 
cases. This allows the investigation of the relationship between VEGFR1 and VEGFR2 
levels with CAA scores and Aβ1-40. In contrast to the cerebral cortex, in which Aβ1-42 is 
deposited, Aβ1-40 makes up the most of Aβ deposited in blood vessels. Aβ1-40 is more soluble 
than Aβ1-42 and when it is secreted from cells it travels via perivascular drainage and can 
become deposited in blood vessel walls 320, 321. CAA severity in the brain had previously 
been assessed using a semi-quantitative scale 231 and the levels of soluble and insoluble 
96 
 
Aβ1-40 had been measured in the parietal cortex and white matter. This facilitated the 
investigation of the relationship between VEGFR1 and VEGFR2 levels with CAA scores and 
Aβ1-40. SVD encompasses degenerative changes in the vessel wall of small arteries and 
arterioles, including arteriolosclerosis 65 (1.1.2.2). SVD has been correlated with reduced 
CBF 322, 323 and increasing SVD severity correlated with biochemical evidence of reduced 
white matter perfusion, in a post-mortem study 314. Increasing SVD severity has also been 
linked to a decline in cognitive function 324-326. SVD severity had been measured on a semi-
quantitative scale 230, 231 allowing receptor levels to be related to pathology. Both CAA and 
SVD are prevalent in AD and can disrupt endothelial cell function so I hypothesised that with 
increasing severity of SVD and/or CAA, endothelial VEGF receptor levels would decrease 
327-329. 
Aβ may also have a direct effect on the VEGF-VEGFR2 system in AD. Aβ has been found to 
impair capillary formation in human brain endothelial cells in culture 306 and in a transgenic 
mouse model of CAA 306. There is also evidence that Aβ inhibits angiogenesis by blocking 
VEGF-induced mitogenesis via the Akt1 pathway 308, 330, and Aβ1-42 has been implicated as 
an antagonist of VEGFR2 307, 308. The group also showed a peptide fragment common to 
both Aβ1-40 and Aβ1-42 able to exhibit the same anti-angiogenic effects 308. There have been 
no studies into the effect of Aβ on VEGFR1 level. Soluble and insoluble levels of Aβ1-40 and 
Aβ1-42 had previously been measured in the parietal cortex and white matter in my cohorts. 
This provided the opportunity to investigate the effect of Aβ concentration on the levels of 
VEGFR1 and VEGFR2. Understanding the relationship between VEGFR1 and VEGFR2 with 
Aβ species could provide insight into the effect Aβ pathology might have on blood vessel 
formation in AD, though there has been little work in this area, the effect of Aβ, if any, on 
receptor is difficult to predict. 
5.1.1 Hypotheses 
[1] The level of VEGF will be elevated in AD and VaD compared to control in cortex and 
white matter.  
[2] The level of vWF will be elevated in VaD and remain unchanged in AD compared to 
control in cortex and white matter. 
[3] VWF will not correlate positively in AD but are correlated in control and VaD. vWF will not 
correlate positively with VEGF in AD, but will correlate in control and VaD. Since VEGFR1 
protein was shown to be decreased in AD compared to control ( Chapter 3) and VEGF level 
has been shown to be elevated in AD compared control, therefore it is hypothesised that  
VEGFR1 will negatively correlate with VEGF in parietal cortex. VEGFR2 protein level was 
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unchanged in AD and VaD compared to control (Chapter 4). Therefore it is hypothesised 
that VEGFR2 will display no correlation with VEGF in control, AD and VaD. 
[4] As a result of deteriorating blood vessel structure and endothelial cells, it is hypothesised 
that VEGFR1 and VEGFR2 decrease with increasing CAA and SVD severity. 
[5] VEGFR1 protein was shown to be decreased in AD compared to control (Chapter 3), it is 
hypothesised that VEGFR1 level will decrease with increasing Braak score.  VEGFR2 
protein level was unchanged in AD and VaD compared to control (Chapter 4),  it is 
hypothesised that VEGFR2 will decrease with increasing Braak scores. 
5.1.2 Aims 
[1] To determine the level of VEGF in control, AD and VaD parietal white matter by ELISA. 
[2] To determine the level of VWF in control, AD and VaD parietal cortex and white matter by 
ELISA. 
[3] To assess the relationship between VEGF, VEGF receptor levels and vWF. 
[4] To determine whether VEGFR1 and VEGFR2 levels are related to with CAA and SVD 
scores.  
[5] To examine the relationship of VEGFR1 and VEGFR2 levels to Braak stage and the 
levels of Aβ1-40, Aβ1-42 and Aβ42:40 in the parietal cortex. 
5.2 Methods 
5.2.1 VEGFR1 dot blot  
The method and results of VEGFR1 dot blot to measure protein level in control and AD 
cortex is detailed in Chapter 3. 
5.2.2 VEGFR2 ELISA 
The method and results of VEGFR2 ELISA to measure protein levels in control, AD and VaD 
cortex and white matter is detailed in Chapter 4.  
5.2.3 VEGF sandwich ELISA 
VEGF levels were measured by the VEGF duoset ELISA kit specific for VEGF121 and 
VEGF165. This kit has previously been optimised for brain tissue 78. Frozen brain samples 
were homogenised as detailed in 2.2.3 using an SDS lysis buffer. The assay was carried out 
according to manufacturer’s instructions summarised in 2.6. Readings were blank corrected 
and a 7-point curve was constructed using VEGF recombinant standards. A 4-parameter 
logistic curve fit was applied and sample values interpolated. 50 µl each of standard and 
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sample were added to each well. Samples were measured in duplicate on each plate. Spike 
and recovery testing was not performed as this assay has been validated on human tissue.  
The VEGF level had previously been measured in control and AD cortex from the parietal 
cortex by the Dementia Research Group, University of Bristol, UK. VEGF levels were 
measured in VaD cases and white matter of control and AD cases in this study. VEGF 
measurement in parietal cortex could not be repeated on the same samples as there was 
not enough remaining dissected tissue for homogenisation.  
5.2.4 Von Willebrand factor dot blot 
VWF is a multimeric glycoprotein and endothelial cell marker 331. VWF, measured by dot 
blot, has previously been established as an accurate measure of vessel density in human 
brain 68, 72, 315.  
Dot blotting was carried out as described in 2.5. Briefly, samples were spun at 16,200 g for 
10 minutes. Samples were kept at 4°C to reduce interference of sample matrix with the 
assay. Serial dilutions of homogenate standard were prepared using a 1:100 starting dilution 
in TBS. Homogenate samples were diluted at a concentration of 1:1000 in TBS. The 
nitrocellulose membrane was blocked with 5% milk/TBS-T; anti-human-vWF antibody, at a 
concentration of 1:3000 in 5% milk/TBS-T, was applied overnight at 4˚C. After washing, a 
peroxidase conjugated rabbit secondary antibody was applied for 1 hour. The background-
adjusted volume was calculated for each dot and a 7-point standard curve was created for 
each blot. Relative values for each sample were calculated by interpolating from the 
standard curve. The coefficient of variation (CoV) between samples on each blot was 
calculated to assess intra-assay reliability. Each sample was measured on two membranes 
and inter-assay reliability also assessed by calculation of the CoV.  
5.2.5 Von Willebrand factor sandwich ELISA 
VWF level was determined using human vWF ELISA kit () according to the manufacturer’s 
guidelines. The ELISA was validated using spike, recovery and linearity testing as described 
in 3.4.1.3. The ELISA used a vWF antibody as a capture antibody and a biotinylated vWF 
detection antibody. Briefly, samples were diluted 1:10 with supplied sample diluent and 50 µl 
of samples were added in duplicate and incubated for 2 h at room temperature. Absorbance 
was measured at 450 nm and vWF concentration was interpolated from a standard curve 
generated by serial dilution of human recombinant vWF (2.5–80 mU/ml). 
5.2.5.1 Spike, recovery and linearity testing 
The vWF ELISA kit had been validated for use on cell culture supernatant, serum and 
plasma samples by the supplier. To validate the ELISA kit for use on human brain tissue, 
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homogenates were spiked with recombinant protein, and recovery and linearity testing was 
performed. 16 mU/ml of vWF recombinant protein was used to ‘spike’ brain tissue 
homogenate (diluted 1:10) to make the spiked sample, and added to control diluent (PBS) to 
make the control spike. Recovery and linearity values were within the acceptable range of 
80-120% shown in Table 5-1.  
 
% Recovery 
Spiked Unspiked Control 
1:10 98.2 - - 
1:20 116.3 120.4 111.4 
Table 5-1 Percentage recovery and linearity of brain tissue homogenate on vWF ELISA. Spiked 
samples were treated with 16 mU/ml of vWF recombinant protein and diluted. Unspiked 
samples contained brain homogenate only. Percentage recovery and linearity of brain 
homogenates were within the manufacturer’s acceptable range of 80-120%. Control samples 
contained PBS diluent spiked with 16 mU/ml of vWF and remained within the accepted range. 
5.2.5.2 Interassay reliability 
The interassay reliability of the vWF ELISA was tested by measuring the same sample on 
two different plates. The CoV was used to compare the mean values of the first plate to the 




VWF (mU/ml) CoV (%) 
Plate 1 Plate 2 
BBN_9026 15.0 17.1 9.3 
BBN_9162 12.3 11.3 6.0 
BBN_9173 15.5 17.6 9.0 
BBN_9275 57.4 53.1 5.5 
Table 5-2 VWF ELISA interassay reliability. Homogenates from the same samples were 
measured on two different plates. CoV was performed to assess the relative variability of 
sample readings. The CoV was less than 10% for each of the samples tested. CoV: coefficient 
of variation. 
5.2.6 MAG:PLP ratio as a measure of cerebral hypoperfusion 
Oligodendrocytes are specialist glia that provide the myelin sheath that surrounds the axons 
of neurons in the central nervous system. The myelin sheath acts to insulate the axon and 
allow increases speed of action potential transmission from the neuronal cell body, down the 
axon to the synapse. Loss or damage of myelin can disrupt transmission of the action 
potential. Our group has previously shown the ratio of myelin-associated glycoprotein (MAG) 
and myelin proteolipid protein (PLP) to be a biochemical measure of cerebral hypoperfusion 
72, 78, 314. MAG is located predominantly in the periaxonal membrane of CNS myelin 
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internodes in the myelin sheath 332, 333 making it more vulnerable to injury than PLP which is 
expressed at higher levels due to its distribution throughout the myelin sheath 334: the 
periaxonal membrane is furthest from the oligodendrocyte cell body and therefore it requires 
more energy to transport MAG for insertions into the sheath in comparison to other proteins, 
such as PLP, inserted at shorter distances from the cell body 335. It is probably this that 
makes MAG more susceptible to reduction in energy supply. The disproportionate reduction 
in MAG has been reported in stroke and ischaemic-type plaques in multiple sclerosis 336, 337. 
MAG loss in white matter lesions is associated with nuclear expression of HIF-1α 336 a 
marker of reduced oxygenation (1.2.3). MAG loss has also been previously described in AD 
and VaD 314, 338. MAG level was found to decrease in AD and VaD whereas PLP expression 
remained stable. Additionally, an increased MAG:PLP ratio declined with increasing CAA 
and SVD severity 314. 
5.2.6.1 MAG direct ELISA 
A MAG ELISA was developed and previously validated by the Dementia Research Group, 
University of Bristol, UK and used to establish MAG level in human brain samples 314. Frozen 
brain samples were homogenised using an SDS lysis buffer. Briefly, samples were spun at 
16,200 g for 10 minutes at 4°C to reduce interference of sample matrix with the assay and 
were diluted 1:10 in PBS. Recombinant MAG was used to create a 7-point standard curve 
(400, 200, 100, 50, 25, 12.5 and 6.25 ng/mL). 50 µl of standard and sample were added to 
each well of a clear 96 well plate and incubated for two hours. The plate was washed 5 times 
with 0.05% PBS-T and tapped dry after the final wash. Each well was incubated with 100 μl 
of mouse-anti-human MAG antibody for 2 hours. The plate was washed as previously 
described, and incubated with 100 μl of biotinylated anti-mouse antibody 1:500 in PBS, for 
20 minutes and protected from light. After further washing, 100 μl of HRP-labelled 
streptavidin diluted 1:500 in PBS was loaded to each well and incubated for another 20 
minutes and protected from light. A final wash stage was performed and each well was 
incubated with 100 μl substrate in the absence of light to visualise the captured antigen. The 
reaction was stopped using 50 μl of 2N sulphuric acid and the optical density was measured 
using a plate reader at 450 nm. Readings were blank corrected and a 7-point curve was 
constructed using MAG recombinant standards. Sample values were determined by 
interpolated. Samples were measured in duplicate on each plate and corrected for the total 
protein concentration of each sample.  
5.2.7 Aβ measurement 
The following data on Aβ concentration was previously collected by members of the 
Dementia Research Group, University of Bristol, UK. All protein data were adjusted for total 
protein concentration. Soluble and insoluble homogenates were prepared from frozen tissue 
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from the parietal cortex and white matter were prepared as described in 72, 79, 339. 200 mg of 
tissue was homogenised in 1 ml of TBS extraction buffer for 30 seconds in a homogeniser. 
Homogenates were spun at 20,817g for 15 minutes at 4°C and the supernatant (soluble 
fraction, containing soluble Aβ) was stored at -80°C until used. The pellet was homogenised 
in 6.25 M guanidine HCL in 50 mM Tris (pH 8.0), incubated for 4 hours at 25°C and spun at 
20,817g for 20 minutes at 4°C. The supernatant was saved as the guanidine-HCL-soluble 
fraction (containing insoluble Aβ) and stored at -80°C until use.  
5.2.7.1 Aβ1-40 levels 
A 96-well clear plate was coated with a mouse monoclonal anti-human Aβ1-16 (Covance) at a 
concentration of 2 μg/ml in PBS and incubated overnight at room temperature. The plate 
was washed and non-specific binding blocked with 300 μl protein-free PBS blocking buffer 
(Thermo scientific) for 2 hours, followed by further washing. The test samples were diluted 
(1:49 for guanidine extracts and 1:3 for soluble extracts) in PBS containing 1% 1,10-
phenanthroline and added, in duplicate, to the plate along with duplicates of the human Aβ1-
40 recombinant standards, for 2 hours. The plates were again washed and incubated with the 
detection mouse monoclonal anti-human Aβ1-40 antibody (Covance) at a concentration of 1 
μg/ml, which had been biotinylated using the biotin conjugation kit (Lightning-Link Innova 
Bioscience) and left to incubate for 2 hours, before being washed off. A streptavidin-
peroxidase antibody diluted 1:200 in 0.05% Tween-20/PBS was applied for 1 hour at room 
temperature. The plate was washed and the substrate was added in the absence of light to 
visualise the amount of antigen captured. The luminescence was measured using the plate 
reader at 450 nm and Aβ1-40 levels were interpolated from a standard curve generated from 
serial dilutions of recombinant human Aβ1-40. Each measurement was repeated on two 
separate occasions and the average calculated.  
5.2.7.2 Aβ1-42 level 
A 96-well clear plate was coated with a mouse monoclonal anti-human Aβ1-16 at a 
concentration of 2 μg/ml in PBS and incubated overnight at room temperature. The plate 
was washed and non-specific binding blocked with 300 μl protein-free PBS blocking buffer 
(Thermo scientific) for 3 hours, followed by further washing. The test samples diluted (1:49 
for guanidine extracts and 1:3 for soluble extracts) in PBS containing 1% 1,10-
phenanthroline were added, in duplicate, to the plate along with duplicates of the human Aβ1-
42 recombinant standards for 5 hours. The plates were again washed and incubated with the 
detection mouse monoclonal anti-human Aβ1-42 antibody (Covance) at a concentration of 1 
μg/ml, which had been biotinylated using the biotin conjugation kit and left to incubate for 2 
hours, before being washed off. This was followed by a streptavidin-peroxidase antibody 
(diluted 1:200) in 0.05% Tween-20/PBS, which was applied for 30 minutes at room 
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temperature. The plate was washed and the substrate was added in the absence of light to 
visualise the amount of antigen captured. Sample luminescence was measured using the 
plate reader at 450 nm and levels of Aβ1-42 were interpolated from a standard curve 
generated from serial dilutions of recombinant human Aβ1-42. Each measurement was 
repeated on two separate occasions and the average calculated. 
5.2.8 Neuropathology 
For each case in the cohort the Braak stage was established. In addition, parietal cortex and 
white matter were scored for CAA severity and SVD severity by a neuropathologist as 
detailed in Chapter 2.  
5.2.8.1 Braak stage 
Braak stage was semi-quantitatively assessed in the mid-parietal lobe and 4 other cortical 
areas as part of the routine neuropathological assessment as described in 2.2.1. Braak 
stage is determine by the localisation of NFT in the brain: Stages I and II: NFT in 
transentorhinal region of the brain; Stages III and IV = NFT present in limbic regions; Stages 
V and VI: NFT in the neocortex. 
5.2.8.2 CAA scoring 
CAA was semi-quantitatively assessed in the parenchymal and meningeal vessels in five 
cerebral regions, including the parietal cortex. CAA severity was rated on the following scale: 
0 = none; 1 = sparse or mild; 2 = moderate; 3 = frequent or severe 231. CAA score was 
provided for the parietal cortex and white matter of control, AD and VaD cases.  
5.2.8.3 SVD scoring 
SVD was semi-quantitatively assessed in the parenchymal and meningeal vessels in four 
cerebral regions, including the parietal lobe. SVD severity was rated on the following scale: 0 
= normal vessel wall thickness, 1 = slightly increased thickness, 2 = moderately increased 
thickness, 3 = markedly increased thickness such that for many arterioles the diameter of 
the lumen was <50% of the outer diameter of the blood vessel 230, 231. CAA score was 
provided for the parietal cortex and white matter of control, AD and VaD cases. 
5.2.9 Statistics 
Data sets were tested for normality and returned non-normal distributions as is common in 
for human data. Spearman’s rank correlation coefficient was used to assess correlation 
between two variables. The Mann-Whitney test was used to establish the difference between 
two groups. The Kruskal-Wallis test was used to establish the difference between three or 
more groups. If the Kruskal-Wallis test reported a significant difference in median values, the 
Dunn’s post-hoc test was used to assess pairwise significance between all groups. Median 
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(M) and interquartile range (IQR) are displayed as horizontal bars in the scatterplots. 
Spearman r and p values are displayed on scatter plots.  
5.3 Results 
5.3.1 Von Willebrand factor levels in human parietal cortex and white matter 
VWF has previously been assessed by dot blot 72, 315, 316. Samples were assessed fo intra 
and interassay reliability. Dot blots for vWF were not found to be reproducible as assessed 
by interassay reliability (Appendix 20). This was attributed to the use of a NP-40 based lysis 
buffer as opposed to an SDS buffer with which the assay was previously optimised 68, 72, 315. 
As a result, and in order to make use of samples already homogenised in NP-40, a sandwich 
ELISA kit was used to determine the concentration of vWF. Spike, recover and linearity 
testing was performed and confirmed the suitability of the assay for use with human brain 
tissue. 
To ensure that changes in receptor level were not due to a reduction in blood vessel density 
in AD or VaD, vWF was measured in both the parietal cortex and white matter homogenates 
from each individual. In the cortex there was a significant difference between the groups (p = 
0.007) and pairwise analysis reported a significant reduction in VaD compared to AD (p < 
0.01, Figure 5-1A). There was no difference in vWF level between any of the groups in the 
white matter (Figure 5-1B). There was no significant difference in VWF between Braak 




Figure 5-1 VWF level in parietal cortex and white matter of control, AD and VaD samples. [A] 
There was a significant difference between medians of three white matter groups (p= 0.007, C: 
M= 34.65, IQR= 39, n= 36; AD: M= 44.35, IQR= 21.77 n= 50, VaD: M= 30.72, IQR= 17.94, n= 19). 
Pairwise analysis revealed the vWF level was significantly lower in VaD cortex when compared 
to AD (p< 0.01). [B] The level of vWF did not differ significantly between the white matter of 
control, AD and VaD brains (p= 0.07, C: M= 14.37, IQR= 19.5 n = 36, AD: M= 11.77, IQR= 12.66, n 
= 50, M= 21.43, IQR= 7.72 VaD: n= 19). [C] The level of vWF did not differ significantly between 
the Braak stages in control and AD samples in the parietal cortex (I-II: M= 31.61, IQR= 34.67; III-
IV: M= 49.57, IQR= 32.49; V-VI: M= 43.92, IQR= 22.66). [D] The level of vWF did not differ 
significantly between the Braak stages in control and AD samples in the parietal cortex (I-II: 
M= 15.34, IQR= 18.85; III-IV: M= 13.66, IQR= 18.12; V-VI: M= 11.93, IQR= 12.4). The median ± IQR 
is displayed. ** p< 0.01 
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5.3.2 VEGF levels in human parietal cortex and white matter 
VEGF level was measured in homogenates, as an indicator of hypoxia. VEGF 
measurements had previously been conducted on control and AD cortex and new measures 
were performed for VaD parietal lobe and the control and AD white matter. There was a 
trend towards an increase in VEGF in the AD brains, although this did not reach significance 
(p = 0.069, Figure 5-2A). There was a significant difference between medians in the white 
matter (p = 0.019) and pairwise analysis reported a significant decrease in VEGF level in the 
white matter of VaD compared to control (p < 0.05, Figure 5-2B).  
  
Figure 5-2 VEGF level in parietal cortex and white matter of control, AD and VaD samples. [A] 
VEGF level was higher in AD than control cortex although this did not reach significance (p= 
0.069, C: M= 321, IQR= 174.5, n = 31, AD: M= 386.9, IQR= 436.3, n = 45) [B] There was a 
significant group difference between medians of three white matter groups (p= 0.019, C: M= 
473.6, IQR= 319.5, n = 31, AD: M= 397, IQR= 227.8, n = 45, VaD: M= 308, IQR= 218.4, n= 19). 
Pairwise analysis revealed VEGF level was significantly lower in VaD when compared to 
control white matter (p< 0.05). * p< 0.05. 
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5.3.3 MAG level in control and VaD white matter 
In order to further investigate hypoperfusion the relative level of myelin protein, MAG, was 
used as a biochemical measure of cerebral hypoperfusion. A decrease in VEGF level in VaD 
compared to control was reported in Figure 5-2, so the state of perfusion in these cases was 
investigated. There was a significant decrease in the MAG concentration in the white matter 
of VaD cases compared to control (p= 0.0058) (Figure 5-3).  
5.3.4 Relationship between VEGF and vWF in parietal cortex and white matter 
No correlation was seen between VEGF and vWF in control (p= 0.525, r= 0.119) or AD (p= 
0.437, r= −0.119) parietal cortex (Figure 5-4A). There was no correlation between VEGF and 
vWF in the white matter of control (p= 0.956, r= -0.01) or AD subjects (p= 0.132, r= 0.226) 
(Figure 5-4B). A significant positive correlation was seen in the white matter of VaD cases 
(p= 0.037, r= 0.481, Figure 5-4B). Details of correlations are provided in Appendix 21. 
 
Figure 5-4 Relationship between VEGF and vWF in parietal cortex and white matter. [A] No 
correlation was observed between VEGF and vWF in control (p= 0.525, r= 0.119, n= 31) or AD 
(p= 0.437, r= −0.119, n= 45) parietal cortex. [B] No correlation was observed between VEGF and 
Figure 5-3 MAG level in control and VaD white matter. There was a significant decrease in the 
MAG level in VaD (M= 287.9, IQR= 173.8, n= 36) compared to control (p= 0.0058, M= 204.5, 
IQR= 108.2, n= 19). ** p< 0.01. 
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vWF in control white matter (p= 0.956, r = -0.01, n= 36) or AD white matter (p= 0.132, r= 0.226, 
n= 48). A significant positive correlation was observed between VEGF and vWF in VaD white 
matter (p= 0.037, r= 0.481, n= 19). 
5.3.5 Relationship between VEGF receptors and VEGF and vWF in parietal cortex 
and white matter 
The correlation between VEGFR1 level and VEGF or vWF was examined in control and AD 
cortex. VEGFR1 correlated positively with vWF in AD cortex (p= 0.003, r= 0.438) (Figure 
5-5A). There was no correlation between VEGFR1 and VEGF in control (p= 0.192, r= 0.229, 
Figure 5-5B) or AD cortex (p= 0.413, r= −0.133).   
Next VEGFR2 was correlated with VEGF and vWF in control, AD and VaD cortex and white 
matter. A significant positive correlation was found between vWF and VEGFR2 in AD cortex 
(p= 0.048, r= 0.287, Figure 5-5C) but no correlation was found in control (p= 0.135, r= 0.254) 
or VaD cortex (p= 0.764, r= 0.074). There was no correlation reported between VEGF and 
VEGFR2 in control or AD cortex (p= 0.013, r= 0.366, Figure 5-5D) and no correlation 
between VEGFR2 and VEGF in control cortex (p= 0.071, r= 0.328). No correlation was 
found between VEGFR2 and vWF (Figure 5-5E) or VEGF (Figure 5-5F) and VEGFR2 in the 
white matter or control, AD or VaD cases. Summary tables of VEGFR1 and VEGFR2 




Figure 5-5 Relationship between VEGF receptors and VEGF and vWF. [A] A significant positive 
correlation was observed between vWF and VEGFR1 in AD cortex (p= 0.003, r= 0.438, n= 34). 
No correlation was observed in control cortex (p= 0.192, r= 0.229, n= 44). [B] No correlation 
between VEGF and VEGFR1 in control (p= 0.192, r= 0.229, n= 29) or AD cortex (p= 0.413, r = 
−0.133, n= 45) [C] A significant correlation between vWF and VEGFR2 in AD cortex (p= 0.048, r 
= 0.287, n= 48). No correlation between vWF and VEGFR2 in control cortex (p= 0.135, r= 0.254, 
n= 36) or VaD cortex (p= 0.764, r= 0.074, n= 19). [D] A significant correlation between VEGF and 
VEGFR2 in AD cortex (p= 0.013, r= 0.366, n= 45). No correlation between VEGF and VEGFR2 in 
control (p= 0.071, r= 0.328, n= 31). [E] No correlation between vWF and VEGFR2 in control 
white matter (p= 0.475, r= 0.123, n= 36), AD white matter (p= 0.917, r= 0.016, n= 48) and VaD 
white matter (p= 0.473, r= −0.175, n= 19). [F] No correlation between VEGF and VEGFR2 in 
control white matter (p= 0.918, r= -0.018, n= 36), AD white matter (p= 0.956, r= −0.008, n= 48) 
and VaD white matter (p= 0.3, r= 0.251, n= 19).  
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5.3.6 Relationship between VEGF receptors and CAA 
The relationship between VEGFR1 and VEGFR2 and CAA severity was examined. There 
was no difference in VEGFR1 between cases with no or sparse CAA and those with 
moderate to severe CAA in the parietal cortex (Figure 5-6A). Similarly, there was no change 
in VEGFR2 level with increasing CAA severity in cortex (Figure 5-6B) or white matter (Figure 
5-6C). Summary statistics are provided in Appendix 25. 
 
 
Figure 5-6 VEGFR1 and VEGFR2 level in relation to CAA score. [A] No significant difference 
between the cortex VEGFR1 cases with no or mild CAA, scored 0-1 (M= 70.6, IQR= 43.5, n= 46), 
and those with moderate to severe CAA, scored 2-3 (p= 0.82, M= 67.99, IQR= 30.39, n= 28). [B] 
No significant difference between the cortex of VEGFR2 cases with a CAA severity score of 0-1 
(M= 340, IQR= 476.9, n= 65) and those with scores of 2-3 (p= 0.55, M= 490.9, IQR= 475.3, n= 32). 
[C] No significant difference between the white matter of VEGFR2 cases with a CAA severity 
score of 0-1 (M= 166.4, IQR= 108.5, n= 64) and those with scores of 2-3 (p= 0.834, M= 154.7, 




5.3.7 Relationship between VEGF receptor level and SVD 
The relationship between SVD score and VEGFR1 and VEGFR2 level in cortex and white 
matter was investigated. No significant differences in the level of VEGFR1 were observed 
between control and AD cases with no or mild SVD and those with moderate to severe SVD 
in the cortex (Figure 5-7A). Similarly, VEGFR2 level in control, AD and VaD cases was 
unchanged with increasing SVD severity in the cortex and white matter (Figure 5-7B, C). 
Summary statistics are provided in Appendix 26. 
 
Figure 5-7 VEGFR1 and VEGFR2 level in relation to SVD score. [A] No significant difference 
between the cortex VEGFR1 cases with no or mild SVD, scored 0-1 (M= 72.87, IQR= 33.69, n= 
46), and those with moderate to severe SVD, scored 2-3 (p = 0.105, M= 60.59, IQR= 49.26, n= 
28). [B] No significant difference between the cortex of VEGFR2 cases with a SVD severity 
score of 0-1 (M= 328.9, IQR= 499.2, n= 55) and those with scores of 2-3 (p= 0.473, M= 391.1, 
IQR= 443, n= 46). [C] No significant difference in the white matter of VEGFR2 cases with a SVD 
severity score of 0-1 (M= 157.8, IQR= 144.8, n= 53) and those with scores of 2-3 (p = 0.637, M= 
155.4, IQR= 102.3, n= 46). The horizontal lines indicate the grand median. 
5.3.8 VEGFR1 and VEGFR2 level in relation to Braak stage in control and AD 
VEGFR1 and VEGFR2 levels from control and AD cohorts were examined in relation to 
Braak stage as a measure of AD progression. Controls are defined here as Braak stage 0-II. 
There was a significant difference between the median VEGFR1 levels in different Braak 
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stage (p= 0.02) and pairwise analysis reported a significant decrease in the level of VEGFR1 
between cases at 0-II and those at stages V-VI (p < 0.05, Figure 5-8A). There was no 
significant difference between VEGFR2 level and Braak stage in the cortex (p= 0.456, Figure 
5-8B) or white matter (p= 0.223, Figure 5-8C). Summary statistics are provided in Appendix 
27. 
 
Figure 5-8 VEGFR1 and VEGFR2 level in relation to Braak stage. [A] There was a significant 
difference between the medians (p = 0.02) and pairwise analysis revealed a significant 
reduction in VEGFR1 between Braak stages 0-II and V-VI (p < 0.05) (0-II: M= 78.21, IQR= 37.36, 
n= 30; III-IV: M= 65.6, IQR= 46.82, n= 8; V-VI: M=59.59, IQR= 45.71, n= 41). [B] No significant 
difference in VEGFR2 level in the cortex when comparing Braak stage (p = 0.456) (0-II: M= 
326.8, IQR= 232.9, n= 31; III-IV: M= 495.4, IQR= 551.2, n= 8; V-VI: M= 395.4, IQR= 489.1, n= 
47).[C] No significant difference in VEGFR2 level in the cortex when comparing Braak stage (p 
= 0.223) (0-II: M= 169.1, IQR= 133.2, n= 29; III-IV: M= 137.2, IQR= 108.44, n= 8; V-VI: M= 178.2, 
IQR= 114.2, n= 45). The horizontal lines indicate the grand median. * p < 0.05 
5.3.9 Relationship between VEGF receptors and Aβ in control and AD 
To investigate any relationship between VEGF receptor expression and Aβ in AD, the levels 
of VEGFR1 and VEGFR2 were assessed in relation to the levels of soluble and insoluble 




5.3.9.1 VEGFR1 in relation to Aβ in parietal cortex  
VEGFR1 displayed no correlation with soluble or insoluble Aβ1-40 or Aβ1-42 in control or AD 
cortex (Figure 5-9A-F). 
Figure 5-9 Relationship of VEGFR1 cortex level and Aβ. [A] No correlation between VEGFR1 
and soluble Aβ1-40 in control (p = 0.549, r = 0.118, n = 28) or AD cortex (p = 0.48, r = −0.115, n = 
40). [B] No correlation between VEGFR1 and insoluble Aβ1-40 in control (p = 0.22, r = 0.235, n = 
29) or AD cortex (p = 0.227, r = 0.2, n = 40). [C] No correlation between VEGFR1 and soluble 
Aβ1-42 in control (p = 0.388, r = −0.167, n = 29) or AD cortex (p = 0.8, r = 0.042, n = 39). [D] No 
correlation between VEGFR1 and insoluble Aβ1-42 in control (p = 0.518, r = −0.125, n = 29) or AD 
cortex (p = 0.532, r = 0.102, n = 40). [E] No correlation between VEGFR1 and soluble Aβ42:40 in 
control (p = 0.337, r = −0.188, n = 28) or AD cortex (p= 0.405, r = 0.137, n = 39). [F] No 
correlation between VEGFR1 and insoluble Aβ42:40 in control (p= 0.135, r = −0.284, n = 29) or AD 
cortex (p = 0.69, r = −0.065, n = 40). 
113 
 
5.3.9.2 VEGFR2 in relation to Aβ in parietal cortex 
No correlation was observed between VEGFR2 and soluble or insoluble Aβ1-40 in control or 
AD cortex (Figure 5-10A, B). A significant negative correlation was identified between 
VEGFR2 and soluble Aβ1-42 in controls (p = 0.011, r = −0.449, Figure 5-10C). There was no 
correlation between VEGFR2 and insoluble Aβ1-42 in control or AD cortex (Figure 5-10 D). A 
significant negative correlation was seen between VEGFR2 and Aβ42:40 in control cortex (p = 
0.005, r = −0.503, Figure 5-10E). VEGFR2 correlated positively with the insoluble Aβ42:40 in 
AD cases (p = 0.047, r = 0.298, Figure 5-10F). 
 
Figure 5-10 Relationship of VEGFR2 level and Aβ in cortex. [A] No correlation between 
VEGFR2 and soluble Aβ1-40 in control (p= 0.144, r= −0.273, n = 30) or AD cortex (p= 0.129, r= 
−0.23, n= 45). [B] No correlation between VEGFR2 and insoluble Aβ1-40 in control (p = 0.98, r= 
0.005, n= 31) or AD cortex (p= 0.38, r= −0.135, n= 45). [C] No correlation between VEGFR2 and 
soluble Aβ1-42 in control cortex (p = 0.011, r= −0.449, n= 31) or AD cortex (p= 0.414, r= 0.126, n= 
44). [D] No correlation between VEGFR2 and insoluble Aβ1-42 in control (p= 0.292, r= −0.195, n= 
31) or AD cortex (p= 0.222, r= 0.186, n= 45). [E] A significant negative correlation was observed 
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between VEGFR2 and soluble Aβ42:40 in control (p= 0.005, r= −0.503, n= 30). No correlation was 
observed in AD cortex (p= 0.152, r= 0.22, n = 44). [F] No correlation between VEGFR2 and 
insoluble Aβ42:40 in control (p= 0.993, r= 0.002, n= 31). A significant positive correlation was 
found in AD cortex (p= 0.047, r= 0.298, n= 44). * p < 0.05, ** p < 0.05 
5.3.9.3 VEGFR2 in relation to Aβ in parietal white matter 
No correlation was observed between VEGFR1 or VEGFR2 level and Aβ1-40 or Aβ1-42 in the 
cortex or white matter of control and AD parietal lobe (Figure 5-11A-F).  
Figure 5-11 Relationship of VEGFR2 level and Aβ in white matter. [A] No correlation between 
VEGFR2 and soluble Aβ1-40 in control (p= 0.549, r= 0.118, n= 32) or AD white matter (p= 0.22, r= 
0.235, n= 45). [B] No correlation between VEGFR2 and insoluble Aβ1-40 in control (p= 0.388, r= 
−0.167, n= 31) or AD white matter (p= 0.227, r= 0.195, n= 43). [C] No correlation between 
VEGFR2 and soluble Aβ1-42 in control (p= 0.388, r= −0.167, n= 32) or AD white matter (p= 0.799, 
r= 0.042, n= 44). [D] No correlation between VEGFR2 and insoluble Aβ1-42 in control (p= −0.125, 
r= 0.518, n= 32) or AD cortex (p= 0.532, r= 0.102, n= 44). [E] No correlation between VEGFR2 
and soluble Aβ42:40 in control (p= 0.337, r= −0.188, n= 32) or AD white matter (p= 0.405, r= 0.137, 
n= 45). [F] No correlation between VEGFR2 and insoluble Aβ42:40 in control (p= 0.135, r= −0.284, 
n= 31) or AD white matter (p= 0.69, r= −0.065, n= 43). 
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5.3.10 VEGFR1 and VEGFR2 level in relation to age and post mortem delay 
VEGFR1 or VEGFR2 were investigated in relation to age and post-mortem delay. No 
correlation was found between VEGFR1 and age or post-mortem delay in the cortex or white 
matter of control, AD or VaD (Figure 5-12A, B). No correlation was found between VEGFR2 
and age or post-mortem delay in the cortex (Figure 5-12C, E) or white matter of control, AD 
or VaD (Figure 5-12D, F). 
 
Figure 5-12 Relationship between VEGFR1 and VEGFR2 level to age and post-mortem delay. 
[A] No correlation between VEGFR1 and age in control (p= 0.428, r= 0.141, n= 34) or AD cases 
(p= 0.133, r= 0.23, n= 44). [B] No correlation between VEGFR1 and post-mortem delay in 
control (p= 0.66, r= 0.072, n= 34) or AD cases (p= 0.979, r= −0.004, n= 44). [C] No correlation 
between VEGFR2 level in cortex and age in control (p= 0.423, r= −0.136, n= 36), AD (p= 0.364, 
r= 0.131, n= 50) or VaD cases (p= 0.772, r= 0.071, n= 19). [D] No correlation between VEGFR2 
level in white matter and age in control (p= 0.23, r= 0.205, n= 36), AD (p= 0.883, r= −0.022, n= 
48) or VaD cases (p= 0.451, r= −0.184, n= 19) [E] No correlation between VEGFR2 level in 
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cortex and post-mortem delay in control (p= 0.423, r= −0.136, n= 36), AD (p= 0.364, r= 0.131, n= 
50) and VaD cases (p= 0.772, r= 0.72, n= 19). [F] No correlation between VEGFR2 level in white 
matter and post-mortem delay in control (p= 0.684, r= −0.07, n= 36) AD (p= 0.41, r= −0.12, n= 48) 
or VaD cases (p= 0.201, r= 0.31, n= 19). 
5.4 Discussion 
VEGFR1 and VEGFR2 have been investigated in the brain to understand the VEGF-VEGFR 
system and to find out whether abnormalities in this system might contribute to disruption of 
angiogenesis in AD. To assess the extent of hypoperfusion and microvessel density, the 
levels of VEGF and vWF were determined and these were then examined in relation to 
VEGFR1 and VEGFR2. The possible impact of CAA and SVD on receptor levels was also 
investigated, as were the effect of AD progression/ severity (as indicated by Braak tangle 
stage) and the level of Aβ. 
Firstly, VWF level was determined in the parietal cortex and white matter of control, AD and 
VaD cases. In agreement with Thomas et al (2015) 78, no change was observed in vWF level 
between control and AD cortex. There was a decrease in the vWF level in VaD cortex but 
this finding should be interpreted with caution in view of the smaller sample size in this 
subgroup. In white matter, vWF level was unchanged across control, AD and VaD groups, in 
agreement with previous with what was reported previously72. There was no significant 
difference in VWF level between Braak stages in control and AD. This supports previous 
work finding that though overall brain mass was reduced capillary density was not reduced in 
AD compared to control 104. 
The VEGF level was measured and there was a trend (p= 0.069) towards an increase in 
VEGF in AD cortex, in keeping with previous observations 78. In contrast to prior studies by 
my research group this result was not statistically significant. The current study continues to 
support an increase in VEGF concentration in AD compared to control in the largest cohort 
tested to date. 
In agreement with Barker et al (2014), there was no change in VEGF level between the 
control and AD white matter 72. Unexpectedly, there was a decrease in VEGF in the white 
matter of VaD cases. This was not expected as the group had previously measured VEGF in 
parietal white matter and found no change in VEGF level compared to control 72 and VEGF 
had been elevated in VaD cortex compared to control 78. This was further investigated by 
establishing the level of MAG as a measure for hypoperfusion in the white matter of control 
and VaD cases. A PLP assay was not performed so the ratio of MAG:PLP was not 
calculated. In future it would be desirable to complete the PLP assay to compare to the MAG 
levels in the same samples. There was a significant reduction in MAG in VaD cases as 
117 
 
expected in the presence of hypoperfusion. The reason for the reported decrease in VEGF 
level in VaD white matter despite hypoperfusion may be due to the age of some of the post-
mortem samples. In the VaD cohort, 17 of the 19 samples were donated over 15 years 
previously, the oldest donation being 32 years previous. Despite the aliquoting of my 
samples to prevent multiple freeze thaw, the likelihood of multiple freeze thaw cycles when 
brain slices were removed from storage over many years may have degraded the proteins of 
interest and make replicating results from earlier studies difficult. Comparison with a VaD 
cohort from another brain bank would provide a valuable control in future work. The present 
finding is in overall agreement with previously published work showing a trend to increase in 
VEGF in AD compared to control.  
Assessment of VEGF in relation to vWF revealed no relationship between the two markers in 
the cortex of control or AD cases. In the white matter, however, there was a positive 
correlation between VEGF and vWF in VaD cases. The correlation might be expected, as in 
VaD white matter, VEGF level increases and so, therefore, should vessel density, though not 
sufficiently to correct cerebral hypoperfusion. In contrast, in the AD white matter, although 
VEGF level increases there is no corresponding increase in vessel density. Previously 
published work on the white matter in a pure VaD cohort and a mixed AD and VaD cohort 
which there was a positive correlation between VEGF and vWF 72. In this study, AD and VaD 
data were correlated individually rather than being pooled together and analysed as in 
Barker et al. 72 highlighting the importance of examining cohorts separately. In agreement 
with Barker et al (2014), this work shows that ischaemic changes may be affecting the cortex 
and white matter differently and the importance of analysing both regions. 
VEGFR1 and VEGFR2 correlated positively with vWF level in the AD cortex. VEGFR2 
correlated with VEGF in the AD cortex whereas there was no correlation with VEGFR1 and 
VEGF. Prior to establishing that VEGFR1 level is decreased in AD (3.4.2.1) it might have 
been expected that VEGFR1 would correlate positively with VEGF level as both can be 
upregulated by hypoxia 145, 247. Similarly, the unchanged level of VEGFR2 in control and 
disease (4.4.2.1) resulted in no correlation with VEGF.  
To investigate the possibility of VEGFR1 and VEGFR2 alteration as a result of amyloid or 
non-amyloid small vessel disease, VEGF receptor levels were analysed with respect to the 
severity of CAA and SVD. CAA and SVD both effect blood vessel function could potentially 
interfere with vascular cells expressing VEGFR1 and VEGFR2 327-329. However, changes in 
VEGF receptor levels were found not to be related to CAA or SVD severity. 
Lastly, the relationship between receptor level and severity of AD neuropathology was 
examined. As hypothesised, VEGFR1 level decreased with increasing Braak stage and 
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VEGFR2 remained unchanged in both cortex and white matter. VEGFR1 did not correlate 
with the level of soluble or insoluble Aβ1-40 or Aβ1-42 suggesting that VEGFR1 reduction in AD 
is not driven directly by Aβ level and may result from some other abnormality in AD, such as 
reduction in CBF and consequent tissue hypoxia. VEGFR2 was negatively correlated with 
soluble Aβ1-42 and soluble Aβ42:40 in control cortex. A reduction in the levels VEGFR2 with 
increasing soluble Aβ1-42 may result from interaction between Aβ and VEGF. This could be 
due to sequestration of VEGF by Aβ222 which would reduce the availability of VEGF to bind 
to VEGFR2 and regulate expression. In addition, Aβ interaction with VEGFR2 itself may 
decrease VEGFR2 expression again preventing the binding of its ligand VEGF which 
regulates receptor expression. In AD cortex however, there was no correlation of VEGFR2 
level with soluble Aβ1-42 and only a weak positive correlation with insoluble Aβ1-40. This study 
found no relationship between VEGFR levels and age or post-mortem delay. 
The present findings may be influenced by the number of late-stage AD cases in this study. 
Reduction in CBF is an early change in AD, and the disparity between metabolic demand 
and tissue oxygenation/blood supply becomes less pronounced in advanced disease 74. Any 
changes in receptor levels may therefore be more prominent in the early stages of disease. 
In this study the majority of AD cases had Braak tangle stages of V or VI. In future studies 
the cohort should be expanded to include Braak stages III-IV.  
In this chapter findings on examining the relationship between VEGF receptor levels and 
cerebrovasculature, and AD pathology were described. vWF level, a marker of microvessel 
density, is unchanged in the parietal lobe despite a trend towards elevated VEGF level and 
there is a negative relationship between VEGF and vWF level in AD white matter. VEGFR1 
and VEGFR2 correlated with vWF in the AD cortex but were not associated with severity of 
CAA or SVD. Receptor levels were only weakly related to the levels of Aβ. Factors that may 
account for the reduced or unchanged microvessel density in hypoperfused cortex in AD 78 
include sequestration of VEGF by Aβ1-42 222 or decreased VEGFR1:sVEGFR1 ratio (3.5.2.1), 





Chapter 6 VEGFR1 and VEGFR2 in human brain 
microvascular endothelial cells and pericytes 
6.1 Introduction 
With evidence of elevated VEGF and unchanged levels of receptor VEGFR2 in response to 
brain hypoperfusion in AD, further questions are raised about the mechanism behind the 
unchanged microvessel density in AD. As previously discussed by Thomas et al.78, since 
VEGFRs can be independently upregulated in response to hypoxia there may be reduced 
receptor activation due to VEGF sequestering by Aβ222. There is also evidence that Aβ1-42 
can interact and bind to the extracellular domain of VEGFR2 and block VEGF-induced 
tyrosine phosphorylation of VEGFR2 in human brain microvascular endothelial cells 
(HBMECs) and human brain vascular pericyte (HBVP) models 308. 
Endothelial cells and pericytes are key members of the neurovascular unit and contribute to 
angiogenesis in the brain (1.2.3). Though endothelial cells have been the main focus of 
studies of angiogenesis, the importance of pericytes is increasingly being recognised not 
only in relation to vessel function but also for normal angiogenesis. Pericytes modulate BBB 
permeability, CBF, clearance of metabolites into the bloodstream, and neuroinflammation 340, 
341. The highest density of pericytes in the body is found in the brain, 342 where they cover an 
estimated 70%-80% of capillary tubes in the CNS 343.  
Pericytes maintain integrity of the BBB by controlling the expression of BBB-specific proteins 
in endothelial cells and the polarisation of astrocyte end-feet 344, 345. Pericytes can control 
blood flow at the capillary level within the brain. They do this by contracting and relaxing 
within capillary walls, altering vessel diameter. Pericytes respond to neuronal activity, 
neurotransmitter activity and depolarisation 341.  
Pericytes also regulate angiogenesis and vessel stability and their absence in development 
leads to the formation of microaneurysms 346. Pericytes have roles in multiple stages of 
angiogenesis. They secrete angiogenic factors, including VEGF, which stimulate sprouting 
formation and endothelial proliferation (1.2.3). They also secrete matrix metalloproteinases 
(MMPs) which degrade basement membrane proteins and facilitate endothelial cell 
migration. Pericytes help to conclude angiogenesis by preventing proliferation and by 
inhibition of MMP-mediated degradation of basement membrane proteins 343. Pericytes are 
able to stabilise the vascular wall, promote endothelial cell maturation and contribute to 
basement membrane structure 343. They can also phagocytose small molecules and may 
help to clear certain macromolecules such as Aβ 340, 343, 347. Pericytes probably have a role in 
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neuroinflammation, as they can phagocytose, present antigens, and release inflammatory 
mediators 340, 348. 
The degeneration of pericytes has been implicated in neurovascular dysfunction and 
neurodegeneration in AD. Pericyte loss has been reported in the cortex and hippocampus in 
human AD post-mortem studies 349. Pericyte loss, as indicated by loss of the pericyte marker 
PDGFRβ, was strongly linked to cerebral hypoperfusion in the AD precuneus 350. A pericyte-
deficient mouse model displayed vascular dysfunction including reduction in brain 
microcirculation resulting in a reduction in blood flow. This caused chronic hypoxia and BBB 
breakdown leading to secondary neurodegenerative changes 345. Pericyte deficient mice 
have also shown reduced capillary blood flow resulting in reduced oxygen supply in the brain 
351. Some studies have suggested vascular factors, such as hypertension, contribute to 
pericyte loss 343. The accumulation of Aβ has also been implicated in pericyte degeneration. 
Aβ is toxic to cultured brain pericytes 352 and amyloid deposits have been identified in 
pericytes in post-mortem human studies 353, 354. A mouse model overexpressing mutant APP, 
when crossed with a pericyte deficient mouse, showed accelerated deposition of Aβ1-40 and 
Aβ1-42, due to reduced clearance. The loss of pericytes also resulted in tau deposition and 
early degeneration not usually seen in this mouse model 347. ApoE4 carriers with AD have 
been shown to have increased pericyte degeneration, and ApoE4 was shown to be 
associated with BBB breakdown in both mouse models 355 and man, as evidenced by a rise 
in CSF albumin 356 and an increase in perivascular leakage of plasma proteins in human 
brain tissue 354, 357.  
The VEGF system is important in the maintenance of pericytes and in cross-talk with 
endothelial cells. Pericytes secrete VEGF which acts through autocrine and paracrine 
signalling. VEGF induces proliferation and migration of pericytes via mbVEGFR1 as shown 
in primary bovine retinal pericytes in hypoxia 214. VEGF derived from pericytes promotes 
endothelial cell survival, stability 358, 359, angiogenesis and vascular permeability 340, 360 via its 
activation of VEGFR2.  
VEGF levels were upregulated in pericytes in a rat model of brain trauma 361. VEGF was 
reported to promote pericyte coverage of brain capillaries and improve CBF in subsequent 
transient brain ischaemia in a mouse model of stroke 362. Contrary to this, there are reports 
that pericytes also migrate from areas of ischaemia. Pericytes were shown to migrate away 
from endothelial cells in a  study of acute ischaemia in the feline brain 363 and a rat model of 
head trauma, whilst pericytes which continued to abut the endothelial cells were positive for 
an apoptotic marker 361. 
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VEGFR1 is the dominant VEGF receptor on pericytes. The first study into VEGF receptors 
on primary bovine retinal pericytes identified only VEGFR1 by mRNA 215. Yamagishi et al. 
(1999) later showed the expression of VEGFR1 and VEGFR2 on bovine retinal pericytes 214. 
In that study, both VEGFR1 and VEGFR2 were detected by PCR, with VEGFR1 as the 
dominant receptor. The expression of VEGFR1 mRNA increased further with decreasing O2 
and was two to three times higher at 2.5% and 0% O2 than at atmospheric levels. In 
contrast, VEGFR2 mRNA expression remained stable in pericytes and even tended to be 
reduced in hypoxia. Under normoxic conditions, VEGFR1 protein was clearly detectable in 
pericytes while VEGFR2 was almost undetectable by western blot. Elevated VEGF and 
VEGFR1 in hypoxia increase pericyte proliferation and migration 214. This should promote 
angiogenesis, resulting in increased perfusion. The group did not measure the level of 
sVEGFR1 by mRNA or protein in conditioned media of the pericytes, but in this study it is 
hypothesised that sVEGFR1 are also increased in hypoxia to negatively regulate VEGF. 
Pericytes have recently been shown to regulate VEGF-induced endothelial cell sprouting via 
expression of sVEGFR1 in the mouse retina 364, highlighting the importance of crosstalk 
between pericytes and endothelial cells.  
In AD, pericyte degeneration has been demonstrated but there has been little investigation 
of the VEGF-VEGFR system despite the importance of pericytes in maintaining capillaries 
and sustaining normal neurovascular function. HBMECs and HBVP cultures were used in 
this study to investigate the influence of hypoxia and Aβ on mbVEGFR1, sVEGFR1 and 
VEGFR2 receptor levels. 
6.1.1 Hypothesis 
[1] HBMECs and HBVPs will express VEGFR1 and VEGFR2.  
[2] HBMEC will increase expression of VEGFR1 and VEGFR2 in hypoxia but this response 
will be impaired in the presence of Aβ1-40 or Aβ1-42.  
[3] HBMEC will increase expression of sVEGFR1 in hypoxia but this response will be 
impaired in the presence of Aβ1-40 or Aβ1-42. 
[4] HBVP will increase expression of VEGFR1 and VEGFR2 in hypoxia but this response will 
be impaired in the presence of Aβ1-40 or Aβ1-42. 
[5] HBVP will increase expression of sVEGFR1 in hypoxia but this response will be impaired 




[1] To characterise expression of VEGFR1 and VEGFR2 on HBMECs and HBVPs by 
immunofluorescence. 
[2] To measure the level of VEGFR1 and VEGFR2 on HBMECs in normoxic and hypoxic 
conditions by ELISA, with and without exposure of the cells to Aβ1-40 or Aβ1-42. 
[3] To measure the level of sVEGFR1 in the culture medium of HBMECs grown in normoxic 
and hypoxic conditions by ELISA, with or without exposure of the cells to Aβ1-40 or Aβ1-42. 
[4] To measure the level of VEGFR1 and VEGFR2 in HBVPs in normoxic and hypoxic 
conditions by ELISA, with or without exposure of the cells to Aβ1-40 or Aβ1-42. 
[5] To measure the level of sVEGFR1 in the culture medium of HBVPs grown in normoxic 
and hypoxic conditions by ELISA, with or without exposure of the cells to Aβ1-40 or Aβ1-42. 
6.2 Methods 
6.2.1 HBMEC culture 
HBMECs were sourced from ScienCell and maintained in accordance with supplier’s 
directions and as described in 2.13.5. Plates and coverslips were coated in fibronectin 
overnight at a concentration of 2 μg/cm2 in Ca2+ and Mg2+-free PBS and then washed twice in 
dH2O. Cells were seeded at 1.5x104 cells per well in a 24 well plate to prepare for 
immunofluorescence.  
6.2.2 HBVP culture 
HBVP were cultured and maintained by Scott Miners of the Dementia Research Group, 
University of Bristol, UK. HBVPs were sourced from ScienCell and maintained in accordance 
with supplier’s directions and as described in 2.13.6. Plates and coverslips were coated and 
poly-L-lysine (ScienCell) at a concentration of 2 μg/cm2 in dH2O for 1 hour and then washed 
twice with dH2O. Cells were seeded at 3x104 cells per well in a 24-well plate to prepare for 
immunofluorescence. 
6.2.3 Aβ preparation 
Aβ1-40 (Anaspec, AS-24236) and Aβ1-42 (Anaspec, AS-24224) were lyophilised in 35% 
acetonitrile-H2O and added to cells at a final concentration of 1 µM. This concentration was 
selected as it represents a physiologically relevant level of Aβ present in the brain. Levels of 
soluble Aβ1-40 and Aβ1-42 measured in human brain were shown in Chapter 5 and did not 
exceed 1 µM. 
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6.2.4 Hypoxic chamber 
Hypoxia workstation (Ruskin SCI-tive) was set to 2% O2 and 5% CO2 and a temperature of 
37°C.  
6.2.5 Exposure of cells to Aβ1-40, Aβ1-42 and hypoxia 
HBMEC and HVPCs were seeded in T75 flasks or on coverslips as described in 6.2.1 and 
6.2.2. Once cells were 90% confluent, complete medium was exchanged for serum free 
medium prepared as detailed in (2.13.5 and 2.13.6). 6 flasks were prepared for each cell 
type according to the conditions outlined in Table 6-1. Following exposure, cells were 
processed as detailed in 6.2.6 and 6.2.7. Each experiment was repeated at least 3 times. 
Normoxia 
24 hours 
1. Serum free medium 
2. Serum free medium + 10 µg/ml Aβ1-40 
3. Serum free medium + 10 µg/ml Aβ1-42 
Hypoxia (2%) 
24 hours 
1. Serum free medium 
2. Serum free medium + 10 µg/ml Aβ1-40 
3. Serum free medium + 10 µg/ml Aβ1-42 
Table 6-1 Experimental conditions for exposure of HBMECs and HBVPs to Aβ1-40, Aβ1-42 and 
hypoxia. 
6.2.6 Cell lysis 
Conditioned media was collected from cells and stored at −80°C until use. Cells were 
detached from the flask using accutase (Sigma) and incubated for 5 minutes at 37°C. PBS 
was added to the flask to make 10 ml in total and the tube centrifuged at 200 g to produce a 
pellet. The pellet was washed in 1 ml of PBS and transferred to a 1.5 ml tube and 
centrifuged again. Finally, PBS was removed, and the pellet was re-suspended in 90 µl of 
lysis buffer (CelLytic M Cell Lysis reagent, Sigma). Total protein level was measured as 
described in 2.3 and lysates stored at −80°C until required. 
6.2.7 Immunofluorescence 
Coverslips were washed in 100% ethanol and autoclaved prior to use. Coverslips were 
coated as required and washed in dH2O. Cells were plated at the desired density and left to 
adhere overnight. Serum free media was removed, and cells gently washed in PBS. Cells 
were then fixed using 4% paraformaldehyde in PBS at room temperature for 10 minutes, 
permeabilised with methanol if required, and washed 3 times in PBS. Cells were incubated 
with 3% BSA-PBST or normal serum for 1 hour at room temperature to block non-specific 
binding. Desired concentration of primary antibody was prepared in 1% BSA-PBST and cells 
were incubated overnight at 4°C. Cells were washed 3 times in PBS and incubated with 
secondary antibody in 1% BSA-PBST for 1 hour in the dark at room temperature. Cells were 
washed 3 times with PBS and mounted using mounting medium containing DAPI to 
counterstain cell nuclei. Coverslips were sealed on slides using nail varnish to prevent 
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drying. Coverslips were imaged on a fluorescent microscope using 488 nm laser to visualise 
the protein of interest and 405 nm laser to visualise DAPI. Both images were then overlaid. 
No primary controls were performed for each of the immunoglobulins tested. HBMECs were 
imaged at passage 2 (p2) and pericytes were imaged at p6.  
vWF was used as an endothelial marker. Fibroblast surface protein (FSP) was used a 
fibroblast marker. Fibroblast surface protein was chosen as it has been reported to be 
specific to fibroblasts unlike more traditional markers such as vimentin that may be able to 
recognise multiple cell types. Details of antibody conditions and concentrations are 
presented in Table 6-2. Initial pericyte characterisation of HBVPs was carried out by Scott 
Miners of the Dementia Research Group, University of Bristol, UK. Platelet derived growth 
factor receptor-β (PDGFRβ) was used as a pericyte marker. As pericytes express smooth 
muscle actin (SMA), although it is not specific for this cell type, antibody to SMA was also 

















IgM Alexa Fluor 488 
PDGFRβ 100% Methanol, 5% 
donkey serum:PBS 
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SMA 100% methanol, 5% 
donkey serum:PBS 
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Table 6-2 Antibodies used for immunofluorescence of HBMECs and HBVPs. FSP was used as 
a fibroblast marker. SMA and PDGFRβ were used as a pericyte markers. VWF was used as an 
endothelial marker. 
6.2.8 VEGFR1 ELISA 
A human total VEGFR1 (FLT1) duoset IC ELISA kit was used to measure VEGFR1 protein 
level in cell culture supernatant and conditioned media. The ELISA kit had been validated for 
use on cell culture supernatant, serum and plasma samples by the manufacturer. The ELISA 
was performed as detailed in 3.4.1.2. Briefly, cell culture supernatant was diluted 1:20 with 
1% BSA-PBS and conditioned media was added neat. 50 µl of standard and diluted sample 
was added to each well. Samples were measured in triplicate on the plate. Readings were 
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blank corrected, and a 7-point curve was constructed from VEGFR1 recombinant standards 
and sample values were interpolated. 
6.2.9 VEGFR2 ELISA 
A human total VEGFR2 (KDR) duoset IC ELISA kit was used to measure VEGFR2 protein 
level in cell culture supernatant. The ELISA kit had been validated for use on cell culture 
supernatant, serum and plasma by the manufacturer. The ELISA was performed as detailed 
in 4.4.1.2. Briefly, cell culture supernatant was diluted 1:10 with reagent diluent #14. Fifty µl 
of standard and diluted sample was added to each well. Samples were measured in triplicate 
on the plate. Readings were blank corrected, and a 7-point curve was constructed from 
VEGFR2 recombinant standards and sample values were interpolated. 
6.2.10 Statistics 
The Kruskal-Wallis test was used to test for significant difference between three or more 
groups. If the Kruskal-Wallis test indicated a significant difference in median values, Dunn’s 
post-hoc test was used to assess pairwise significance between the mean rank of the control 
group and all other groups. Median and interquartile range are displayed on scatter bars.  
6.3 Results 
Immunofluorescence was first performed to characterise HBMECs and HBVPs and to 
identify any visible changes in receptor labelling in the presence of Aβ1-40 or Aβ1-42, with and 
without hypoxia. This was followed by measuring the level of the receptor proteins by ELISA. 
Work in Chapter 3 identified changes in the sVEGFR1 level in the AD parietal cortex 
compared to control. ELISA of the culture medium of the cells allowed the quantification of 
sVEGFR1 production.  
6.3.1 Characterisation of HBMECs 
To establish the phenotype of HBMECs, immunofluorescence was used to identify 
endothelial cell markers and the presence of VEGFR1 and VEGFR2. Endothelial cells are 
known to differentiate into fibroblasts with increasing passage. An endothelial marker, vWF, 
and a fibroblast marker, FSP, were used to establish the phenotype of HBMECS. VEGFR2 
itself is also used as a marker for endothelial cells and endothelial progenitors 365, 366. 
HBMECs clearly expressed vWF in Figure 6-1. Some expression of fibroblast surface protein 
was also observed. VEGFR1 was clearly observed in all HBMECs and VEGFR2 was also 




Figure 6-1 Characterisation of HBMECs. [A] HBMECs were immunopositive for VWF. VWF is a 
marker of endothelial cells. [B] HBMECs were weakly positive for FSP. FSP is a marker of 
fibroblasts. [C] HBMECs expressed VEGFR1. VEGFR1 appears expressed on the cell surface 
with some evidence of colocalization around the nucleus in some cells. [D] HBMECs 
expressed VEGFR2. VEGFR2 appears expressed uniformly on the cell surface. VEGFR2 was 
expressed to a lesser extent that VEGFR1.  
6.3.2 VEGFR1 immunofluorescence in HBMECs exposed to hypoxia, and Aβ1-40 or 
Aβ1-42 
Immunofluorescence of VEGFR1 after cells were exposed to hypoxia, and Aβ1-40 or Aβ1-42 
(Figure 6-2). Cells were positive for VEGFR1 in all conditions. VEGFR1 expression 




Figure 6-2 VEGFR1 immunofluorescence in HBMECs exposed to hypoxia, Aβ1-40 or Aβ1-42. [A] 
VEGFR1 was detected on HBMECs in normoxia. [B] VEGFR2 was detected on HBMECs in 
hypoxic conditions. There were no observable difference between VEGFR1 expression under 
hypoxia compared to normoxia. [C] VEGFR1 was detected on HBMECs exposed to Aβ1-40. The 
expression of VEGFR1 appeared induced by Aβ1-40 when compared to normoxia. [D] VEGFR1 
was detected on HBMECs exposed to Aβ1-40 in hypoxic conditions. The expression of VEGFR1 
appeared induced by hypoxia and Aβ1-40 when compared to normoxia and Aβ1-40. [E] VEGFR1 
was detected on HBMECs exposed to Aβ1-42. The expression of VEGFR1 appeared induced by 
Aβ1-42 when compared to normoxia. [F] VEGFR1 was detected on HBMECs exposed to Aβ1-42 in 
hypoxic conditions. The expression of VEGFR1 appeared induced by hypoxia and Aβ1-42 when 
compared to normoxia and Aβ1-42. Scale bar represents 100 µm. 
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6.3.3 Effect of hypoxia, and Aβ1-40 or Aβ1-42 on VEGFR1 and sVEGFR1 levels in 
HBMECs 
There was no significant effect of hypoxia, Aβ1-40, or Aβ1-42 on the level of VEGFR1 in 
HBMECs (Figure 6-3A). The cell-conditioned culture medium was collected from each 
treatment group and VEGFR1 ELISA used to measure the level of sVEGFR1. There was a 
significant difference the groups (p= 0.009, Figure 6-3B). Pairwise analysis revealed a 
significant increase in sVEGFR1 level in HBMECs under conditions of hypoxia (p< 0.01; M= 
129.9, IQR= 41.1, n= 8), hypoxia with Aβ1-40 (p< 0.05, M= 125.8, IQR= 44.4, n= 6) and 
hypoxia with Aβ1-42 (p< 0.05, M= 111.6, IQR= 43.3, n= 6) compared to normoxia (M= 100, 
IQR= 0, n= 8). There was no change in sVEGFR1 level in the presence of Aβ alone. Details 
of individual values are provided in Appendix 29. 
6.3.4 VEGFR2 immunofluorescence on HBMECs exposed to hypoxia, and Aβ1-40 or 
Aβ1-42 
Punctate VEGFR2 immunopositivity was detectable in the cells in all conditions studied. 
There was no clear change in the expression of VEGFR2 in hypoxia or in the presence of 
Aβ1-40, and Aβ1-42. 
Figure 6-3 VEGFR1 and sVEGFR1 levels in HBMECs lysate and conditioned media as 
measured by VEGFR1 ELISA. All groups are normalised to the control group (normoxia) and 
displayed as a percentage of control. [A] VEGFR1 level in HBMEC lysate in the presence of 
hypoxia ± Aβ1-40, or Aβ1-42. There was no significant difference between normoxic conditions 
and cells under incubated in hypoxic conditions with or without the presence of 1µM Aβ1-40, or 
1µM Aβ1-42. [B] sVEGFR1 level in HBMEC-conditioned media under conditions of hypoxia ± Aβ1-
40 or Aβ1-42. Kruskal Wallis test indicated a significant difference between groups compared (p= 
0.009) and post-hoc tests revealed a significant increase in the level of sVEGFR1 in hypoxia 
(p< 0.01), hypoxia with Aβ1-40 (p< 0.05) and hypoxia with Aβ1-42 (p< 0.05) when compared to 




Figure 6-4 VEGFR2 immunofluorescence in HBMECs exposed to hypoxia, Aβ1-40 or Aβ1-42. [A] 
VEGFR2 was detected on HBMECs in normoxia. [B] VEGFR2 was detected on HBMECs in 
hypoxic conditions. There were no observable differences between VEGFR2 expression under 
hypoxia conditions compared to normoxia. [C] VEGFR2 was detected on HBMECs exposed to 
Aβ1-40. There were no observable differences between VEGFR2 expression in the presence of 
Aβ1-40 when compared to normoxia. [D] VEGFR2 was detected on HBMECs exposed to Aβ1-40 in 
hypoxic conditions. [E] VEGFR2 was detected on HBMECs exposed to Aβ1-42. here were no 
observables difference between VEGFR2 expression in the presence of Aβ1-42 compared to 
normoxia. [F] VEGFR2 was detected on HBMECs exposed to Aβ1-42 in hypoxic conditions. 
Scale bar represents 100 µm. 
130 
 
6.3.5 Characterisation of HVPCs 
To establish the phenotype of pericytes, immunofluorescence was used to identify cell 
markers and the presence of VEGFR1 and VEGFR2. PDGFRβ and SMA are established 
markers of pericytes and were expressed on cultured pericytes as shown in Figure 6-4. 
VEGFR1 was strongly expressed on pericytes in normoxia. VEGFR2 was expressed on 
pericytes but to a lesser extent than VEGFR1. No primary controls are presented in the 
Appendix 28.  
 
Figure 6-5 Characterisation of HBVPs. [A] HBVPs were positive for PDGFRβ which is a marker 
of pericytes. [B] HBVPs were positive for SMA which is an additional marker of pericytes. [C] 
VEGFR1 was clearly detected on HBVPs. [D] VEGFR2 was detected on HBVPs. VEGFR2 
expression appeared less than VEGFR1.  
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6.3.6 VEGFR1 immunofluorescence on HBVPs exposed to hypoxia, and Aβ1-40, or 
Aβ1-42 
Immunofluorescence showed VEGFR1 in the cells in all conditions (Figure 6-5). There 
appeared to be a reduction in VEGFR1 under conditions of hypoxia + Aβ1-40. 
 
Figure 6-6 VEGFR1 immunofluorescence in HBVPs exposed to hypoxia, Aβ1-40 or Aβ1-42. [A] 
VEGFR1 was expressed on HBVPs in normoxia. [B] VEGFR1 was expressed on HBVPs in 
hypoxic cells. There was no observable visual difference when compared to VEGFR1 
expression in normoxia. [C] VEGFR1 was expressed on cells in the presence of Aβ1-40. There 
was no observable visual difference between HBVPs in normoxia alone. [D] VEGFR1 was 
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expressed on HBVPs in the presence of hypoxia and Aβ1-40. There appeared to be a reduction 
in VEGFR1 under conditions of hypoxia + Aβ1-40 when compared to Aβ1-40 in normoxia and 
hypoxia alone. [E] VEGFR1 was expressed on HBVPs in the presence of Aβ1-42. There was no 
observable difference when compared to other conditions. [F] VEGFR1 was expressed on 
HBVPs in the presence of hypoxia and Aβ1-42. There was no observable difference when 
compared to other conditions. Scale = 50 µm 
6.3.7 Effect of hypoxia, and Aβ1-40 or Aβ1-42, on VEGFR1 and sVEGFR1 in HBVPs 
There was no significant change in the level of VEGFR1 in HBVPs under conditions of 
hypoxia, and Aβ1-40 or Aβ1-42 (Figure 6-6A). There was a trend towards an increase in 
VEGFR1 in the presence of hypoxia and either Aβ1-40 or Aβ1-42, compared to normoxia. 
There was a significant difference in sVEGFR1 level between the groups (p= 0.032, Figure 
6-6B). Pairwise analysis revealed that the level of sVEGFR1 was significantly increased in 
hypoxia (p< 0.05, M= 141.4, IQR= 150.9, n= 8) when compared to normoxia (M= 100, IQR= 
0, n= 8). There was no significant change in sVEGFR1 level in normoxia or hypoxia, and 
when Aβ species were present. There seemed to be a reduction in sVEGFR1 level in 
hypoxia in the presence of Aβ1-40, but on analysis this was shown not to be significant. 
Details of individual values are provided in Appendix 30. 
Figure 6-7 VEGFR1 and sVEGFR1 levels in HBVPs lysate and conditioned media as measured 
by VEGFR1 ELISA. All groups are normalised to the control group (normoxia) and displayed as 
a percentage of control. [A] VEGFR1 level in HBVP exposed to hypoxia ± Aβ1-40, and Aβ1-42. No 
significant difference was reported between the groups (p= 0.078). [B] sVEGFR1 level in HBVP 
conditioned media exposed to hypoxia ± Aβ1-40, and Aβ1-42. A significant difference was 
reported between groups (p= 0.032). Pairwise comparison revealed a significant increase in 




6.3.8 VEGFR2 immunofluorescence on HVPCs exposed to hypoxia, and Aβ1-40 or 
Aβ1-42 
There was punctate VEGFR2 immunolabelling of the cells in all conditions (Figure 6-7) but 
no clear change in the expression of VEGFR2 in hypoxia or in the presence of Aβ1-40 or Aβ1-
42. 
 
Figure 6-8 VEGFR2 immunofluorescent labelling of HBVPs exposed to hypoxia, Aβ1-40 or Aβ1-42. 
[A] VEGFR2 was detectable in the HBVPs in normoxia. [B] VEGFR2 was expressed on HBVPs 
in hypoxic cells. There was no observable visual difference when compared to VEGFR2 
expression in normoxia. [C] VEGFR2 was expressed on cells in the presence of Aβ1-40. There 
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was no observable difference between HBVPs in normoxia alone. [D] VEGFR2 was expressed 
on HBVPs in the presence of hypoxia and Aβ1-40. There was no observable difference 
compared to Aβ1-40 in normoxia and hypoxia alone. [E] VEGFR2 was expressed on HBVPs in 
the presence of Aβ1-42. There was no observable difference when compared to other 
conditions. [F] VEGFR2 was expressed on HBVPs in the presence of hypoxia and Aβ1-42. There 
was no observable difference when compared to other conditions. Scale = 50 µm 
6.3.9 Effect of hypoxia, Aβ1-40 and Aβ1-42 on VEGFR2 receptor levels in HBVPs 
A significant difference in VEGFR2 level was found between groups (p= 0.0002, Figure 6-9). 
Pairwise analysis revealed a significant decrease in VEGFR2 levels in HBVP in the 
presence of hypoxia compared to normoxia. This significant decrease was evident with 
hypoxia alone (p< 0.001, M= 33.03, IQR= 22.61, n= 7), or when combined with Aβ1-40 (p< 
0.01, M= 44.08, IQR= 35.15, n=7) or Aβ1-42 (p< 0.05, M= 41.2, IQR= 47.66, n= 7). There was 
no change in VEGFR2 level in the presence of Aβ alone. Details of individual values are 
provided in Appendix 30. 
6.4 Discussion 
The HBMECs were characterised before starting any further experimental work. It was 
confirmed that HBMECs expressed VWF and VEGFR2 which are both makers of endothelial 
cells. The HBMECs also showed weak immunopositivity for FSP, a marker of fibroblasts. 
Figure 6-9 VEGFR2 level in HBVP exposed to hypoxia ± 1µM Aβ1-40 or 1µM Aβ1-42. A significant 
difference was found between the groups (p= 0.0002). Pairwise comparison revealed a 
significant decrease in VEGFR2 level in hypoxia (p< 0.001), hypoxia + Aβ1-40 (p< 0.01) or 
hypoxia + Aβ1-42 (p< 0.05, compared to normoxia. * p< 0.05, ** p< 0.01, *** p< 0.001. 
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This may be due to the cell line displaying both endothelial and fibroblastic characteristics at 
early passage. Despite the presence of the fibroblast marker, the expression of endothelium-
specific markers supports their use for in vitro study of hypoxic responses of cerebral 
endothelial cells. 
A VEGFR1 ELISA was used to measure the level of VEGFR1 in cell lysate and the level of 
sVEGFR1 in conditioned media. Cells were exposed to Aβ1-40, Aβ1-42  in normoxic and 
hypoxic conditions. There was no change in the level of VEGFR1 in HBMECs under any of 
the conditions studied whereas the level of sVEGFR1 was significantly increased in all 
hypoxic conditions compared to normoxia. The increase in sVEGFR1 under hypoxic 
conditions is in keeping with other evidence of the role of the receptor in negative regulation 
of VEGF in hypoxia 143, 148. The increase in sVEGFR1 is relevant to my findings on analysis 
of human brain tissue in AD, in which sVEGFR1 subtypes appeared to be increased 259, 
possibly in response to reduced oxygenation of the tissue in this disease. However, the 
unchanged level of VEGFR1 in vitro does not mirror changes in post-mortem brain tissue, in 
which a decrease in VEGFR1 was observed in AD. Despite repeated attempts, I was unable 
to measure VEGFR2 in HBMECs by ELISA. This may be due to the reduced expression of 
VEGFR2 on HBMECs when compared to VEGFR1 meaning the sample was below 
detection by the VEGFR2 ELISA. In future, it would be beneficial to increase the protein 
concentration of the lysate by extraction for a great number of cells. This should allow the 
detection of VEGFR2 by ELISA in all conditions.  
Following the completion of this work, a paper was published describing measurement of the 
level of mbVEGFR1, sVEGFR1 and VEGFR2 mRNA as well as mbVEGFR1 and VEGFR2 
protein in HUVECs and HBMECs exposed to Aβ1-40 367. HUVECs were exposed to 10 μM of 
Aβ1-40 for 8 hours. VEGFR1 mRNA was unchanged between Aβ1-40-treated and control cells, 
while VEGFR2 mRNA was reduced significantly after Aβ1-40 exposure.  HUVECs were then 
exposed to 10 μM and 20 μM of Aβ1-40 for 24 hours. Western blots displayed no change in 
mbVEGFR1 protein, but VEGFR2 level fell with increasing Aβ1-40 concentration. To 
investigate sVEGFR1 levels the group looked at HUVECs exposed to 10 μM of Aβ1-40 for 8 
and 24 hours and HBMECs exposed to 10 μM of Aβ1-40 for 24 hours. They found that 
sVEGFR1 mRNA was significantly reduced in cells exposed to Aβ1-40. Data on sVEGFR1 
protein levels were not provided. The concentration of Aβ used in that work was at least 10-
fold higher than that used in the present study and the findings may therefore be less 
physiologically relevant. This study did not extract mRNA from cell lysate. It was thought 
measurement receptor proteins would provide the most physiologically relevant data and it is 
known that the level of mRNA does not always predict protein levels 368. The extraction of 
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VEGFR1 and VEGFR2 mRNA would provide a useful addition to this study and allow direct 
comparison of the work. 
The absence of change in the level of mbVEGFR1 in HUVECs367 is consistent with my 
findings that VEGFR1 was unchanged in HBMECs when exposed to Aβ1-40. However, as the 
group measured only mRNA, not protein, the results are not directly comparable and limit 
the usefulness of speculation as to why the authors found that exposure of the HUVECs to 
Aβ1-40 caused sVEGFR1 mRNA to fall whereas I did not find a corresponding change in 
sVEGFR1 protein.  
The group also measured sVEGFR2 mRNA and protein in HUVECs and HBMECs 367. In the 
current study sVEGFR2 could not be detected in cell culture medium conditioned by 
HBMECs. No band for sVEGFR2 was observed using the ELISA detection antibody 
(Appendix 17) indicating that the antibody is specific for the intracellular domain, not present 
in sVEGFR2. sVEGFR2 was not of direct relevance to the investigation of disrupted VEGF 
angiogenesis as VEGF-C is the main ligand for sVEGFR2 which mediates lymphogenesis 
(1.2.2.2.1). However further understanding of the VEGF-VEGFR system in the presence of 
Aβ is needed. Future work could include use of the same sVEGFR2 antibody used by Cho 
et al. (2017) and a sVEGFR2-specific ELISA to measure sVEGFR2 after hypoxia and Aβ 
exposure. 
HBVPs were immunopositive for two pericyte markers, SMA and PDGFRβ. 
Immunofluorescence showed mbVEGFR1 expression on HBVPs to be more prominent than 
VEGFR2 expression. Measurement of protein levels in cell lysates showed that hypoxia 
upregulated mbVEGFR1 in HBVP while the level of VEGFR2 was reduced. The elevation in 
sVEGFR1 and mbVEGFR1 in hypoxia was predicted, as hypoxia directly regulates VEGFR1 
expression and mbVEGFR1. sVEGFR1 secreted from HBVPs increased in hypoxic 
conditions, though there was no change in sVEGFR1 in the presence of Aβ1-40 and Aβ1-42. 
VEGFR1 level displayed a non-significant trend towards an increase in hypoxic conditions. 
Immunofluorescence showed stronger labelling of VEGFR1 than of VEGFR2 in HBVP, 
which supported results of the VEGFR1 and VEGFR2 ELISAs. Upregulation of VEGFR1 in 
pericytes by hypoxia has previously been reported 214. 
Contrary to my initial hypothesis, VEGFR2 level in HBVPs was reduced in hypoxic 
conditions. Hypoxia alone was enough to reduce VEGFR2 in pericytes and the presence of 
Aβ did not affect the level of VEGFR2. This work supports a previous study in which 
VEGFR2 expression in pericytes were reduced by hypoxia 214. The presence of VEGFR2 on 
pericytes and its subsequent reduction in hypoxia is in keeping with the role of pericytes as 
support cells for endothelium in hypoxia. Pericytes are known to secrete VEGF 343 and the 
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reduction in VEGFR2 in pericytes under hypoxic conditions is likely to favour paracrine 
signalling of endothelial cells by pericyte-secreted VEGF over its autocrine activity 340. 
To develop this work, several variables could be altered in future studies. In this study one 
hypoxia timepoint and O2 percentage were used. This does not reflect physiological 
conditions in the human brain in dementia but was an acute model to gain initial insights into 
the receptor system. Similarly, one concentration of Aβ1-40 or Aβ1-42 was used. In future work, 
it would be of interest to examine the effects of several O2 and Aβ concentrations to establish 
the dose responses in both cell types. It would also be useful to quantify the 
immunofluorescent labelling of mbVEGFR1 and VEGFR2 in both cell types, with or without 
hypoxia and additional exposure to Aβ1-40 or Aβ1-42 to complement the ELISA measurements 
of these receptor proteins. Further investigation into phosphorylation would provide 
information about the functional level of receptors under hypoxia and in the presence of Aβ. 
The sVEGFR2 ELISA and/or anti-p-VEGFR2 antibodies could be tested and used to indicate 
the phosphorylation level in both cell types. In addition, data on the functional implications for 
hypoxia and Aβ on both types could be measured. A tube-formation assay for could be used 
to measure the effect of hypoxia and Aβ on HBMEC ability to form capillary-like structures. A 
proliferation assay combined with a cell live/dead assay could be used to assess the effect 
of hypoxia and Aβ on pericytes. These assays would provide further insight into the effect of 
hypoxia and Aβ on the VEGF system, as VEGF is known to stimulate both proliferation and 
migration by its action on VEGFR1106 and VEGFR2 129, 168. 
In conclusion, the level of sVEGFR1 increased in hypoxia in HBMECs and pericytes, while 
there was no change in mbVEGFR1 level. The level of VEGFR2 in pericytes decreased in 
hypoxia. The findings support other evidence that VEGFR1 is the main VEGF signal 
mediator in pericytes and is in keeping with the previously described role of pericytes as 
important vasculotropic cells in hypoxia. Aβ alone did not have a significant effect on the 




Chapter 7 Discussion 
In this thesis, human tissue and cell-based work was used to expand the literature on 
VEGFR1 and VEGFR2 in AD and VaD. This chapter will provide an overview of the main 
findings, their implications and future work. 
7.1 Are VEGFR1 and VEGFR2 altered in the AD brain? 
The localisation, mRNA and protein level of VEGFR1 and VEGFR2 were measured in 
human control and AD brain tissue, as described in Chapters 3 and 4 respectively. 
Localisation of receptors was unchanged in the AD brain compared to control. The mRNA 
level of both proteins was significantly increased in AD compared to control. This was 
hypothesised as the presence of cerebral hypoperfusion and resulting hypoxia would 
increase transcription of VEGFR1 and the increase in VEGF concentration would increase 
VEGFR2 transcription. This study supports previous work in animal models of hypoxia 
showing elevated VEGFR1 127, 229-231 and VEGFR2 253 301 302 levels when compared to 
normoxia.  
Unexpectedly, the level of total VEGFR1 protein was reduced in AD compared to control 
while the relative level of sVEGFR1 was increased. The increased proportion of 
sVEGFR1:mbVEGFR1 in AD may contribute to the lack of microvessel growth in AD despite 
elevated levels of VEGF. The unchanged level of VEGFR2 protein indicates that the 
impaired angiogenic response in AD is not caused by deficiency of this receptor. 
An interpretation of the relevance of VEGFR1 and VEGFR2 in the context of vascular 
homeostasis and hypoperfusion of the parietal cortex in AD is summarised in Figure 7-1. 
Numerous factors may contribute to the reduced CBF in early AD, including cerebrovascular 
pathology, a reduction in cholinergic innervation and an increase in vasoconstrictors (Figure 
7-1). Reduced tissue oxygenation is thought to induce the increase in VEGF but is not 
associated with a corresponding increase in vWF in the parietal lobe. The increase in 
proportion of sVEGFR1 is a possible contributor to this disparity, but other abnormalities of 
VEGFR1 or VEGFR2 receptor signalling or VEGF metabolism (see below) cannot be 
excluded.  
In this study only those with late stage, established AD were studied. At this stage of 
disease, we are limited by the possible ceiling effect of AD. Amyloid deposition and MAPT 
distribution is established leading to a variety of changes and delirious effects in the brain 
including neuronal death. Therefore, this study is unable may be too late to detect some 




Figure 7-1 The relevance of present findings in the context of vascular homeostasis and 
hypoperfusion of the parietal cortex in late AD (Braak stages V and IV). CAA, decreased 
cholinergic innervation of intracerebral blood vessels 94, 95, reduced NO production 92, 93, 369, 370 
and an increase in vasoconstrictors EDN1 90, 226 and AngII, through upregulation of 
angiotensin-converting enzyme (ACE)-1 and downregulation of ACE-2 91, 227 may all contribute 
to reduced CBF. Reduced tissue oxygenation leads to increased VEGF 72, 78, 198, 212, 314 that is not 
accompanied by an increase in vWF level 78. Reduction in VEGFR1 is probably a physiological 
response to reduced oxygenation but an increase in sVEGFR1 may contribute to impaired 
angiogenesis. VEGFR2 level remains unchanged. Arrows denote an increase (↑) or decrease 
(↓) in protein in AD compared to control. Horizontal double arrow (↔) indicates no change in 




As mentioned above the investigation of VEGF receptors was performed in cases with 
advanced AD, therefore do not reflect the changes that may have occurred in the early 
stages of AD. Parietal lobe one of the earliest regions of the cortex to be affected by reduced 
CBF 371. This made the parietal lobe an area beneficial for investigating hypoperfusion and 
the chronic effects of hypoxia and Aβ on VEGF and VEGF receptors. To investigate the 
effect of early hypoperfusion in AD on VEGF receptors and changes over the course of 
disease it would be beneficial to include samples from early AD and from multiple brain 
areas. 
Figure 7-2 presents the hypothesised changes in receptor. Reduced CBF will lead to 
hypoxia in the brain and an acute response which could include the upregulation of VEGFR1 
and VEGFR2 protein levels. After an initial elevation in VEGFR levels, there would be a 
reduction in receptor concentration as the hypoxia became chronic.  
Figure 7-2 Hypothesised mechanisms in the context of vascular homeostasis and 
hypoperfusion of the parietal cortex in early AD (Braak stages I and II). Changes compared to 
late AD are written in blue text. Under acute hypoxia in very early stages of AD it is possible 
that VEGFR1 and VEGFR2 levels may increase resulting in increased blood vessel density. 
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String vessels have been reported in the AD brain which may be in part due to the initial 
presence of blood vessel, but due to pathological changes ongoing in AD, including the 
presence of Aβ. Arrows denote an increase (↑) or decrease (↓) in protein in AD compared to 
control. Horizontal double arrow (↔) indicates no change in AD compared to controls. 
7.2 Are VEGFR1 and VEGFR2 altered in the VaD brain? 
This study investigated the levels of VEGFR1 and VEGFR2 protein in VaD brain. Initial 
studies had found that the level of microvessel density increased as the level of VEGF 
increased in VaD72. It was hypothesised that the increase VEGF would accompany an 
increase microvessel density. Since VaD is defined by reduced CBF in the brain due to CAA 
and SVD, any increase in blood vessel density would be unlikely to result in reperfusion for 
large areas of the brain. 
The level of VEGFR1 in VaD was not measured in this study. The level of VEGFR2 protein 
was unchanged compared to control and AD samples in the parietal cortex. There was a 
reduction in VEGFR2 level in the VaD white matter compared to AD. This indicates that the 
receptor level remains unchanged due to chronic hypoperfusion. In the in vitro experiments 
in this study the level of VEGFR1 and VEGFR2 were increased on endothelial cells in acute 
hypoxia. There may be an increase in VEGFR2 in the early stages of disease when hypoxia 
is acute as described above in AD.  
VaD samples in this study had low levels of AD pathology and were therefore a ‘pure VaD’ 
cohort. VaD was studied in order to determine the effect of AD pathology on receptor 
expression. Aβ pathology was not present, or present in minimal amounts, compared to AD. 
As both AD and VaD samples showed no change in VEGFR2 level when compared to 




Figure 7-3 VaD mechanisms in the context of vascular homeostasis and hypoperfusion of the 
parietal cortex in VaD. CBF in VaD is reduced leading to chronic hypoxia and neuronal death in 
VaD. Chronically elevated would result from ongoing hypoxic conditions. Despite increased 
VEGF There was no change in blood vessel density in VaD. With no increase in blood vessel 
density the hypoxic condition remains. Arrows denote an increase (↑) or decrease (↓) in 
protein in VaD compared to control. Horizontal double arrow (↔) indicates no change in VaD 
compared to controls. 
7.3 Does Aβ interfere with VEGF-VEGFR signalling? 
There have been several reports of VEGF binding to Aβ in AD brain 222, 372 and of Aβ binding 
to VEGFR2 in vitro and in vivo 307, 308. VEGF has been found sequestered in Aβ plaques in 
human AD brain and VEGF was found to bind to Aβ with the same affinity as it binds to its 
own receptors 222. This would reduce the bioavailiblity of VEGF despite it being present in 
higher concentrations. In HUVECs and HBMECs, Aβ was found to bind to VEGFR2 and 
VEGFR2 phosphorylation was reduced with increasing Aβ concentration. This reduced the 
ability of cells to migrate and form tubules as tested with a tube formation assay. Therefore 
VEGF could be present in high concentrations but not have access to the receptors due to 
the presence of Aβ binding to VEGFR2. Despite elevated VEGF levels there is no increase 
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in microvessel density in the AD brain. This raises the possibility that VEGF signalling may 
be altered in AD. It seems likely that a combination of VEGF sequestration and lack of 
access to receptors could contribute to reduced VEGF-VEGFR signalling.  
At the time of this study there had been no investigation into the interaction between 
VEGFR1 and Aβ binding. This is due to the minimal role of VEGFR1 in cellular signalling 
when compared to VEGFR2. VEGFR1 and VEGFR2 share 33.3% sequence homology in 
the extracellular domain125 and are structural analysis has shown VEGFR1 able to bind 
VEGF similarly to VEGFR2 373. As Aβ is able to bind to VEGFR2 it is hypothesised that Aβ 
could bind to VEGFR1. In a recent study the effect of Aβ on HUVEC VEGFR levels was 
investigated and found that VEGFR1 levels were significantly increased. This was then 
attributed to increased cell death. This contradicts the work in this study and provides 
grounds for further investigation of the interaction between VEGFR1 and Aβ 374. This would 
be of interest due to the presence of VEGFR1 on endothelial cells where they regulate 
VEGF mediated angiogenesis 375. VEGFR1 is also present neurons where it is hypothesised 
to have a similar role in regulating VEGF as a neurotrophic factor and on microglia 142.  
This study established that the level of VEGFR2 in parietal lobe was unchanged between 
control and AD indicating that it is an alteration in ligand binding or downstream signalling 
that is occurring rather than a lack of binding sites.  
After establishing that receptor levels were unchanged the role of Aβ in VEGF-VEGFR 
signalling was investigated. There was no change to the levels of VEGFR1 and VEGFR2 
when endothelial cells and pericytes were exposed to Aβ1-40 and Aβ1-42 alone. It was only 
when cells were exposed to hypoxia that an effect on receptor level was reported. Despite 
efforts to measure the phosphorylation level of VEGFR2 in human tissue via assay and 
western blot, no suitable methods were optimised. In vitro work determined that the effects 
of VEGFR1 and VEGFR2 levels were dictated by hypoxia, Aβ itself having no effect. It is 
however possible for Aβ to be affecting receptor signalling though due to a lack of suitable 
antibody to p-VEGFR2 this was not investigated in this project. 
This thesis has focused on the VEGF-VEGFR system in blood vessel maintenance and 
formation; however, there are several other receptor systems and signalling pathways 
involved in these processes. Notch signalling is vital in angiogenesis and interaction with 
VEGFR signalling well characterised 130. Notch can control the level of VEGFR expression 
and high levels of VEGFR1 expression can result in blood vessel regression 376 Notch and 
VEGF signalling are also known to interact in neurogenesis in the SVZ 376. Alteration of 
signalling of VEGFR can have other effects on the activity of Notch signalling. The role of 
pericytes was investigated in the final results chapter. PDGFRβ is used as a pericyte marker 
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and one of the receptors for platelet derived growth factor (PDGF). VEGFR1, VEGFR2 and 
PDGFRβ were shown to be co-expressed by pericytes, as reported in this thesis. Not only is 
VEGF able to bind to PDGFRβ 377 but there is evidence that PDGF can bind to VEGFR2 378. 
The changes in bioavailability of VEGF could reduce PDGF signalling by pericytes as well as 
endothelial cells, neurons and astrocytes, from which PDGF is also released.  
7.4 What are the implications of VEGF–VEGFR dysfunction on the AD 
brain? 
The role of VEGF system in disrupted angiogenesis motivated investigation of the receptors 
in the control, AD and VaD brain. VEGF, however, has several other roles in nervous system 
tissue, so disruption to VEGF signal transduction could lead to multiple adverse effects in 
AD. These include disruption to the BBB, astrocytic and neuronal function.  
This study did not have the scope to address impacts of increased VEGF on the blood brain 
barrier or alter flow and consequences of BBB damage and permeability. This would be of 
particular interest in early AD when BBB changes are first thought to occur. Endothelial cells 
are a key component of the BBB and disrupted signalling, as described in 7.3 could reduce 
the ability of these endothelial cells to proliferate and migrate to maintain the BBB. Indeed 
the death of endothelial cells has been suggested as a contributing factor to BBB 
breakdown379. VEGF was first discovered as a permeability factor and Increases in the 
concentration of VEGF could be a contributing factor to the breakdown of the BBB. 
Alterations in VEGF level on BBB breakdown have been consistently reported in AD. 
Increased permeability would lead to infiltration of neurotoxic molecules from the periphery, 
immunoglobulins and immune cells which can result in increased oxidative stress and 
inflammation contributing to neurodegeneration 380.  
It has been proposed that the main role for VEGF in the adult nervous system is not 
angiogenesis. This study observed VEGFR1 and VEGFR2 on endothelial cells in the AD 
brain, as expected. Furthermore, VEGFR1 is present on neurons (Chapter 3) and VEGFR2 
is present on both neurons and astrocytes in control and AD (Chapter 4). Despite the major 
role of VEGF in angiogenesis via endothelial cells, it has been noted that astrocytes are a 
major producer of VEGF. The role of astrocytes in neuronal and endothelial signalling has 
been well established but the role of VEGF in these interactions is not entirely clear.  
VEGF mediates both LTP and hippocampal neurogenesis. VEGF is essential for LTP and 
increases synaptic strength independent of its effects on angiogenesis and neurogenesis 211, 
381. A more recent study has shown VEGF to mediates its effect by causing the redistribution 
of NMDA type glutamate receptors on neurons 382. VEGF acts on VEGFR2 on hippocampal 
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neurons. The silencing of VEGFR2 lead to impaired synaptic plasticity and memory 
consolidation 382. 
If VEGF-VEGFR signalling is disrupted, by hypoxia or Aβ, this could have a direct effect on 
synaptic function. As the reduction in CBF and resultant reduced perfusion of brain tissue is 
one of the first changes in AD, changes in the level of sVEGFR1 may occur early in disease. 
Following reduced CBF, increases in Aβ1-42 may have a direct effect on the receptor system 
on neurons 308 or the binding of VEGF with Aβ1-42222 may reduce the bioavailability of VEGF 
resulting in reduced VEGFR2 signalling and therefore reduced LTP and neurogenesis in the 
AD brain. Furthermore, the interference with VEGF signalling may also contribute to the 
inhibitory effects of Aβ1-42 on synaptic transmission 383-385.  
7.5 Does promotion of angiogenesis offer therapeutic potential in AD? 
Due to the overlap of clinical symptoms and involvement of the vascular system in dementia, 
understanding the role of brain perfusion and its dysfunction in disease could provide novel 
clinical insights to slow the progression of disease. Indeed, VEGF administration has been 
investigated as a neuroprotective, proangiogenic therapy in AD 134, 386, 387. 
Increasing CBF in early disease has the potential to slow the progression of AD. Reduced 
CBF is one of the first changes in disease and Aβ is increased in ischaemic conditions so 
preventing hypoxia may well slow Aβ accumulation in the brain. 
Initiating angiogenesis via the VEGF system by either VEGF administration or VEGFR 
agonists may be beneficial in disease. There are however, significant drawbacks due to the 
potent effect of this ligand-receptor system and dosing would need to be carefully targeted 
and regulated. Elevated VEGF levels would risk aberrant angiogenesis, a known cause of 
disease and increased permeability of the BBB leading to further neuronal damage. 
Targeted delivery of VEGF containing biodegradable nanospheres to the CNS has been 
trialled in mice 386. This direct administration of nanospheres to the brain promoted 
angiogenesis, and reduced neuronal loss and cerebrovascular abnormalities 386. This offers 
therapeutic potential, though delivery through the BBB would need to be optimised to be of 
benefit.  
The caveats for increasing VEGF level may prohibit its use in the CNS but it is possible that 
other members of this ligand family may be more clinically appropriate. VEGF-B is only able 
to activate VEGFR1 resulting in weaker angiogenic activity than VEGF while retaining 
neuroprotective effects. As a result, VEGF-B has been suggested as an alternative ligand for 
increasing angiogenesis and neuronal survival in the CNS. VEGF-B was found to have 
neuroprotective effects both in primary cultured motor neurons and in a mouse model of 
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motor neurone disease 244. In the same study VEGF-B did not cause BBB permeability or 
aberrant vessel growth seen with a similar dose of VEGF 244. In a more recent study, VEGF-
B was administered to a mouse model of ischaemic stroke which resulted in the formation of 
stable microvasculature 388. The authors found this was effect was mediated by the 
activation of VEGFR1 on pericytes, as opposed to endothelial cells. 
The apparent specificity of VEGF-A isoforms offers a useful opportunity to be able to enact 
changes to the system with minimal side effects. Subtypes of VEGFxxxa, in particular or 
VEGF-Ax. The VEGFxxxb family are unlikely to be suitable as there is evidence they are 
antiangiogenic and increase permeability 389. As although they have been shown to be 
neuroprotective 125. To take full advantage the system must first be understood in the CNS. 
Possible therapeutic options are also offered from existing registered drugs. For example, a 
combination treatment of memantine, an NMDA inhibitor, and rosuvastatin, a statin, were 
administered to a rat model of permanent cerebral hypoperfusion 390. The paper reported the 
NMDA inhibitor upregulated brain derived neurotrophic factor (BDNF) and the statin 
upregulated VEGF, inducing cell proliferation and leading to neovascularisation. The two 
drugs in combination increased LTP and level of growth factors more than either treatment 
alone. The authors point out that the treatment should be further validated in newly 
developed models of cerebral hypoperfusion that do not induce acute brain damage 391, 392. 
This provides evidence that combination treatment could provide an effective way of 
modulating brain function.  
This use of existing drug treatments provides a clear opportunity to avoiding severe side 
effects of administering VEGF directly while still benefitting from the role of the growth factor 
in angiogenesis and LTP. 
Prior to the investigation of these as therapeutics in the CNS, more must be elucidated about 
the function and effect of these subtypes on receptors both within the VEGFR system and 
possible cross-reactivity with other receptor systems. 
7.6 Future work 
This thesis investigated VEGFR1 and VEGFR2 in the grey and white matter of the parietal 
lobe. VEGF expression level has shown regional variation in human brain post-mortem 
studies 78 so it would be beneficial to study the expression of the receptors in multiple brain 
regions.  
A further study would also benefit from using human brain tissue at an earlier stage of 
disease. As indicated in Figure 7-2, the use of an AD cohort at Braak stages I-III would allow 
147 
 
changes in VEGF receptor levels to be investigated when cerebral hypoperfusion will be 
present but before extensive deposition of tau and Aβ. Detection of changes in the receptor 
system at this stage would provide evidence for the role in VEGF disruption in the 
pathophysiology of AD.  
Other areas of work arising immediately from this study include the exploration of sVEGFR1 
mRNA levels in human brain tissue by qPCR. The levels of sVEGFR1 isoforms have been 
measured by qPCR in other studies and this would add to the understanding of the possible 
increase in sVEGFR1 as a negative regulator of VEGF function in AD.  
Two methods for measuring p-VEGFR2 were tested in this thesis. Neither the p-VEGFR2 
ELISA or antibody could be optimised adequately to be used on human tissue or cell lysate. 
Further work should include further optimisation of a method for measuring p-VEGFR2 in 
vitro to clarify the effect of Aβ and hypoxia on VEGFR signalling. 
Further work arising from the cell studies include the measurement of cell proliferation and 
migration. A cell proliferation assay combined with a cell live and death assay could be used 
assess the effect of hypoxia and, or, Aβ on cell proliferation and viability. Migration can could 
be assessed in HBMECs using a tube formation assay. This would assess any functional 
effect hypoxia and, or, Aβ would have on cell migration. 
The work in this thesis relates to VEGF, with no attempt to discriminate between VEGFxxxa 
and VEGFxxxb subtypes. The has been no detailed investigation of VEGFxxxa isoforms in the 
brain, with the focus of this study on VEGF165a. There has been one investigation of the anti-
angiogenic splice variant, VEGF165b in the AD brain to date 125. Further studies would be of 
interest, as the ratio of VEGF165a: VEGF165b subtypes was found to be altered in lung 
disease 393 and an alteration in the ratio of these subtypes might have a significant impact on 
angiogenesis in AD.  
The other members of the VEGF family, VEGFR3 and their neuropilin co-receptors are all 
yet to be investigated in dementia. VEGF-B and VEGF-C are known to have direct effects on 
neurons but the effect of dementia on the localisation, level and activity of these proteins is 
still to be elucidated. 
Chronic cerebral hypoperfusion is a key abnormality leading to vascular cognitive 
impairment and dementia. Closing the translational gap between rodent models and human 
vascular cognitive impairment and dementia is likely to be a key step in making progress in 
this field 394. Current models can reduce blood flow following implementation of microcoils395 
or constrictors around the carotid arteries 391 to mimic hypoperfusion in AD or VaD. However, 
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there are limitations of these animal models of cerebral hypoperfusion and the development 
of better models would allow translational work to proceed more effectively. 
7.7 Final conclusions 
Data in this thesis support the hypothesis that VEGF receptor signalling is disrupted in AD 
and this may affect the progression of AD. This has implications of the role of reduced blood 
flow in the pathogenesis of AD. The disruption of signalling may also have wider impact on 
neuronal, astrocyte and pericyte function in disease, though further investigation is needed. 
This work adds to the understanding of VEGF-VEGFR system in dementia. Further work is 
needed to elucidate the receptor system in VaD and to determine precisely why this 
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Appendix 1 Chemicals and reagents 
Consumables  Manufacturer 
10x Trypsin-EDTA Sigma 
2 ml screw-top tubes ThermoFisher Scientific  
24-well plates Starstdt 
30% Acrylamide Bio-Rad Laboratories 
96 well plate – Black Nunc 
96 well plate – Clear Nunc 
96 well plate - Clear removable strips (ELISA) Biotechne 
Accutase Sigma 
Acetonitrile  ThermoFisher Scientific  
Aprotinin Sigma 
APS Sigma 





Bijoux (7ml) Greiner 
Biotinylated Goat anti-Rabbit IgG (H+L) Vector Laboratories, 
BLUeye prestained protein ladder  Geneflow  
Bovine serum albumin  Sigma  
Cell culture flasks (vented)- T25 and T75 Greiner 
CelLytic M Cell Lysis Reagent Sigma-Aldrich 
Chloroform Sigma  
Clearene  Leica 
Compressed gas (O2, Air, N2) BOC 
Copper sulphate (CuSO4)  BDH Merck 
Coverslips Surgipath 
Cryovials  Greiner 
DAB peroxidase (HRP) substrate kit (with nickel), 3,3’-
diaminobenzidine 
Vector Laboratories 
Di-sodium hydrogen orthophosphate 12-hydrate Sigma 
Disposible pipettes (sterile) - 5ml, 10ml, 25ml  Greiner 
DMSO Sigma 
DNase I recombinant Roche 
DPX mountant Sigma 
Dried skimmed milk powder Marvel  
Dulbecco’s Phosphate Buffered Saline (without calcium 
or magnesium) 
Sigma 
Eagle’s Minimum Essential Medium Sigma 
EDTA BDG 
Endothelial cell medium (Complete kit) ScienCell  
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Enhanced chemiluminescence (ECL) western blotting 
substrate  
ThermoFisher Scientific  
Eppendorf tubes - 0.2ml, 1.5ml, 2ml  Eppendorf  
Ethanol ThermoFisher Scientific  
Falcon tubes (15 ml, 50 ml) Greiner 
Fast Taqman qPCR master mix  Applied Biosystems 
Fetal bovine serum  ThermoFisher Scientific  
Fibroblast surface protein antibody  Abcam 
Fibronectin  ScienCell 
Foetal bovine serum (FBS) Gibco 
GFAP Dako 
Gill II Hematoxylin Leica 
Glycogen from Mytilus edulis (Blue mussel) Sigma  
Goat anti-Mouse IgG (H+L), Alexa Fluor 488 conjugate ThermoFisher Scientific  
Goat anti-Mouse IgM (µ chain), Alexa Fluor 488 conjugate Abcam 
Goat anti-Rabbit IgG (H+L), Alexa Fluor 546 conjugate ThermoFisher Scientific  
High capacity cDNA reverse transcription kit  ThermoFisher Scientific  
HLA-DP, DQ, DR Dako 
HRP Goat Anti-Rabbit IgG Antibody (Peroxidase) Vector Laboratories, 
HRP Horse Anti-Mouse IgG Antibody (Peroxidase) Vector Laboratories, 
Human brain microvascular endothelial cells  ScienCell  
Human brain vascular pericytes  ScienCell 
Human phospho-VEGF R2/KDR DuoSet IC ELISA kit R&D Systems 
Human total VEGFR2 (KDR) DuoSet IC ELISA kit R&D Systems 
Human VEGF-A DuoSet ELISA kit R&D Systems 
Human VEGFR1 (Flt1) DuoSet ELISA kit R&D Systems 
Human Von Willebrand factor ELISA kit  Abcam 
Hydrogen peroxide (30%) ThermoFisher Scientific 
Isopropranol ThermoFisher Scientific  
Leupeptin  Sigma 
MAG recombinant  Abnova  
Magnesium chloride (MgCl2) ThermoFisher Scientific  
Methanol  ThermoFisher Scientific  
MicroAmp fast optical 96-well reaction plate ThermoFisher Scientific  
MicroAmp optical adhesive film ThermoFisher Scientific  
Microscope slides Superfrost Plus ThermoFisher Scientific  
Myelin-associated glycoprotein (MAG) antibody Abcam  
Nitrocellulose membrane  Thermo Fisher Scientific  
Normal goat serum  Vector Laboritories  
PAP pen Daido Sangyo Co. 
PDGFRβ antibody ThermoFisher Scientific 
Pericyte medium (Complete kit) ScienCell  
Peroxidase substrate for ELISA R&D systems 




Polyacrilimide gels (7.5%, 4-20%) BioRad 
Poly-L-lysine  ScienCell 
PureLink RNA Mini Kit ThermoFisher Scientific  
Quant-iT PicoGreen Kit  Invitrogen 
Rabbit (DA1E) mAb IgG XP Isotype Control Cell Signalling 
Restore western blot stripping buffer ThermoFisher Scientific  
RNase- free water Sigma  
RNAse-free filter tips (10 µl, 20µl, 200 µl 1000 µl STARLAB 
Scalpels Apelton woods 
SDS Sigma 
Sodium chloride (NaCl) Sigma 
Sodium dihydrogen orthophosphate dihydrate Sigma 
Streptavidin, Alexa Fluor® 555 Conjugate Invitrogen 
Sudan Black  Sigma  
Sulfuric Acid (2N) Sigma 
Taqman Fast Advanced Master Mix  ThermoFisher Scientific  
Taqman primers ThermoFisher Scientific  
TEMED Bio-Rad Laboratories 
Total protein kit Sigma 
Tris Sigma 
Trisodium citrate ThermoFisher Scientific 
TRIzol  ThermoFisher Scientific  
Trypan blue solution, 0.4% ThermoFisher Scientific  
Tween 20 Sigma 
Vectorsheild mounting medium  Vector Laboratories 
Vectorsheild mounting medium with DAPI  Vector Laboritories  
Vectorstain Elite ABC kit (Universal) Vector Laboratories 
VEGFR1 antibody Abcam  
VEGFR2 antibody  Cell Signalling 
Very intense purple substrate kit  Vector Laboratories 
Virkon disinfectant tablets ThermoFisher Scientific 
Von Willebrand factor (vWF) antibody Dako 
Von Willebrand factor (vWF) ELISA kit Abcam 
Zirconia/Silica (ceramic) beads (2.3 mm diameter) Stratech Scientific 
α-Smooth muscle actin antibody  Abcam 
β-Actin antibody  Sigma 




Appendix 2 Equipment 
Details of laboratory equipment  Manufacturer  
Autoclave  Priorclave 
Balance Sartorius 
Bench top centrifuge (cell culture) ThermoFisher Scientific 
Bio-Rad Laboratories Mini-PROTEAN 3, electrophoresis module  Bio-Rad Laboratories 
Class II laminar flow hood MDH InterMed 
CO2 incubator Sanyo Electric co. 
CoolCell LX controlled-rate alcohol-free cell freezing container Biocision  
CTR6000 Fluorescence Microscope  Leica  
DFC350FX Camera - Fluorescence Microscope  Leica  
DMR Light microscope  Leica 
Dot blot manifold  BioRad 
Eclipse TS100 Inverted microscope  Nikon 
Fine Balance BR221S Sartorius 
FLUOstar OPTIMA, microplate reader BMG Labtech  
Fume hood  Surgipath Europe 
Haematocytometer Hawksley 
Hypoxic chamber (SCI-tive) Baker Ruskinn  
Magnetic stirrer  Bibby  
Microcentrifuge Scotlab  
Mini-Sub Cell GT Cell electrophoresis tank  Bio-Rad Laboratories 
Molecular Imager Gel Doc XR System Bio-Rad Laboratories 
Orbital shaker platform GrantBio 
pH meter Hanna instruments  
Pico17 Heraeus Centrifuge  Thermo Scientific 
Plate spinner Labnet 
Power Pack  Bio-Rad Laboratories 
Precellys 24, mechanical homogeniser Bertin Technologies  
QICAM digital camera  QImaging 
Refrigerated centrifuge Biofuge  
Thermal cycler Applied Biosystems  
ViiA7 Real-Time PCR system Applied Biosystems  
Vortex HATi  
Water Still  Purite Select Fusion  




Appendix 3 Software and publishers 
Software Version  Publisher  
GraphPad Prism 6.07 GraphPad Software, La Jolla California USA 
BioRad ImageLab 5.2 Bio-Rad Laboratories, Hercules, California, 
United States 
BMG Labtech Optima 2.2 R2 BMG LABTECH GmbH Ortenberg, Germany 
MARS Data Analysis 3.01 R2 BMG LABTECH GmbH Ortenberg, Germany 
Details of software and publishers. 
Appendix 4 Solution compositions 
Solution Composition  Technique 
10x Running Buffer 
  
0.25 M Tris 
1.92 M Glycine 
1% w/v SDS  
Western blotting  
  
10x Blotting buffer  
  
0.25M Tris (0.25 M) 
1.92 glycine (1.92M) 
Western blotting 
  
1x Blotting buffer 
  
10% v/v 10x blotting buffer 






0.2 M Tris base 
5 M NaCl 
pH 7.6 
Western blotting 




10% v/v TBS 
  
Western blotting 
Dot blotting  
0.05% TBST 
  










BSA block/antibody buffer  
  
3% w/v BSA 
TBST 
Western blotting  
Dot blotting 
BSA block/antibody buffer  5% w/v BSA 
PBST 
Immunofluorescence 
Citrate buffer  10 mM trisodium citrate 




EDTA buffer 1 mM EDTA, 





Copper sulphate 0.5 mM CuSO4  





Phosphate Buffered Saline (PBS) 0.15 M NaCl 
7.5 mM Di-sodium hydrogen 
orthophosphate 12-hydrate 
1.9 mM Sodium dihydrogen 
orthophosphate dihydrate 
Immunohistochemisty 




PBS-T 0.05% v/v Tween 20 
PBS 
ELISA 
SDS Buffer 1% SDS,  
10 mM Tris base (pH 6.0) 
0.1 mM NaCl 
1 μM PMSF,  
1 μg/ml aprotinin 
Protein extraction 
PBS 137 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.5 mM KH2PO4,  
pH 7.2 - 7.4 




Reagent diluent #12 1% NP-40 
20 mM Tris (pH 8.0) 
137 mM NaCl, 
10% glycerol 
2 mM EDTA 




Reagent diluent #14 20 mM Tris, 
 137 mM NaCl 
0.05% Tween 20 
0.1% BSA 
pH 7.2 - 7.4. 
VEGFR2 ELISA 
p-VEGFR2 ELISA 
Lysis Buffer #9 1% NP-40 
20 mM Tris (pH 8.0) 
137 mM NaCl, 
10% glycerol 
2 mM EDTA 
1 mM activated sodium 
orthovanadate 
10 µg/mL aprotinin 
10 µg/mL leupeptin 
VEGFR2 ELISA 
p-VEGFR2 ELISA 




Appendix 5 Commercial kit components 
Name  Contents  Supplier 
DAB Peroxidase (HRP) 
Substrate Kit (with 
Nickel), 3,3’-
diaminobenzidine 
Buffer stock solution Vector Laboratories 
SK-4100 Hydrogen peroxide solution 
DAB stock solution 
Nickel solution 
Endothelial cell medium 
(Complete kit) 
Basal medium  ScienCell  
1001 Penicillin/Streptomycin solution, 5 ml 
Fetal bovine serum, 10 ml 
Endothelial cell growth supplement 
High capacity cDNA kit 
10X RT buffer Applied Biosystems 
4368814 10X RT random primers 
25X dNTP mix (100 mM) 
MultiScribe® reverse transcriptase (50 U/µL) 
Human VEGF-A DuoSet 
ELISA 
Mouse anti-human VEGF capture antibody R&D Systems DY293B 
Biotinylated goat anti-human VEGF detection 
antibody 
Recombinant human VEGF standard 
Streptavidin-HRP 
Human VEGFR1 (Flt1) 
DuoSet ELISA 
Mouse anti-human VEGF R1 capture antibody: R&D Systems 
DY321B Biotinylated mouse anti-human VEGF R1 
detection antibody 
Recombinant human VEGF R1 standard 
Streptavidin-HRP 
Human phospho-VEGF 
R2/KDR DuoSet IC ELISA 





Human phospho-VEGF R2/KDR control 
Human total VEGFR2 
(KDR) DuoSet IC ELISA 
Total VEGF R2 capture antibody R&D Systems 
DYC1780-5 Total VEGF R2 detection antibody 
Total VEGF R2 standard 
Streptavidin-HRP 
Human Von Willebrand 
Factor ELISA Kit  
Von Willebrand factor microplate (12 x 8 well 
strips) 96 wells   
Abcam  
ab108918 
Von Willebrand factor standard 1 vial   
10X Diluent N concentrate 
50X Biotinylated human von Willebrand factor 
antibody 
100X Streptavidin-peroxidase conjugate 
Chromogen substrate 





Basal medium  ScienCell 
1201 Penicillin/Streptomycin solution, 5 ml 
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Fetal bovine serum, 10 ml 
Pericyte growth supplement 
PureLink® RNA Mini Kit 
Lysis buffer Ambion 
12183018A Wash buffer I 
Wash buffer II 
RNase-free water 
Spin cartridges (with collection tubes) 
Collection tubes 
Recovery tubes 
Quant-iT Picogreen DNA 
Assay Kit 
Quant-iT PicoGreen dsDNA reagent Invitrogen 
P11496 
20X TE buffer 
Lambda DNA standard 
Quant-iT RiboGreen RNA 
Assay Kit 
Quant-iT RiboGreen RNA reagent Invitrogen 
R11490 
20X TE buffer 
Ribosomal RNA standard - 16S and 23S rRNA 
from E. coli 
Total protein kit 
Protein standard (human albumin) Sigma 
TP0100 Brilliant Blue protein reagent 
Vectorstain Elite ABC kit 
(Universal) 
Normal horse serum Vector Laboratories 
PK-6200 Concentrated universal biotinylated anti-
mouse/rabbit IgG secondary antibody 
Concentrated A and B reagents 
Very intense purple (VIP) 
substrate kit 
Reagent 1 Vector Laboratories 
SK-4600 Reagent 2  
Reagent 3 
Hydrogen peroxide solution 




Appendix 6 Recombinant proteins 
Protein  Origin Catalogue # Manufacturer 
VEGFR1 N terminus of Human VEGF 
receptor 1 
842596 R&D Systems 
VEGFR2 Recombinant fragment 
corresponding to Human VEGF 
Receptor 2 aa 20-757 
841436 R&D Systems 
MAG Human MAG full-length ORF 
(NP_002352.1, 1 a.a. - 626 a.a.) 
recombinant protein with GST-tag at 
N-terminal. 
H00004099-P01 Abnova 
Aβ1-40 - AS-24236 Anaspec 
Aβ1-42 - AS-24224 Anaspec 




Appendix 7 Primary antibodies 
Name of 
Antibody 








Tissue, cells or virus 
corresponding to human 









ß-chain of the α ß 
heterodimer of all products 
of the gene families DP, 








corresponding to amino 
acids 119-208 of human 




PDGFRβ A synthetic peptide derived 






Rabbit IgG Isotype control is not 




3900 Cell Signalling 
VEGFR1 N terminus of Human 




VEGFR2 Recombinant fragment 
corresponding to Human 
VEGF Receptor 2 aa 20-
757 
 - Mouse, 
monoclonal 
Ab9530 Abcam 
VEGFR2 Carboxy-terminal 150 
amino acid residues of 
human VEGF receptor 2 
55B11 Rabbit, 
monoclonal 




Von Willebrand Factor 







 a synthetic peptide 
corresponding to N-
terminus of actin from 




β-Actin N-terminal end of the β-
isoform of actin 





Amino acid residue 1-16 of 
beta amyloid. The epitope 
lies within amino acids 3-8 








C-terminus of β-amyloid 
and is specific for the 









C-terminus of β-amyloid 
and is specific for the 









Appendix 8 Secondary antibodies 
Name of Antibody Manufacturer and 
Catalogue # 
Application 
















Donkey anti-Rabbit IgG (H+L), Alexa Fluor 488 
conjugate 
Invitrogen,  Immunofluorescence 
 














Streptavidin, Alexa Fluor 555 Conjugate Invitrogen 
S32355 
Immunofluorescence 





Concentrated universal biotinylated anti-



























Control BBN_4205 87 M 24 2 1 1 
BBN_4229 87 F 47 3 0 1 
BBN_8651 95 F 46 2   
BBN_8671 78 F 24 2 1 2 
BBN_8700 64 M 12 2 0 0 
BBN_8702 58 M 20 0 0 0 
BBN_8706 72 M 42 1 0 1 
BBN_8708 90 M 45 2 0 0 
BBN_8717 77 M 55 1 0 1 
BBN_8722 78 M 12 2 0 1 
BBN_8723 80 M 67 3 2 2 
BBN_8725 73 M 36 2 0 0 
BBN_8739 93 F 18 2 0 1 
BBN_8751 82 M 30 2 0 2 
BBN_8759 75 M 48 2  1 
BBN_8776 73 M 33 1 0 1 
BBN_8779 69 M 66 2 0 1 
BBN_8835 73 F 59 1 0 1 
BBN_8898 83 F 24 2 0 0 
BBN_8923 82 M 3 2 1 1 
BBN_8949 79 M 24 - - - 
BBN_8957 76 F 12 - - - 
BBN_8980 72 F 24 0 0 2 
BBN_8983 78 M 48 1 0 1 
BBN_9028 76 M 23 2 0 1 
BBN_9092 75 M 6 3   
BBN_9292 73 M 35 3 0 1 
BBN_9299 90 M 5.5 2 0 1 
BBN_9311 93 M 37.75 3 1 2 
BBN_9329 80 M 45.75 0 2 2 
BBN_9340 94 F 21 2 2 2 
BBN_9344 92 M 34.25 2 0 2 
BBN_9354 85 M 30.5 2 0 0 
BBN_9359 77 M 42 1 2 1 
BBN_9365 86 F 32 2 3 1 
BBN_9389 68 F 38.75 0 0 0 




















AD BBN_4202 64 M 66.5 5 0 0 
BBN_4204 65 M 38.5 4 0 2 
BBN_4215 80 F 26 5 2 0 
BBN_8834 78 F 9 5 0 2 
BBN_8848 77 F 43 4 0 0 
BBN_8883 90 M 40 6 0 1 
BBN_8910 71 M 30 6 2 2 
BBN_8912 82 F 24 6 3 1 
BBN_8921 75 F 40 6 3 1 
BBN_8997 74 F 12 6 3 1 
BBN_9005 89 F 4 6 3 1 
BBN_9026 79 M 28 6 1 1 
BBN_9030 65 M 27 6 2 1 
BBN_9031 85 M 66 6 3 1 
BBN_9044 86 M 48 5 0 2 
BBN_9052 57 F 24 5 0 1 
BBN_9076 84 F 20 6 0 3 
BBN_9106 93 M 20 5 0 1 
BBN_9112 74 F 52.5 5 3 1 
BBN_9122 83 F 5 5 0 2 
BBN_9123 74 F 35 6 3 2 
BBN_9136 77 F 26 6 3 1 
BBN_9155 79 M 27 6 1 2 
BBN_9162 63 M 43 6 0 0 
BBN_9163 69 F 71 5 3 1 
BBN_9164 92 F 24 5 3 0 
BBN_9173 86 F 31 6 2 2 
BBN_9179 64 M 9 5 1 1 
BBN_9181 80 F 48 5 2 1 
BBN_9182 74 M 24 6 1 2 
BBN_9186 75 F 21 6 1 1 
BBN_9189 78 F 21 5 3 2 
BBN_9194 89 F 39 6 3 2 
BBN_9198 77 F 14 6 0 2 
BBN_9205 85 F 85 5 3 2 
BBN_9261 83 M 48 6 2 2 
BBN_9262 81 M 4 5 3 2 
BBN_9263 74 M 48 5-6 1 3 
BBN_9266 80 M 72 6 2 1 
BBN_9274 78 M 49 6 2 0 
BBN_9275 87 M 36 5 0 1 
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BBN_9280 76 M 11 6 0 3 
BBN_9295 85 M 49.5 5 0 3 
BBN_9303 69 M 12 6 0 1 
BBN_9315 67 F 24.25 6 1 2 
BBN_9323 84 F 20.5 6 2 3 
BBN_9342 65 F 11.5 5 2 1 
BBN_9361 83 M 11 6 0 1 
BBN_9367 77 M 19 5 3 1 
BBN_9378 84 F 22 3 1 2 


















VaD BBN_4208 78 F 54 - 0 3 
BBN_8642 84 F 60 - - 2 
BBN_8662 81 M 66 - 0 2 
BBN_8667 84 F 20 - 1 3 
BBN_8669 93 M 30 - 2 3 
BBN_8711 80 F 70 - 1 2 
BBN_8724 72 M 41 - 0 2 
BBN_8760 86 F 28 - - 1 
BBN_8787 77 F 85 - 0 3 
BBN_8799 90 F 31 - 0 2 
BBN_8861 89 M 30 - 0 1 
BBN_8927 67 M 54 - 0 2 
BBN_8944 97 F 66 - 0 2 
BBN_8952 84 M 30 - 0 3 
BBN_8975 76 M 40 - 0 3 
BBN_9108 79 M 56 - 2 3 
BBN_9192 79 M 77 - - 3 
BBN_9224 89 F 22 - 0 1 
BBN_9387 90 M 45  1 3 





Appendix 10 AD and control demographic details for FFPE cases 




delay (hours) Gender 
Control 
BBN_8732 75 48 M 
BBN_8741 80 92 F 
BBN_9028 76 23 M 
BBN_9354 85 30.5 M 
AD 
BBN_4215 80 26 F 
BBN_9164 92 24 F 
BBN_9268 72 65 M 
BBN_9304 60 37.5 M 
BBN_9331 97 34 M 





Appendix 11 Correlation between cycle threshold and cDNA volume 
added to qPCR reaction for all genes of interest 
 
Correlation between cycle threshold and cDNA volume added to qPCR reaction for all genes of 
interest. Cycle threshold (CT) values fell between the range of 20-39 for all genes of interest. 
There was no correlation between cDNA volume added to reaction and resulting CT, meaning 
PCR reaction was not overloaded. 
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Appendix 12 VEGFR1 immunofluorescence 
VEGFR1 immunofluorescence was attempted to confirm co-localisation of VEGFR1 on glial 
cells. (A) No treatment. VEGFR1 applied at 1:200 GFAP applied at 1:200 (B) Copper sulphate 
pretreatment and sudan black post treatment (not shown) were used to minimise lipofuscin-
like fluorescence. DAPI used to stain cell nuclei. Levels background fluorescence remained 




Appendix 13 qPCR Primer alignment maps 
 
Primer for ACTB. Designed to bind to all isoforms of ACTB. Adapted from ThermoFisher 
Genomic Map.  
 
Primer for ALDH1L1. Designed to bind to all isoforms of ALDH1L1. Adapted from 
ThermoFisher Genomic Map.  
 










Primer for FLT1. Designed to bind to mbVEGFR1 and sVEGFR1 (not intracellular VEGFR1). 








Appendix 14 AD and control: demographic details of cases used for 








Control BBN_8651 95 46 F 
BBN_8671 78 24 F 
BBN_8706 72 42 M 
BBN_8722 78 12 M 
BBN_8739 93 18 F 
BBN_8751 82 30 M 
BBN_8776 73 33 M 
BBN_8898 83 24 F 
BBN_8923 82 3 M 
BBN_8949 79 24 M 
BBN_8957 76 12 F 
BBN_8980 72 24 F 
AD BBN_8848 77 43 F 
BBN_8910 71 30 M 
BBN_8921 75 40 F 
BBN_8997 74 12 F 
BBN_9112 74 52.5 F 
BBN_9136 77 26 F 
BBN_9164 92 24 F 
BBN_9261 83 48 M 
BBN_9315 67 24.25 F 
BBN_9342 65 11.5 F 
BBN_4215 80 26 F 
BBN_9361 83 11 M 




Appendix 15 VEGFR1 western blot – whole membrane 
The whole membrane of a VEGFR1 western blot used for mbVEGR1:sVEGFR1 analysis. 
VEGFR1 was detected at 180 kDa, and sVEGFR1 isoforms were detected from 80 - 135 kDa in 




Appendix 16 VEGFR2 immunofluorescence 
Double immunofluorescence of VEGFR2 and GFAP on AD frontal lobe FFPE. [A] Double IF 
showed high levels of autofluorescence with no autofluorescence pre-treatment or sudan 
black post-treatment. [B] Biotinylation to amplify VEGFR2 signal improved images but 
autofluorescence remained making colocalisation difficult. Double immunohistochemistry was 
used as an alternative. 
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Double immunofluorescence of VEGFR2 and HLA on AD frontal lobe FFPE. [A] VEGFR2 
displayed minimal signal and autofluorescence was present when no autofluorescence pre-
treatment or sudan black post-treatment was used. [B] Autofluorescence was reduced when 
sudan black post-treatment was used, however this also reduced VEGFR2 signal making it 




Appendix 17 VEGFR2 ELISA detection antibody validation on human 
tissue 
VEGFR2 ELISA detection antibody validation in human tissue. Bands were observed at 230 
kDa and 210 kDa corresponding to glycosylated receptor and non-glycosylated form 
respectively. Bands observed at 120 kDa are attributed to proteolytic cleavage of VEGFR2 396, 
397. VEGFR1 and VEGFR2 recombinant proteins were used to validate specificity. No crossover 
was seen with VEGFR1 recombinant.  
Appendix 18 p-VEGFR2 ELISA spike and recovery testing on human 
tissue 
  % Recovery  
Spiked  Unspiked  Control  
Neat  56.5  -  -  
1:2  159.7  132.6  129.8  
1:4  248.1  151.1  137.0  
The p-VEGFR2 ELISA was validated on human brain tissue homogenates. Spike, recovery and 




Appendix 19 p-VEGFR2 (Tyr996) antibody validation 
p-VEGFR2 (Tyr996) antibody was used to identify p-VEGFR2 in human brain tissue and HUVEC 
lysate. No bands were observed at the predicted molecular weight of immature p-VEGFR2 (150 
kDa), intermediate glycosylated p-Flk-1 (200 kDa) or mature glycosylated p-Flk-1 (230 kDa). The 
antibody could not be used to identify p-VEGFR2 levels in human tissue or cell lysate. Bands 
have been observed at 160 kDa 398 and at 120-130 kDa due to proteolytic cleavage 396, 397. Bands 
and 90 kDa, 50 kDa and 30 kDa could be due to further proteolytic cleavage or non-specific 




Appendix 20 Inter-assay reliability for VWF dot blot. 
MRC 
Identifier 
VWF CoV (%) 
Blot 1 Blot 2 
BBN_4229 226.8 139.7 33.6 
BBN_8923 81.3 180.8 53.7 
BBN_8980 227.3 105.2 51.9 
BBN_9205 282.9 665.0 57.0 
BBN_9261 167.0 374.7 54.2 
BBN_9262 95.9 373.8 83.7 
BBN_9361 133.4 85.8 30.7 
BBN_9365 222.5 118.0 43.4 
Inter-assay reliability for VWF dot blot. Homogenates from the same samples were measured 
on in triplicate on two different blots. CoV was performed to assess the relative variability of 
sample readings. CoV readings show the dot blot is not reliable and as a result the vWF ELISA 
was optimised.  
Appendix 21 Summary statistics for VEGF correlations with VWF 
VEGF and 
vWF 
Control AD VaD 
p r n p r n p r n 
cortex 0.525 -0.119 31 0.437 -0.119 45 - - - 
White 
matter 0.956 -0.01 36 0.132 0.226 48 0.037 0.481 19 
Summary statistics for VEGF correlations with VWF in cortex and white matter.  




p r n p r n 
vWF 0.192 0.229 34 0.003 0.438 44 
VEGF 0.11 0.303 29 0.413 -0.133 29 
Soluble Aβ1-40 0.549 0.118 28 0.48 -0.115 40 
Insoluble Aβ1-40 0.22 0.235 29 0.227 0.2 40 
Soluble Aβ1-42 0.388 -0.167 29 0.8 0.042 39 
Insoluble Aβ1-42 0.518 -0.125 29 0.532 0.102 40 
Soluble Aβ42:40 0.337 -0.188 28 0.405 0.137 39 
Insoluble Aβ42:40 0.135 -0.284 29 0.69 -0.065 40 
Age 0.428 0.141 34 0.133 0.23 44 
Post-mortem 
delay 0.66 0.072 34 0.979 -0.004 44 
Summary statistics for VEGFR1 correlations with variables in parietal cortex.  
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Appendix 23 VEGFR2 correlations in parietal cortex  
Cortex 
VEGFR2 
Control AD VaD 
p r n p r n p r n 
vWF 0.135 0.254 36 0.048 0.287 48 0.074 0.764 19 
VEGF 0.071 0.328 31 0.013 0.366 45 - - - 
Soluble Aβ1-40 0.144 -0.273 30 0.129 -0.23 45 - - - 
Insoluble Aβ1-40 0.98 0.005 31 0.38 -0.135 45 - - - 
Soluble Aβ1-42 0.011 -0.449 31 0.414 0.126 44 - - - 
Insoluble Aβ1-42 0.292 -0.195 31 0.222 0.186 45 - - - 
Soluble Aβ42:40 0.005 -0.503 30 0.152 0.22 44 - - - 
Insoluble 
Aβ42:40 0.993 0.002 31 0.47 0.298 44 - - - 
Age 0.23 0.205 36 0.094 0.24 50 0.838 -0.05 19 
Post-mortem 
delay 0.23 0.205 36 0.883 -0.022 48 0.451 -0.184 19 
Summary statistics for VEGFR2 correlations with variables in parietal cortex.  
Appendix 24 VEGFR2 correlations in parietal white matter 
White matter 
VEGFR2 
Control AD VaD 
p r n p r n p r n 
vWF 0.475 0.123 36 0.917 0.016 48 0.473 -0.175 19 
VEGF 0.918 -0.018 36 0.956 -0.008 48 0.3 0.251 19 
Soluble Aβ1-40 0.549 0.118 32 0.48 -0.115 45 - - - 
Insoluble Aβ1-40 0.22 0.235 31 0.227 0.195 43 - - - 
Soluble Aβ1-42 0.388 -0.167 32 0.799 0.042 44 - - - 
Insoluble Aβ1-42 0.518 -0.125 32 0.532 0.102 44 - - - 
Soluble Aβ42:40 0.337 -0.188 32 0.405 0.137 45 - - - 
Insoluble 
Aβ42:40 0.135 -0.284 31 0.69 -0.065 43 - - - 
Age 0.423 -0.136 36 0.364 0.131 50 0.772 0.071 19 
Post-mortem 
delay 0.684 -0.07 36 0.41 -0.12 48 0.201 0.31 19 
Summary statistics for VEGFR2 correlations with variables in parietal white matter. 
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Total C AD VaD Total C AD VaD 
Cortex 
VEGFR1 70.6 43.5 46 24 21 - 67.99 30.39 28 5 23 - 
VEGFR2 340.8 476.9 65 14 25 14 490.9 475.3 32 4 25 2 
White matter VEGFR2 166.4 108.5 64 26 24 14 154.7 145.9 31 5 24 2 
Summary statistics for CAA score and VEGFR1 and VEGFR2 levels in parietal cortex and white matter.  







Total C AD VaD Total C AD VaD 
Cortex 
VEGFR1 72.87 33.69 46 15 23 - 60.59 49.26 28 3 20 - 
VEGFR2 328.9 499.2 55 25 27 3 391.1 443 46 8 22 16 
White matter VEGFR2 157.8 144.8 53 24 26 4 155.4 102.3 46 9 23 15 
Summary statistics for SVD score and VEGFR1 and VEGFR2 levels in parietal cortex and white matter.  
Appendix 27 Summary statistics for Braak stage and VEGFR1 and VEGFR2 levels 
Braak stage 




 n  
Median IQR 
 n  
Total C AD Total C AD Total C AD 
Cortex 
VEGFR1 78.21 37.36 30 28 0 65.6 46.82 7 4 3 59.59 45.71 41 0 41 
VEGFR2 326.8 232.9 31 29 0 495.4 551.2 8 5 3 395.4 489.1 47 0 47 
White matter VEGFR2 169.1 133.2 29 29 0 137.2 108.44 8 5 3 178.2 114.2 45 0 45 
Summary statistics for Braak stage and VEGFR1 and VEGFR2 levels in parietal cortex and white matter. 
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Appendix 28 No primary control for HBMEC and HBVP 
immunofluorescence 
 
No primary antibody control immunofluorescence. Cells were incubated with primary antibody 
diluent and secondary antibodies specific for primary antibody immunogloblin subtypes. DAPI 
positivity is present in the cell nuclei. No immunofluorescence resembling specific staining 
pattern was seen. 
Appendix 29 Summary values of VEGFR1 and sVEGFR1 levels in 
HBMEC lysates. 
HBMEC  Normoxia N + Aβ1-40 N + Aβ1-42 Hypoxia H + Aβ1-40 H + Aβ1-42 
VEGFR1 
Median 100 131.4 118.5 125.7 130.7 155.3 
IQR 0 59.3 92.26 101.6 136.4 85.51 
N 6 6 6 6 6 6 
sVEGFR1 
Median 100 103.6 98.11 129.9 125.8 111.6 
IQR 0 19.4 37.19 41.1 44.4 43.3 
N 8 6 6 8 6 6 




Appendix 30 Summary values of VEGFR1, sVEGFR1 and VEGFR2 
levels in HBVP lysates. 
HBVP  Normoxia N + Aβ1-40 N + Aβ1-42 Hypoxia H + Aβ1-40 H + Aβ1-42 
VEGFR1 
Median 100 141.3 105.1 119.6 163 148.9 
IQR 0 42.9 105.18 89.9 94.7 105.3 
N 6 6 6 6 6 6 
sVEGFR1 
Median 100 118.4 134.8 141.4 101.8 154.4 
IQR 0 43.06 85.79 150.9 70.68 104.5 
N 8 5 6 8 6 6 
VEGFR2 
Median 100 86.74 98.6 33.03 44.08 41.2 
IQR 0 26.33 25.77 22.61 35.15 47.66 
N 7 7 7 7 7 7 
Summary values of VEGFR1, sVEGFR1 and VEGFR2 levels in HBVP lysates. 
 
